DK1996238T3 - Kimæriske adenovirale vektorer og DsRNA som TLR3-agonist - Google Patents
Kimæriske adenovirale vektorer og DsRNA som TLR3-agonist Download PDFInfo
- Publication number
- DK1996238T3 DK1996238T3 DK07752109.4T DK07752109T DK1996238T3 DK 1996238 T3 DK1996238 T3 DK 1996238T3 DK 07752109 T DK07752109 T DK 07752109T DK 1996238 T3 DK1996238 T3 DK 1996238T3
- Authority
- DK
- Denmark
- Prior art keywords
- nucleic acid
- tlr
- vector
- agonist
- promoter
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims description 123
- 239000000556 agonist Substances 0.000 title claims description 88
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title claims description 18
- 102000040650 (ribonucleotides)n+m Human genes 0.000 title claims description 13
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 title 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 claims description 124
- 102000039446 nucleic acids Human genes 0.000 claims description 96
- 108020004707 nucleic acids Proteins 0.000 claims description 96
- 239000000427 antigen Substances 0.000 claims description 80
- 108091007433 antigens Proteins 0.000 claims description 80
- 102000036639 antigens Human genes 0.000 claims description 80
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 72
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 68
- 229920001184 polypeptide Polymers 0.000 claims description 67
- 239000000203 mixture Substances 0.000 claims description 49
- 210000004027 cell Anatomy 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 38
- 230000028993 immune response Effects 0.000 claims description 37
- 230000002163 immunogen Effects 0.000 claims description 30
- 239000013604 expression vector Substances 0.000 claims description 20
- 230000014509 gene expression Effects 0.000 claims description 17
- 206010022000 influenza Diseases 0.000 claims description 17
- 210000004443 dendritic cell Anatomy 0.000 claims description 16
- 239000004055 small Interfering RNA Substances 0.000 claims description 13
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 10
- 102000002689 Toll-like receptor Human genes 0.000 claims description 10
- 108020000411 Toll-like receptor Proteins 0.000 claims description 10
- 241000282414 Homo sapiens Species 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 5
- 241000701806 Human papillomavirus Species 0.000 claims description 3
- 241000700584 Simplexvirus Species 0.000 claims description 3
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 3
- 210000002490 intestinal epithelial cell Anatomy 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 description 38
- 108090000623 proteins and genes Proteins 0.000 description 37
- 239000002671 adjuvant Substances 0.000 description 35
- 235000001014 amino acid Nutrition 0.000 description 32
- 229940024606 amino acid Drugs 0.000 description 32
- 125000003729 nucleotide group Chemical group 0.000 description 29
- 239000002773 nucleotide Substances 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 description 26
- 241000700605 Viruses Species 0.000 description 22
- 241000701022 Cytomegalovirus Species 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 101100113692 Caenorhabditis elegans clk-2 gene Proteins 0.000 description 18
- 238000002965 ELISA Methods 0.000 description 17
- 239000005090 green fluorescent protein Substances 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 16
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 230000005875 antibody response Effects 0.000 description 15
- 238000009396 hybridization Methods 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 14
- 229960005486 vaccine Drugs 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 230000003612 virological effect Effects 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 108020004705 Codon Proteins 0.000 description 11
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 11
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 102000009016 Cholera Toxin Human genes 0.000 description 10
- 108010049048 Cholera Toxin Proteins 0.000 description 10
- 241001135569 Human adenovirus 5 Species 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 9
- 238000003018 immunoassay Methods 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 231100000655 enterotoxin Toxicity 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 238000009739 binding Methods 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 241000701161 unidentified adenovirus Species 0.000 description 7
- 208000035143 Bacterial infection Diseases 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 102000008230 Toll-like receptor 3 Human genes 0.000 description 6
- 108010060885 Toll-like receptor 3 Proteins 0.000 description 6
- 208000036142 Viral infection Diseases 0.000 description 6
- 230000033289 adaptive immune response Effects 0.000 description 6
- 208000022362 bacterial infectious disease Diseases 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000000147 enterotoxin Substances 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 238000003305 oral gavage Methods 0.000 description 6
- 239000013605 shuttle vector Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 230000028996 humoral immune response Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108091005461 Nucleic proteins Proteins 0.000 description 4
- -1 STARR GLURP Proteins 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 230000021633 leukocyte mediated immunity Effects 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000006820 DNA synthesis Effects 0.000 description 3
- 101710146739 Enterotoxin Proteins 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 102000011931 Nucleoproteins Human genes 0.000 description 3
- 108010061100 Nucleoproteins Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 241000193996 Streptococcus pyogenes Species 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 229940124613 TLR 7/8 agonist Drugs 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000037765 diseases and disorders Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 229920000831 ionic polymer Polymers 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 231100000617 superantigen Toxicity 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 2
- 241001227713 Chiron Species 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 241000759568 Corixa Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102100026720 Interferon beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical class [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 241000710960 Sindbis virus Species 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 241000906446 Theraps Species 0.000 description 2
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 2
- 102000008208 Toll-Like Receptor 8 Human genes 0.000 description 2
- 108010060752 Toll-Like Receptor 8 Proteins 0.000 description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 2
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 2
- 108010067674 Viral Nonstructural Proteins Proteins 0.000 description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000004520 cell wall skeleton Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 229960002751 imiquimod Drugs 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 238000007826 nucleic acid assay Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229950010550 resiquimod Drugs 0.000 description 2
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- ZDSRFXVZVHSYMA-CMOCDZPBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]pentanedioic acid Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 ZDSRFXVZVHSYMA-CMOCDZPBSA-N 0.000 description 1
- UGXDVELKRYZPDM-XLXQKPBQSA-N (4r)-4-[[(2s,3r)-2-[[(2r)-2-[(2r,3r,4r,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxypropanoyl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O UGXDVELKRYZPDM-XLXQKPBQSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- FBFJOZZTIXSPPR-UHFFFAOYSA-N 1-(4-aminobutyl)-2-(ethoxymethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CCCCN)C3=C(N)N=C21 FBFJOZZTIXSPPR-UHFFFAOYSA-N 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 1
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- VUFNLQXQSDUXKB-DOFZRALJSA-N 2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]ethyl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCCOC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 VUFNLQXQSDUXKB-DOFZRALJSA-N 0.000 description 1
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3h-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
- HFHIDKQMGIGARX-UHFFFAOYSA-N 3,3'-(biphenyl-4,4'-diyldidiazene-2,1-diyl)bis(4-aminonaphthalene-1-sulfonic acid) Chemical compound C1=CC=CC2=C(N)C(N=NC3=CC=C(C=C3)C3=CC=C(C=C3)N=NC3=C(C4=CC=CC=C4C(=C3)S(O)(=O)=O)N)=CC(S(O)(=O)=O)=C21 HFHIDKQMGIGARX-UHFFFAOYSA-N 0.000 description 1
- FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ZNJCSEFGCLYXFM-UHFFFAOYSA-N 4-amino-2-[(4-amino-5-hydroxy-1,3-disulfonaphthalen-2-yl)diazenyl]-5-hydroxynaphthalene-1,3-disulfonic acid Chemical compound N(=NC1=C(C2=CC=CC(=C2C(=C1S(=O)(=O)O)N)O)S(=O)(=O)O)C1=C(C2=CC=CC(=C2C(=C1S(=O)(=O)O)N)O)S(=O)(=O)O ZNJCSEFGCLYXFM-UHFFFAOYSA-N 0.000 description 1
- HQWQVBJUIIJTRE-LKRNKTNVSA-N 4-amino-n-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide;(s)-[2,8-bis(trifluoromethyl)quinolin-4-yl]-[(2r)-piperidin-2-yl]methanol;5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine;hydron;chloride Chemical compound Cl.CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1.COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC.C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 HQWQVBJUIIJTRE-LKRNKTNVSA-N 0.000 description 1
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241001489705 Aquarius Species 0.000 description 1
- 101000705294 Arabidopsis thaliana Oxygen-evolving enhancer protein 1-2, chloroplastic Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000608319 Bebaru virus Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 241000232908 Cabassous Species 0.000 description 1
- 101100038180 Caenorhabditis briggsae rpb-1 gene Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241001660259 Cereus <cactus> Species 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241001502567 Chikungunya virus Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000222290 Cladosporium Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 101000822695 Clostridium perfringens (strain 13 / Type A) Small, acid-soluble spore protein C1 Proteins 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 102100031262 Deleted in malignant brain tumors 1 protein Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101150029662 E1 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 101150099000 EXPA1 gene Proteins 0.000 description 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102100029095 Exportin-1 Human genes 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000608297 Getah virus Species 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- 101100024440 Globodera rostochiensis MSP-3 gene Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 101000608720 Helianthus annuus 10 kDa late embryogenesis abundant protein Proteins 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000844721 Homo sapiens Deleted in malignant brain tumors 1 protein Proteins 0.000 description 1
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 101710123134 Ice-binding protein Proteins 0.000 description 1
- 101710082837 Ice-structuring protein Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 108010032038 Interferon Regulatory Factor-3 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241001137872 Leishmania sp. Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- HACHPVCYFLSKSB-UMJDSZQGSA-N ManNAz-DBCO-Pam3CSK4 Chemical compound CCCCCCCCCCCCCCCC(N[C@H](CSCC(COC(CCCCCCCCCCCCCCC)=O)OC(CCCCCCCCCCCCCCC)=O)C(N[C@H](CO)C(N[C@H](CCCCN)C(N[C@H](CCCCN)C(N[C@H](CCCCN)C(N[C@H](CCCCN)C(NCCC(N(C1)C2=CC=CC=C2C2N(C(N[C@H]([C@H](C3)O)[C@H]([C@@H]([C@@H](CO)O)O)O[C@@]3(C(O)=O)O)=O)N=NC2C2=C1C=CC=C2)=O)=O)=O)=O)=O)=O)=O)=O HACHPVCYFLSKSB-UMJDSZQGSA-N 0.000 description 1
- 101710199771 Matrix protein 1 Proteins 0.000 description 1
- 241000608292 Mayaro virus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 108010057081 Merozoite Surface Protein 1 Proteins 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 241000868135 Mucambo virus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 1
- 101100476480 Mus musculus S100a8 gene Proteins 0.000 description 1
- 101000944608 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Chaperonin GroEL 2 Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 101100151229 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) msp-4 gene Proteins 0.000 description 1
- 101100255228 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) msp-5 gene Proteins 0.000 description 1
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 1
- HCUVEUVIUAJXRB-UHFFFAOYSA-N OC1=C(C=C(CNC(CCCC=2SC=CC=2)=O)C=C1)OC Chemical compound OC1=C(C=C(CNC(CCCC=2SC=CC=2)=O)C=C1)OC HCUVEUVIUAJXRB-UHFFFAOYSA-N 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000868134 Pixuna virus Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 101000895911 Plasmodium falciparum (isolate Camp / Malaysia) Erythrocyte-binding antigen 175 Proteins 0.000 description 1
- 241001442539 Plasmodium sp. Species 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101000576807 Protobothrops flavoviridis Small serum protein 2 Proteins 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000710942 Ross River virus Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 101100119348 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) EXP1 gene Proteins 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 101100269618 Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) aliA gene Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- 102000008236 Toll-Like Receptor 7 Human genes 0.000 description 1
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 description 1
- 229940124122 Toll-like receptor 3 agonist Drugs 0.000 description 1
- 101710101607 Toxic shock syndrome toxin-1 Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000220979 Trichomonas sp. Species 0.000 description 1
- 241000223093 Trypanosoma sp. Species 0.000 description 1
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000005466 Western Equine Encephalomyelitis Diseases 0.000 description 1
- 201000005806 Western equine encephalitis Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002361 compost Substances 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000009025 developmental regulation Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 101150079015 esxB gene Proteins 0.000 description 1
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 108700002148 exportin 1 Proteins 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 238000011239 genetic vaccination Methods 0.000 description 1
- 229940085435 giardia lamblia Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 229940124669 imidazoquinoline Drugs 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000011542 interferon-beta production Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229950005634 loxoribine Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000003126 m-cell Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 101150014428 mpt64 gene Proteins 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 238000009258 post-therapy Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 101150089906 resA gene Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003970 toll like receptor agonist Substances 0.000 description 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- LZMSXDHGHZKXJD-VJANTYMQSA-N trypanothione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H]1CSSC[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)NCC(=O)NCCCNCCCCNC(=O)CNC1=O LZMSXDHGHZKXJD-VJANTYMQSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 108010068794 tyrosyl-tyrosyl-glutamyl-glutamic acid Proteins 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000011701 zinc Chemical class 0.000 description 1
- 229910052725 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
DESCRIPTION
BACKGROUND OF THE INVENTION
[0001] Vaccines are an important means for preventing and/or treating a number of diseases and disorders (e.g., viral infection, bacterial infection, and cancer). Nucleic acid-based vaccines have several advantages over protein or attenuated-live vaccines. Introduction of a nucleic acid that expresses an antigen into a target cell allows for rapid development of vaccine that generates an immune response against an antigen of interest. For protein vaccines, an effective and efficient method of protein purification needs to be developed each time a new vaccine is created. For live vaccines, a method of attenuation needs to be identified that doesn't completely stop the growth of the pathogen, yet proven to be completely safe in humans. Development of protein purification and attenuation methodologies are extremely time-consuming processes. In contrast, most nucleic acid-based vaccines can be manufactured very quickly using the same manufacturing techniques each time with just a quick change in the nucleic acid encoding the antigen of interest. Replication incompetent adenovirus is one nucleic acid-based vaccine system which is rapidly, predictably, and inexpensively made at high titer [Polo, J. M. and Dubensky, T. W, Jr., Drug Discov Today, 7(13), 719-727 (2002)]. However, the efficiency of the antigen- specific response following administration of adenoviral vectors known in the art is low. The document US6511845 describes immunization by intranasal administration of an adenovirus vector expressing an antigen, followed by one or more intranasal or intramuscular booster administration(s) of said recombinant adenovirus. The document W02005014038 describes an adjuvant effect of dsRNAon mucosal immunity induced against a subunit antigen or an inactivated antigen of a pathogen. Thus, there is a need in the art for new adenoviral vectors that can be used to efficiently elicit an immune response against an antigen of interest. The present invention satisfies these and other needs.
SUMMARY OF THE INVENTION
[0002] The invention in its broadest sense is as defined in the independent claims.
[0003] One embodiment of the invention provides a chimeric adenoviral expression vector, said vector comprising an expression cassette comprising the following elements: (a) a first promoter operably linked to a nucleic acid encoding a toll-like receptor (TLR)-3 agonist, wherein the TLR-3 agonist is heterologous dsRNA and wherein the nucleic acid encoding the TLR-3 agonist comprises a sequence selected from the group consisting of: SEQ ID NOS: 3, 4, 5, 8, 9, 10, 11, and 12; and (b) a second promoter operably linked to a nucleic acid encoding an immunogenic heterologous polypeptide. In some embodiments, the heterologous polypeptide is selected from an HIV envelope polypeptide (e.g., gp41, gp120 or gp160) and influenza HA polypeptide. In some embodiments, the first and second promoters are the same. In some embodiments, the first and second promoters are different. In some embodiments, the promoters are selected from the beta actin promoter and the CMV promoter. The invention also provides immunogenic compositions comprising the expression vector.
[0004] A further embodiment of the invention provides a chimeric adenoviral expression vector, said vector comprising an expression cassette comprising the following elements: 1. (a) a first promoter operably linked to a nucleic acid encoding a toll-like receptor-3 (TLR-3) agonist, wherein the TLR-3 agonist is heterologous dsRNA; and 2. (b) a second promoter operably linked to a nucleic acid encoding an immunogenic heterologous polypeptide for use in a method of treatment eliciting an immune response, said method comprising administering an immunogenically effective amount of the vector to a mammalian subject such as a human, wherein the immune response is directed against the heterologous polypeptide, and wherein the route of administration is selected from the group consisting of oral, intranasal, and mucosal such as vaginal. The mammalian subject is, e.g., a rodent such as a mouse, a rat, or a guinea pig or a primate such as a chimpanzee, a rhesus macaque, or a human. In some embodiments, the heterologous polypeptide is expressed in a cell selected from a dendritic cell, a microfold cell, and an intestinal epithelial cell.
[0005] A further embodiment of the invention provides an immunogenic composition, said composition comprising: 1. (a) a chimeric adenoviral expression vector comprising a promoter operably linked to a nucleic acid encoding an immunogenic heterologous polypeptide; 2. (b) a TLR-3 agonist, wherein the TLR-3 agonist is heterologous dsRNA; and 3. (c) a pharmaceutically acceptable carrier; for use in a method of treatment eliciting an immune response, said method comprising administering an immunogenically effective amount of the composition to a mammalian subject such as a human, wherein the immune response is directed against the heterologous polypeptide, and wherein the route of administration is selected from the group consisting of oral, intranasal, and mucosal such as vaginal. The mammalian subject is, e.g., a rodent such as a mouse, a rat, or a guinea pig or a primate such as a chimpanzee, a rhesus macaque, or a human.
[0006] The disclosure also provides an isolated nucleic acid comprising the sequence set forth in SEQ ID NOS: 1,2, 6, 7, 13, 14, 15,16, or 17.
BRIEF DESCRIPTION OF THE DRAWINGS
[0007]
Figure 1 illustrates data demonstrating that a chimeric adnenoviral vector of the invention (i.e., DS1) in combination with a TLR-3 agonist is more effective than a standard adenoviral vector (i.e., rAd5) at inducing an antigen specific immune response following oral vector delivery. Figure 1A illustrates data depicting the antibody titer to HIV envelope protein (i.e., gp120) at 3 weeks following oral delivery of the adenoviral vectors. Figure IB illustrates data depicting the antibody titer to HIV envelope protein (i.e., gp120) at 6 weeks following oral delivery of the adenoviral vectors.
Figure 2 illustrates data demonstrating that a chimeric adenoviral vector of the invention (i.e., DS1b or DS1c) in combination with a TLR-3 agonist is more effective at inducing an antigen specific immune response than a standard adenoviral vector (i.e., rAd5). Figure 2A illustrates data depicting the anti-GFP IgG titer at 3 weeks following oral administration of the vectors. Figure 2B illustrates data depicting the CD8+ T cell response to GFP at 10 weeks following administration of the vector at 0, 4, and 8 weeks. Figure 2C illustrates data depicting the anti-HA antibody titer at 3 weeks following oral administration of the vectors.
Figure 3 illustrates data demonstrating that the chimeric adenoviral vectors of the invention are superior for eliciting immune responses when administered non-parenterally.
Figure 3A illustrates data depicting the anti-gp120 antibody titer 3 weeks following intramuscular administration of DS1. Figure 3B illustrates data depicting the anti-HA antibody titer three weeks following intransal administration of DSIc.
Figure 4 illustrates data demonstrating that the expressed TLR-3 ligand agonists can induce activation of antigen presenting cells. Figure 4A illustrates data depicting dendritic cell activation by the expressed dsRNA TLR-3 agonist lud. Figure 4B illustrates data depicting dendritic cell activation by the expressed dsRNA TLR-3 agonists lucl and ml.
Figure 5 is a graphic illustration of the chimeric adenoviral vectors of the invention, i.e., chimeric adenoviral vectors comprising nucleic acids encoding expressed ds RNA TLR-3 agonists.
Figure 6 illustrates data demonstrating that the chimeric adenoviral vectors of the invention are effective at inducing an antigen-specific immune response following oral delivery. Figure 6 illustrates data depicting anti-gp120 antibody titer 3 weeks following oral administration of a chimeric adenoviral comprising a nucleic acid sequence encoding the dsRNA TLR-3 agonist lud.
Figure 7 illustrates data demonstrating that TLR-7/8 agonists have poor effectiveness in inducing an antigen-specific immune response.
Figure 8 illustrates data demonstrating that chimeric adenoviral vectors of the invention are effective at inducing an antigen-specific immune response following oral delivery. Figure 8A illustrates data depicting the anti-HA antibody titer 4 weeks following oral administration of a chimeric adenoviral comprising a nucleic acid sequence encoding the dsRNA TLR-3 agonist lud. Figure 8B illustrates data depicting the anti-HA antibody titer 4 weeks or 7 weeks following administration of a chimeric adenoviral comprising a nucleic acid sequence encoding the dsRNA TLR-3 agonist lud. Figure 8C illustrates data depicting the anti-HA antibody titer 3 weeks following oral or intranasal administration of a chimeric adenoviral comprising a nucleic acid sequence encoding the dsRNA TLR-3 agonist lud.
BRIEF DESCRIPTION OF THE SEQUENCES
[0008] SEQ ID NO: 1 sets forth the nucleotide sequence for the chimeric adenoviral vector DS1. SEQ ID NO:2 sets forth the nucleotide sequence for the chimeric adenoviral vector DS2. SEQ ID NO:3 sets forth a nucleotide sequence encoding a TLR-3 agonist. SEQ ID NO:4 sets forth a nucleotide sequence encoding a TLR-3 agonist. SEQ ID N0:5 sets forth a nucleotide sequence encoding a TLR-3 agonist. SEQ ID N0:6 sets forth a nucleotide sequence for a chimeric adenoviral vector comprising a nucleic acid encoding influenza HA and a nucleic acid encoding a TLR-3 agonist (luc), wherein the influenza HA and the TLR-3 agonist are in the same orientation. SEQ ID NO: 7 sets forth a nucleotide sequence for a chimeric adenoviral vector comprising a nucleic acid encoding influenza HA and a nucleic acid encoding a TLR-3 agonist (luc), wherein the influenza HA and the TLR-3 agonist are in the opposite orientation. SEQ ID NO: 8 sets forth a nucleotide sequence encoding a short hairpin RNA TLR-3 agonist. Complementary portions of the sequence are shown in capital letters and the linker sequence is shown in lower case letters. SEQ ID NO: 9 sets forth a nucleotide sequence encoding a short hairpin RNATLR-3 agonist (g1). Complementary portions of the sequence are shown in capital letters and the linker sequence is shown in lower case letters. SEQ ID NO: 10 sets forth a nucleotide sequence encoding a short hairpin RNATLR-3 agonist (luc). Complementary portions of the sequence are shown in capital letters and the linker sequence is shown in lower case letters. SEQ ID NO: 11 sets forth a nucleotide sequence encoding a short hairpin RNATLR-3 agonist (ml). Complementary portions of the sequence are shown in capital letters and the linker sequence is shown in lower case letters. SEQ ID NO: 12 sets forth a nucleotide sequence encoding a short hairpin RNATLR-3 agonist. Complementary portions of the sequence are shown in capital letters and the linker sequence is shown in lower case letters. SEQ ID NO: 13 sets forth the nucleotide sequence for the chimeric adenoviral vector DS 1c. The sequence comprises a nucleotide encoding HA(PR8/34). SEQ ID NO: 14 sets forth the nucleotide sequence for the chimeric adenoviral vector DS2beta-luc. The vector comprises a sequence encoding the TLR-3 agonist luc under the control of the beta actin promoter. The vector also comprises open cloning sites for insertion of nucleic acid sequence(s) encoding an antigen of interest. SEQ ID NO: 15 sets forth the nucleotide sequence for the chimeric adenoviral vector DS2C-luc The vector comprises a sequence encoding the TLR-3 agonist luc under the control of the CMV promoter. The vector also comprises open cloning sites for insertion of nucleic acid sequence(s) encoding an antigen of interest. SEQ ID NO: 16 sets forth the nucleotide sequence for the pShuttle vector comprising a nucleic acid sequence encoding the TLR-3 agonist luc under the control of the CMV promoter and a nucleic acid sequence encoding HA (avian flu) under the control of a separate CMV promoter. SEQ ID NO: 17 sets forth the nucleotide sequence for the chimeric adenoviral vector ND1.1 214. The nucleic acid encoding the heterologous antigen is in bold text and is flanked by a Cla I recognition site on the 5' end and a Not 1 recognition site on the 3'end. The nucleic acid sequence encoding the TLR-3 agonists is in italic, with the linker sequence in bold.
DETAILED DESCRIPTION OF THE INVENTION
[0009] The invention in its broadest sense is as defined in the independent claims. I. Introduction [0010] The present invention provides novel chimeric adenoviral vectors that can be administered non-parenterally to elicit an immune response against an antigen of interest. The chimeric adenoviral vectors of the invention comprise a nucleic acid encoding a heterologous polypeptide and a nucleic acid encoding a TLR-3 agonist. The chimeric adenoviral vectors elicit strong and effective immune responses specific for the heterologous polypeptide, particularly when administered via a non-parenteral route (e.g., orally, intranasally, or mucosally).
[0011] The invention is based on the suprising discovery that administration of dsRNA TLR-3 agonists are effective adjuvants when administered in conjunction with viral vectors. In fact, the use of dsRNA as an adjuvant for viral vectors would be counterintuitive considering that the major proposed utility of the dsRNA mimetic poly l:C was as an antiviral agent [Nemes, et al., Proc Soc Exp Biol Med. (1969) 132:776; Schafer, et al, Nature. (1970) 226:449; Fenje, et al, Nature (1970) 226:171.]. II. Definitions [0012] The term "chimeric" or "recombinant" as used herein with reference, e.g., to a nucleic acid, protein, or vector, indicates that the nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein. Thus, for example, chimeric and and recombinant vectors include nucleic acid sequences that are not found within the native (non-chimeric or non-recombinant) form of the vector. A chimeric adenoviral expression vector refers to an adenoviral expression vector comprising a nucleic acid sequence encoding a heterologous polypeptide.
[0013] An "expression vector" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.
[0014] The terms "promoter" and "expression control sequence" are used herein to refer to an array of nucleic acid control sequences that direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. Promoters include constitutive and inducible promoters. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.
[0015] The terms "TLR agonist" or "Toll-like receptor agonist" as used herein refers to a compound that binds and stimulates a Toll-like receptor including, e.g., TLR-2, TLR-3, TLR-6, TLR-7, or TLR-8. TLR agonists are reviewed in MacKichan, IAVI Report. 9:1-5 (2005) and Abreu et al., J Immunol, 174(8), 4453-4460 (2005). Agonists induce signa transduction following binding to their receptor.
[0016] The terms "TLR-3 agonist" or "Toll-like receptor 3 agonist" as used herein refers to a compound that binds and stimulates the TLR-3. TLR-3 agonists have been identified including double-stranded RNA, virally derived dsRNA, several chemically synthesized analogs to double-stranded RNA including polyinosine-polycytidylic acid (poly l:C) - polyadenylic-polyuridylic acid (poly A:U) and poly l:poly C, and antibodies (or cross-linking of antibodies) to TLR-3 that lead to IFN-beta production [Matsumoto, M, et al, Biochem Biophys Res Commun 24:1364 (2002), de Bouteiller, et al, J Biol Chem 18:38133-45 (2005)]. TLR-3 agonists also include expressed dsRNA(e.g., dsRNA encoded by a nucleic acid comprising a sequence set forth in SEQ ID NOS: 3, 7, 8, 9, 10, 11, or 12).
[0017] The terms "TLR-7/8 agonist" or "Toll-like receptor 7/8 agonist" as used herein refers to a compound that binds and stimulates either the TLR-7 or TLR-8 receptors; these receptors recognize several of same ligands. Several TLR-7/8 agonists have been identified such as viral single-stranded RNA, imiquimod, loxoribine, polyuridylic acid, or resiquimod.
[0018] The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).
[0019] The terms "nucleic acid" and "polynucleotide" are used interchangeably herein to refer to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs).
[0020] Unless otherwise indicated, a particular nucleic acid sequence also encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)). The term nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide, and polynucleotide.
[0021] Antigen- refers to a protein or part of a polypeptide chain that can be recognized by T cell receptors and/or antibodies. Typically, antigens are derived from bacterial, viral, or fungal proteins.
[0022] An "immunogenically effective dose or amount" of the of the compositions of the present invention is an amount that elicits or modulates an immune response specific for the heterologous polypeptide. Immune responses include humoral immune responses and cell-mediated immune responses. An immunogenic composition can be used therapeutically or prophylactically to treat or prevent disease at any stage.
[0023] "Humoral immune responses" are mediated by cell free components of the blood, i.e., plasma or serum; transfer of the serum or plasma from one individual to another transfers immunity.
[0024] " Cell mediated immune responses" are mediated by antigen specific lymphocytes; transfer of the antigen specific lymphocytes from one individual to another transfers immunity.
[0025] A "therapeutic dose" or "therapeutically effective amount" or "effective amount" of a chimeric adenoviral vector or a composition comprising a chimeric adenoviral vector is an amount of the vector or composition comprising the vector which prevents, alleviates, abates, or reduces the severity of symptoms of diseases and disorders associated with the source of the heterologous polypeptide (e.g., a virus, bacteria, a parasite, or a cancer).
[0026] Antibody- refers to a polypeptide encoded by an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgDand IgE, respectively.
[0027] T cells- refer to a particular class of lymphocytes that express a specific receptor (T cell receptor) encoded by a family of genes. The recognized T cell receptor genes include alpha, beta, delta, and gamma loci, and the T cell receptors typically (but not universally) recognize a combination of MHC plus a short peptide.
[0028] Adaptive immune response- refers to T cell and/or antibody recognition of antigen.
[0029] Antigen presenting cells (APCs)- as used herein refers to cells that are able to present immunogenic peptides or fragments thereof to T cells to activate or enhance an immune response. APCs include dendritic cells, macrophages, B cells, monocytes and other cells that may be engineered to be efficient APCs. Such cells may, but need not, be genetically modified to increase the capacity for presenting the antigen, to improve activation and/or maintenance of the T cell response, to have antitumor effects per se and/or to be immunologically compatible with the receiver (i.e., matched HLA haplotype). APCs may be isolated from any of a variety of biological fluids and organs including bone marrow, peripheral blood, tumor and peritumoral tissues, and may be autologous, allogeneic, syngeneic or xenogeneic cells. APCs typically utilize a receptor from the major histocompatability (MHC) locus to present short polypeptides to T cells.
[0030] Adjuvant- is a non-specific immune response enhancer. Suitable adjuvants include, for example, cholera toxin, monophosphoryl lipid A (MPL), Freund's Complete Adjuvant, Freund's Incomplete Adjuvant, Quil A, and AI(OH). Adjuvants can also be those substances that cause APC activation and enhanced presentation of T cells through secondary signaling molecules like Toll-like receptors. Examples of Toll-like receptors include the receptors that recognize double-stranded RNA, bacterial flagella, LPS, CpG DNA, and bacterial lipopeptide (Reviewed recently in [Abreu et al, J Immunol, 174(8), 4453-4460 (2005)]).
[0031] The terms “polypeptide,” "peptide” and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.
[0032] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, y-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an y carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
[0033] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
[0034] "Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence.
[0035] As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" wfnere the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.
[0036] The following eight groups each contain amino acids that are conservative substitutions for one another: 1. 1) Alanine (A), Glycine (G); 2. 2) Aspartic acid (D), Glutamic acid (E); 3. 3) Asparagine (N), Glutamine (Q); 4. 4) Arginine I, Lysine (K); 5. 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6. 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7. 7) Serine (S), Threonine (T); and 8. 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).
[0037] The phrase "selectively (or specifically) hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA).
[0038] The phrase "stringent hybridization conditions" refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acid, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point I for the specific sequence at a defined ionic strength Ph. The Tm is the temperature (under defined ionic strength, Ph, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at Tm, 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at Ph 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background, optionally 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5xSSC, 1% SDS, incubating at 65°C, with wash in 0.2xSSC, and 0.1% SDS at 65°C.
[0039] Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary "moderately stringent hybridization conditions" include a hybridization in a buffer of 40% formamide, 1 M NaCI, 1 % SDS at 37°C, and a wash in 1X SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency.
[0040] "Antibody" refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.
[0041] An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kDa) and one " heavy" chain (about 50-70 kDa). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (V|_) and variable heavy chain (Vh) refer to these light and heavy chains respectively.
[0042] The phrase "specifically (or selectively) binds" to an antibody or "specifically (or selectively) immunoreactive with," when referring to a protein or peptide, refers to a binding reaction that is determinative of the presence of the protein in a heterogeneous population of proteins and other biologies. Thus, under designated immunoassay conditions, the specified antibodies bind to a particular protein at least two times the background and do not substantially bind in a significant amount to other proteins present in the sample. Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein. For example, polyclonal antibodies raised to fusion proteins can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive with fusion protein and not with individual components of the fusion proteins. This selection may be achieved by subtracting out antibodies that cross-react with the individual antigens. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual (1988), for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity). Typically a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 to 100 times background.
[0043] Polynucleotides may comprise a native sequence (/.e., an endogenous sequence that encodes an individual polypeptide or dsRNAor a portion thereof) or may comprise a variant of such a sequence. Polynucleotide variants may contain one or more substitutions, additions, deletions and/or insertions such that the biological activity of the encoded polypeptide is not diminished, relative to a polypeptide comprising native antigens. Polynucleotide variants may contain one or more substitutions, additions, deletions and/or insertions such that the TLR-3 agonist activity of the encoded dsRNA is not diminished, relative to a dsRNA that does not contain the substitutions, additions, deletions and/or insertions. Variants preferably exhibit at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, to a polynucleotide sequence that encodes a native polypeptide or a portion thereof or to a polynucleotide sequence that encodes a dsRNA with TLR-3 agonist activity..
[0044] The terms "identical” or percent "identity," in the context of two or more nucleic acids (e.g., a dsRNA that is a TLR-3 agonist) or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more identity over a specified region), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Such sequences are then said to be "substantially identical." This definition also refers to the compliment of a test sequence. Optionally, the identity exists over a region that is at least about 10 to about 100, about 20 to about 75, about 30 to about 50 amino acids or nucleotides in length.
[0045] For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.
[0046] A "comparison window", as used herein, includes reference to a segment of any one of the number of contiguous positions from about 10 to about 500, about 25 to about 200, 50 to about 150, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTAin the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wl), or by manual alignment and visual inspection (see, e.g., Current Protocols in Molecular Biology (Ausubel et al., eds. 1995 supplement)).
[0047] One example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a tree or dendogram showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng & Doolittle, J. Mol. Evol. 35:351-360 (1987). The method used is similar to the method described by Higgins & Sharp, CABIOS 5:151-153 (1989). The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or amino acids. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. Using PILEUP, a reference sequence is compared to other test sequences to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps. PILEUP can be obtained from the GCG sequence analysis software package, e.g., version 7.0 (Devereauxet al., Nuc. Acids Res. 12:387-395 (1984).
[0048] Another example of algorithm that is suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol. 215:403-410 (1990), respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity Xfrom its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) or 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.
[0049] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001. III. Compositions of the Present Invention [0050] The invention provides compositions comprising chimerical adenoviral vectors. In some embodiments, the chimeric adenoviral vectors of the invention comprise a first promoter operably linked to a nucleic acid encoding a heterologous polypeptide and a second promoter operably linked to a nucleic acid encoding a TLR3 agonist. The first and second promoters may be the same or different. In some embodiments, the first and second promoters are independently selected from: the beta actin promoter and the CMV promoter.
[0051] In some aspects of the invention, the chimeric adenoviral vector comprises the adenoviral genome (minus the E1 and E3 genes) and a nucleic acid encoding a a gene that activates IRF-3 and other signaling molecules downstream of TLR-3. The chimeric vector can be administered to a cell that expresses Ad's E1 gene such that recombinant adenovirus (rAd) is produced by the cell. This rAd can be harvested and is capable of a single round of infection that will deliver the transgenic compostion to another cell within a mammal in order to elicit immune responses to the heterologous polypeptide. A Suitable Adenoviral Vectors [0052] In some embodiments, the adenoviral vector is adenovirus 5, including, for example, Ad5 with deletions of the E1/E3 regions and Ad5 with a deletion of the E4 region. Other suitable adenoviral vectors include strains 2, orally tested strains 4 and 7, enteric adenoviruses 40 and 41, and other strains (e.g. Ad34) that are sufficient for delivering an antigen and eliciting an adaptive immune response to the transgene antigen [Lubeck et al., Proc Natl Acad Sci USA, 86(17), 6763-6767 (1989); Shen et al., J Virol, 75(9), 4297-4307 (2001); Bailey et al., Virology, 202(2), 695-706 (1994)]. In some embodiments, the adenoviral vector is a live, replication incompetent adenoviral vector (such as E1 and E3 deleted rAd5), live and attenuated adenoviral vector (such as the E1B55K deletion viruses), or a live adenoviral vector with wild-type replication.
[0053] The transcriptional and translational control sequences in expression vectors to be used in transforming vertebrate cells in vivo may be provided by viral sources. For example, commonly used promoters and enhancers are derived, e.g., from beta actin, adenovirus, simian virus (SV40), and human cytomegalovirus (CMV). For example, vectors allowing expression of proteins under the direction of the CMV promoter, SV40 early promoter, SV40 later promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, transducer promoter, or other promoters shown effective for expression in mammalian cells are suitable. Further viral genomic promoter, control and/or signal sequences may be used, provided such control sequences are compatible with the host cell chosen. B. Heterologous Polypeptides [0054] Nucleic acids encoding suitable heterologous polypeptides may be derived from antigens, such as, for example, viral antigens, bacterial antigens, cancer antigens, fungal antigens, or parasite antigens.
[0055] Viral antigens may be derived from, for example, human immunodeficiency virus (e.g., gag (p55 and p160), pol, env (gp120 and gp41) as set forth in Shiver et al. Nature 415(6869):331 (2002); the HIV genomic sequences set forth in Genbank Accession Nos. EF363127; EF363126; EF363125; EF363124; EF363123; EF363122; EF192592; and EF192591; the HIV gag sequences set forth in Genbank Accession Nos. EF396891; EF396890; EF396889; EF396888; EF396887; EF396886; EF396885; EF396884; EF396883; EF396882; EF396881; EF396880; EF396879; EF396878; EF396877; EF396876; EF39687; EF396874; EF396873; and EF396872; the HIV pol sequences set forth in Genbank Accession Nos. EF396810; EF396809; EF396808; EF396807; EF396806; EF396805; EF396804; EF396803; EF396802; EF396801; EF396800; EF396799; EF396798; EF396797; EF396796; EF396795; EF396794; EF396793; EF396792; and EF396791; and the HIV env sequences set forth in Genbank Accession Nos. 9: EF367234; EF367233; EF367232; EF367231; EF367230; EF367229; EF367228; EF367227; EF367226; EF367225; EF367224; and EF367223, human papilloma virus (e.g., capsid protein L1 as described in, e.g., Donnelly et al. J Infect Dis. 173:314 (1996) and the sequences set forth in Genbank Accession Nos. EF362755; EF362754; NC 001694; NC 001693; NC_001691; NC_001690; NC_005134; NC_001458; NC_001457; NC_001354; NC_001352; NC_001526; and X94164), Epstein Barr virus, herpes simplex virus, human herpes virus, rhinoviruses, cocksackieviruses, enteroviruses, hepatitis A, B, C, and E (e.g., hepatitis B surface antigen as described in e.g., Lubeck et al, PNAS USA86:6763 (1989) and the sequences set forth in GenBank Accession Nos. AB236481; AB236471; AB206501; AB206489; AB206487; AB221788; AB221777; AB221773; AR933671 ;AR933670; AB236514; AB236513; AB236512; AB236511; AB236510; AB236509; AB236508; AB236507); hepatitis C NS5 (see, e.g., Genbank Accession Nos. X59609; DQ911563; S71627; S70787; S70786; S70341; S62220; S70790; S70789; S70788; and AB204642)), mumps virus, rubella virus, measles virus, poliovirus, smallpox virus , rabies virus, and Variella-zoster virus.
Influenza antigens include, e.g., hemagluttinin (HA), matrix protein 1 (M1), and nucleoprotein (NP) (see, e.g., Donnelly, et al, Vaccine 15:865 (1997) and the influenza HA sequences set forth in Genbank Accession Nos. AB294219; AB294217; AB294215; AB294213; EF102944; EF102943; EF102942; EF102941; EF102940; EF102939; EF102938; EF102937; EF102936; EF102935; EF102934; EF102933; DQ643982; DQ464354; CY019432; CY019424; CY019416; CY019408; CY019400; CY019392; CY019384; CY019376; CY019368; CY019360; CY019352; EF124794; EF110519; EF110518; EF165066; EF165065; EF165064; and EF165063; the influenza M1 sequences set forth in Genbank Accession Nos. AB292791; CY019980; CY019972; CY019964; CY019956; CY019948; CY019940; CY019628; CY019652; CY019644; CY019932; CY019924; CY019916; CY019908; CY019900; CY019892; CY019884; CY019876; CY019868;CY019860; and the influenza NP sequences set forth in Genbank Accession Nos. AB292790; CY019461; CY019974; CY019966; CY019958; CY019950; CY019942; CY019630; CY019654; CY019646; CY019934; CY019926; CY019918 CY019910; CY019902; CY019894; CY019886; CY019878; CY019870; and CY019862.
[0056] Suitable viral antigens also include, e.g., viral nonstructural proteins. The term "Viral nonstructural protein" as used herein refers to proteins encoded by viral nucleic acid that do not encode for structural polypeptides, such as those that make capsid or the protein surrounding a virus. Non-structural proteins include those proteins that promote viral nucleic acid replication and viral gene expression such as, for example, Nonstructural proteins 1, 2, 3, and 4 (NS1, NS2, NS3, and NS4, respectively) from Venezuelan Equine encephalitis (VEE), EEE, or Semliki Forest virus [Dubensky et al., J Virol, 70(1), 508-519 (1996); Petrakova et al J Virol 2005 79(12): 7597-608; U S. Patent Nos.5,185,440; 5,739,026; 6,566,093; and 5,814,482. Several representative examples of suitable alphaviruses include Aura (ATCC VR-368), Bebaru virus (ATCC VR-600, ATCC VR-1240), Cabassou (Genbank Accession Nos. AF398387, ATCC VR-922), Chikungunya virus (ATCC VR-64, ATCC VR-1241), Eastern equine encephalomyelitis virus (Genbank Accession Nos. AY705241, AY705240, ATCC VR-65, ATCC VR-1242), Fort Morgan (ATCC VR-924), Getah virus (ATCC VR-369, ATCC VR-1243), Kyzylagach (ATCC VR-927), Mayaro (ATCC VR-66), Mayaro virus (ATCC VR-1277), Middleburg (ATCC VR-370), Mucambo virus (ATCC VR-580, ATCC VR-1244), Ndumu (ATCC VR-371), Pixuna virus (ATCC VR-372, ATCC VR-1245), Ross River virus (ATCC VR-373, ATCC VR-1246), Semliki Forest (Genbank Accession Nos. AJ251359, ATCC VR-67, ATCC VR-1247), Sindbis virus (Genbank Accession Nos. J02363, ATCC VR-68, ATCC VR-1248), Tonate (ATCC VR-925), Triniti (ATCC VR-469), Una (ATCC VR-374), Venezuelan equine encephalomyelitis (ATCC VR-69), Venezuelan equine encephalomyelitis virus (Genbank Accession Nos. AY986475, AY973944, NC 001449, ATCC VR-923, ATCC VR-1250 ATCC VR-1249, ATCC VR-532), Western equine encephalomyelitis (ATCC VR-70, ATCC VR-1251, ATCC VR-622, ATCC VR-1252), Whataroa (ATCC VR-926), and Y-62-33 (ATCC VR-375).
[0057] Bacterial antigens may be derived from, for example, Staphylococcus aureus, Staphylococcus epidermis, Helicobacter pylori, Streptococcus bovis, Streptococcus pyogenes, Streptococcus pneumoniae, Listeria monocytogenes, Mycobacterium tuberculosis, Mycobacterium leprae, Corynebacterium diphtheriae, Borrelia burgdorferi, Bacillus anthracis, Bacillus cereus, Clostridium botulinum, Clostridium difficile, Salmonella typhi, Vibrio chloerae, Haemophilus influenzae, Bordetella pertussis, Yersinia pestis, Neisseria gonorrhoeae, Treponema pallidum, Mycoplasm sp., Neisseria ransducer s, Legionella pneumophila, Rickettsia typhi, Chlamydia trachomatis, and Shigella dysenteriae, Vibrio cholera(e.g., Cholera toxin subunit B as set forth in Genbank Accession Nos. U25679; A09803; EF158842; X76391; AF390572; cholera toxin-coregulated pilus (TCP) as described in Wu et al., Infection and Immunity Vol. 69(12):7695 (2001) and as set forth in Genbank Accession Nos. NC 002505 and AE004169); Helicobacter pylorii (VacA as set forth in Genbank Accession Nos. AY848858; AF042737; AF042736; AF042735; AF042734; NC 000921; CagA as set forth in Genbank Accession Nos. AF043490; AF043489; AF043488; AF043487; NAP as set forth in Genbank Accession Nos. AF284121; AF284120; AF284119; AF284118; AF284117; AF284116; AB045143; AB045142; AF227081; AF227080; AF227079; AF227078; AF227077; AF227076; AF227075; AF227074; Hsp or catalase as set forth in Genbank Accession No. NC 000921; urease as set forth in Genbank Accession Nos. AM417610; AM417609; AM417608; AM417607; AM417606; AM417605; AM417604; AM417603; AM417602; AM417601; and AM417600; E. coli antigens as set forth in Genbank Accession Nos. NC 000913; U00096; NC 002655; BA000007; AE014075; including E. coli fimbrial antigens as set forth in Genbank Accession Nos. AB214865; AB214864; AB214863; AB214862; E. coli heat-labile enterotoxin as set forth in Genbank Accession Nos. X83966; V00275; X83966; J01646; V00275; M35581; M17873; M17874; K01995; M61015; M17894; M17101; K00433.
[0058] Parasite antigens may be derived from, for example, Giardia lamblia, Leishmania sp., Trypanosoma sp., Trichomonas sp., Plasmodium sp. (e.g., P. faciparum surface protein antigens such as pfs25 sequences as set forth in Genbank Accession Nos. XM 001347551; XD7802; AF193769; AF179423; AF154117; and AF030628, pfs28 sequences as set forth in Genbank Accession No. L25843, pfs45 sequences as set forth in Genbank Accession Nos. EF158081; EF158079; EF158078; EF158076; EF158075; and EF158085, pfs84, pfs 48/45 sequences as set forth in Genbank Accession Nos. AF356146; AF356145; AF356144; AF356143; AF356142; AF356141; AF356140; AF356139; AF356138; AF356137; AF356136; AF356135; AF356134; AF356133; AF356132; AF356131; AF356130; AF356129; AF356128; AF356127, pfs 230 sequences as set forth in Genbank Accession Nos. NC_000910; XM_001349564; AE001393; L22219; L08135; and AF269242, P. max antigens such as Pvs25 sequences as set forth in Genbank Accession Nos. DQ641509; DQ641508; DQ641507; AY639972; AY639971; AY639970; AY639969; AY639968; AY639967; AY639966; and AY639965; and Pvs28 sequences as set forth in Genbank Accession Nos. AB033364; AB033363; AB033362; AB033361; AB033360; AB033359; AB033358; AB033357; AB033356; B033355; AB033354; AB033353; AB033352; AB033351; AB033350; AB033349; AB033348; AB033347; AB033346; and AB033345), Schistosoma sp., Mycobacterium tuberculosis (e.g., Ag85 sequences as set forth in Genbank Accession Nos. AX253506; AX253504; AX253502; and AX211309; MPT64, ESAT-6, CFP10, R8307, MTB-32 MTB-39, CSP, LSA-1, LSA-3, EXP1, SSP-2, SALSA, STARR GLURP, MSP-1, MSP-2, MSP-3, MSP-4, MSP-5, MSP-8, MSP-9, AMA-1, Type 1 integral membrane protein, RESA, EBA-175, and DBA sequences as set forth in Genbank Accession Nos. BX842572; BX842573; BX842574; BX842575; BX842576; BX842577; BX842578; BX842579; BX842580; BX842581; BX842582;BX842583; BX842584 and NC_000962, HSP65 sequences as set forth in Genbank Accession Nos. AY299175; AY299174; AY299144; AF547886; and AF547885).
[0059] Cancer antigens include, for example, antigens expressed, for example, in colon cancer, stomach cancer, pancreatic cancer, lung cancer, ovarian cancer, prostate cancer, breast cancer, skin cancer (e.g., melanoma), leukemia, lymphoma, or myeloma, exemplary cancer antigens include, for example, HPV L1, HPV L2, HPV E1, HPV E2, placental alkaline phosphatase, AFP, BRCA1, Her2/neu, CA 15-3, CA 19-9, CA-125, CEA, Hcg, urokinase-type plasminogen activator (Upa), plasminogen activator inhibitor.
[0060] Fungal antigens may be derived from, for example, Tinea pedis, Tinea corporus, Tinea cruris, Tinea unguium, Cladosporium carionii, Coccidioides immitis, Candida sp., Aspergillus fumigatus, and Pneumocystis carinii.
[0061] The nucleic acids encoding immunogenic polypeptides, are typically produced by recombinant DNA methods (see, e.g., Ausubel, et al. ed. (2001) Current Protocols in Molecular Biology). For example, the DNA sequences encoding the immunogenic polypeptide can be assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, or amplified from cDNA using appropriate primers to provide a synthetic gene which is capable of being inserted in a recombinant expression vector (/.e., a plasmid vector or a viral vector) and expressed in a recombinant transcriptional unit. Once the nucleic acid encoding an immunogenic polypeptide is produced, it may be inserted into a recombinant expression vector that is suitable for in vivo or ex-vivo expression.
[0062] Recombinant expression-vectors contain a DNA sequence encoding an immunogenic polypeptide operably linked to suitable transcriptional or translational regulatory elements derived from mammalian or viral genes. Such regulatory elements include a transcriptional promoter, an optional operator sequence to control transcription, a sequence encoding suitable mRNA ribosomal binding sites, and sequences which control the termination of transcription and translation. An origin of replication and a selectable marker to facilitate recognition of transformants may additionally be incorporated. The genes utilized in the recombinant expression vectors may be divided between more than one virus such that the gene products are on two different vectors, and the vectors are used for cotransduction to provide all the gene products in trans. There may be reasons to divide up the gene products such as size limitations for insertions, or toxicity of the combined gene products to the virus produce cell-lines. C. TLR-3 Agonists [0063] In the present invention, a TLR-3 agonist that is a heterologous dsRNA is used to stimulate immune recognition of an antigen of interest. TLR-3 agonists include, for example, short hairpin RNA, virally derived RNA, short segments of RNAthat can form double-strands or short hairpin RNA, and short interfering RNA (siRNA). In one embodiment of the invention, the TLR-3 agonist is virally derived dsRNA, such as for example, a dsRNA derived from a Sindbis virus or dsRNA viral intermediates [Alexopoulou et al, Nature 413:732-8 (2001)]. In some embodiments, the TLR-3 agonists is a short hairpin RNA. Short hairpin RNA sequences typically comprise two complementary sequences joined by a linker sequence. The particular linker sequence is not a critical aspect of the invention. Any appropriate linker sequence can be used so long as it does not interfere with the binding of the two complementary sequences to form a dsRNA.
[0064] In some embodiments, the short hairpin RNA comprises a sequence set forth in SEQ ID NOS: 3, 4, 5, 8, 9, 10, 11, or 12, a sequence with substantial identity to a sequence set forth in SEQ ID NOS: 3, 4, 5, 8, 9, 10, 11, or 12, or a variant of a sequence set forth in SEQ ID NOS: 3, 4, 5, 8, 9, 10, 11, or 12. In certain embodiments, dsRNA that is a TLR-3 agonist does not encode a particular polypeptide, but produces a pro-inflammatory cytokine (e.g. IL-6, IL-8, TNF-alpha, IFN-alpha, IFN-beta) when contacted with a responder cell (e.g., a dendritic cell, a peripheral blood mononuclear cell, or a macrophage) in vitro or in-vivo. In some cases, the nucleic acid encoding the TLR-3 agonist (anexpressed dsRNA) and the chimeric adenoviral vector comprising a nucleic acid encoding a heterologous antigen are administered in the same formulation. In some embodiments, the nucleic acid encoding the TLR-3 agonist and the nucleic acid encoding the heterologous antigen are under the control of different promoters.
[0065] Several chemically synthesized analogs to double-stranded RNA are commercially available. These include polyinosine-polycytidylic acid (poly l:C), polyadenylic:polyuridylic acid (poly A:U), and poly Irpoly C. Antibodies (or cross-linking of antibodies) to TLR-3 can also lead to IFN- beta or pro-inflammatory cytokine production [Matsumoto et al, Biochem. Biophys. Res. Common. 24:1364 (2002), de Bouteiller et al, J Biol. Chem. 18:38133-45 (2005)]. Commercially available siRNA segments of any sequence can also be obtained through sources such as Invitrogen. IV. Pharmaceutical Compositions [0066] Pharmaceutical compositions comprising the vectors described herein may also contain other compounds, which may be biologically active or inactive. Polypeptides may, but need not, be conjugated to other macromolecules as described, for example, in U.S. Pat. Nos. 4,372,945 and 4,474,757. Pharmaceutical compositions may generally be used for prophylactic and therapeutic purposes. Pharmaceutical compositions may be composed of methods to protect against stomach degradation such that the administered chimeric adenoviral vector may reach the desired locations. For the oral environment, several of these are available including the Eudragit and the TimeClock release systems as well as other methods specifically designed for adenovirus [Lubeck et al., Proc Natl Acad Sci U SA, 86(17), 6763-6767 (1989); Chourasia and Jain, J Pharm Pharm Sci, 6(1), 33-66 (2003)]. There are also several methods already described for microencapsulation of DNA and drugs for oral delivery (see, e.g., U.S. Patent Publication No. 2004043952). In some embodiments, the Eudragit system will be used to to deliver the chimeric adenoviral vecto to the lower small intestine. However, delivery to other locations of the small intestine should also work.
[0067] As noted above, the chimeric adenoviral vectors on the invention may be delivered using any delivery systems known to those of ordinary skill in the art. Numerous gene delivery techniques are well known in the art, such as those described by Rolland (1998) Crit. Rev. Therap. Drug Carrier Systems 15:143-198, and references cited therein.
[0068] It will be apparent that an immunogenic compostions may contain pharmaceutically acceptable salts of the polynucleotides encoding the heterologous polypeptides {e.g., immunogenic polypeptides). Such salts may be prepared from pharmaceutically acceptable non-toxic bases, including organic bases {e.g., salts of primary, secondary and tertiary amines and basic amino acids) and inorganic bases {e.g., sodium, potassium, lithium, ammonium, calcium and magnesium salts). Some particular examples of salts include phosphate buffered saline and saline for injection.
[0069] Any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention. Suitable carriers include, for example, water, saline, alcohol, a fat, a wax, a buffer, a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and magnesium carbonate, or biodegradable microspheres {e.g., polylactate polyglycolate). Suitable biodegradable microspheres are disclosed, for example, in U.S. Pat. Nos. 4,897,268; 5,075,109; 5,928,647; 5,811,128; 5,820,883. The immunogenic polypeptide and/or carrier virus may be encapsulated within the biodegradable microsphere or associated with the surface of the microsphere.
[0070] Such compositions may also comprise buffers (e.g., neutral buffered saline or phosphate buffered saline), carbohydrates (e.g., glucose, mannose, sucrose or dextrans), mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, bacteriostats, chelating agents such as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide), solutes that render the formulation isotonic, hypotonic or weakly hypertonic with the blood of a recipient, suspending agents, thickening agents and/or preservatives. Alternatively, compositions of the present invention may be formulated as a lyophilizate. Compounds may also be encapsulated within liposomes using well known technology.
[0071] In some disclosures, the compositions further comprise an adjuvant. Suitable adjuvants include, for example, the lipids and non-lipid compounds, cholera toxin (CT), CT subunit B, CT derivative CTK63, E. coli heat labile enterotoxin (LT), LT derivative LTK63, AI(OH)3, and polyionic organic acids as described in e.g., WO 04/020592, Anderson and Crowle, Infect. Immun. 31(1):413-418 (1981), Roterman et al, J. Physiol. Pharmacol, 44(3):213-32 (1993),Arora and Crowle, J. Reticuloendothel. 24(3):271-86 (1978), and Crowle and May, Infect. Immun. 38(3):932-7 (1982)). Suitable polyionic organic acids include for example, 6,6'-[3,3'-demithyl[l,r-biphenyl]-4,4'-diyl]bis(azo)bis[4-amino-5-hydroxy-1,3-naphthalene-disulfonic acid] (Evans Blue) and 3,3'-[1,1'biphenyl]-4,4'-diylbis(azo)bis[4-amino-1-naphthalenesulfonic acid] (Congo Red). It will be appreciated by those of skill in the art that the polyionic organic acids may be used for any genetic vaccination method in conjunction with any type of administration.
[0072] Other suitable adjuvants include topical immunomodulators such as, members of the imidazoquinoline family such as, for example, imiquimod and resiquimod (see, e.g., Hengge et al, Lancet Infect. Dis. 1(3):189-98 (2001). Expressed TLR-3 agonists (e.g., dsRNA) and TLR-7 agonists (e.g., ssRNA) could also be used.
[0073] Additional suitable adjuvants are commercially available as, for example, additional alum-based adjuvants (e.g., Alhydrogel, Rehydragel, aluminum phosphate, Algammulin); oil based adjuvants (Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Mich.), Specol, RIBI, TiterMax, Montanide ISA50 or Seppic MONTANIDE ISA 720); nonionic block copolymer-based adjuvants, cytokines (e.g., GM-CSF or Flat3-ligand); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N. J.); AS-2 (SmithKIine Beecham, Philadelphia, Pa.); salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and Quil A. Cytokines, such as GM-CSF or interleukin-2, -7, or -12, are also suitable adjuvants. Hemocyanins (e.g., keyhole limpet hemocyanin) and hemoerythrins may also be used in the invention. Polysaccharide adjuvants such as, for example, chitin, chitosan, and deacetylated chitin are also suitable as adjuvants. Other suitable adjuvants include muramyl dipeptide (MDP, N acetylmuramyl L alanyl D isoglutamine) bacterial peptidoglycans and their derivatives (e.g., threonyl-MDP, and MTPPE). BCG and BCG cell wall skeleton (CWS) may also be used as adjuvants, with or without trehalose dimycolate. Trehalose dimycolate may be used itself (see, e.g., U.S. Pat. No. 4,579,945). Detoxified endotoxins are also useful as adjuvants alone or in combination with other adjuvants (see, e.g., U.S. Pat. Nos. 4,866,034; 4,435,386; 4,505,899; 4,436,727; 4,436,728; 4,505,900; and 4,520,019. The saponins QS21, QS17, QS7 are also useful as adjuvants (see, e.g, U.S. Pat. No. 5,057,540; EP 0362 279; WO 96/33739; and WO 96/11711). Other suitable adjuvants include Montanide ISA 720 (Seppic, France), SAF (Chiron, Calif., United States), ISCOMS (CSL), MF-59 (Chiron), the SBAS series of adjuvants (e.g., SBAS-2, SBAS-4 or SBAS-6 or variants thereof, available from SmithKIine Beecham, Rixensart, Belgium), Detox (Corixa, Hamilton, Mont.), and RC-529 (Corixa, Hamilton, Mont).
[0074] Superantigens are also contemplated for use as adjuvants in the present disclosure. Superantigens include Staphylococcus exoproteins, such as the α, β, γ and Δ enterotoxins from S. aureus and S. epidermidis, and the α, β, γ and Δ E. coli exotoxins. CommonStaphylococcus enterotoxins are known as staphylococcal enterotoxin A (SEA) and staphylococcal enterotoxin B (SEB), with enterotoxins through E (SEE) being described (Rottef a/, 1992). Streptococcus pyogenes B (SEB), Clostridium perfringens enterotoxin (Bowness ei al., 1992), cytoplasmic membrane-associated protein (CAP) from S. pyogenes (Satoef al, 1994) and toxic shock syndrome toxin 1 (TSST 1) from S. aureus (Schwab ef al., 1993) are further useful superantigens.
[0075] Within the pharmaceutical compositions provided herein, the adjuvant composition can be designed to induce, e.g., an immune response predominantly of the Thl or Th2 type. High levels of Th1-type cytokines (e.g., IFN-gamma, TNF-alpha, IL-2 and IL-12) tend to favor the induction of cell mediated immune responses to an administered antigen. In contrast, high levels of Th2-type cytokines (e.g., IL-4, IL-5, IL-6 and IL-10) tend to favor the induction of humoral immune responses. Following oral delivery of a composition comprising an immunogenic polypeptide as provided herein, an immune response that includes Thl- and Th2-type responses will typically be elicited.
[0076] The compositions described herein may be administered as part of a sustained release formulation (i.e., a formulation such as a capsule or sponge that effects a slow release of compound following administration). Such formulations may generally be prepared using well known technology (see, e.g, Coombes et al. (1996) Vaccine 14:1429-1438). Sustained-release formulations may contain a polypeptide, polynucleotide or antibody dispersed in a carrier matrix and/or contained within a reservoir surrounded by a rate controlling membrane.
[0077] Carriers for use within such formulations are biocompatible, and may also be biodegradable; preferably the formulation provides a relatively constant level of active component release. Such carriers include microparticles of poly(lactide-co-glycolide), as well as polyacrylate, latex, starch, cellulose and dextran. Other delayed-release carriers include supramolecular bio vectors, which comprise a non-liquid hydrophilic core (e.g., a cross-linked polysaccharide or oligosaccharide) and, optionally, an external layer comprising an amphiphilic compound (see, e.g., WO 94/20078; WO 94/23701; and WO 96/06638). The amount of active compound contained within a sustained release formulation depends upon the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.
[0078] The pharmaceutical compositions may be presented in unit-dose or multi-dose containers, such as sealed ampoules or vials. Such containers are preferably hermetically sealed to preserve sterility of the formulation until use. In general, formulations may be stored as suspensions, solutions or emulsions in oily or aqueous vehicles. Alternatively, a pharmaceutical composition may be stored in a freeze-dried condition requiring only the addition of a sterile liquid carrier immediately prior to use. V. Therapeutic Uses of the Invention [0079] One aspect of the present invention involves the immunogenic compositions for use in a method of treatment eliciting an antigen specific immune response from a subject or patient with a disease such as, for example, a viral infection, bacterial infection, a parasitic infection, a fungal infection, or cancer. As used herein, a "subject" or a "patient" refers to any warmblooded animal, such as, for example, a rodent, a feline, a canine, or a primate, preferably a human. The immunogenic compositions may be used to treat any stage of the disease, i.e., at the pre-cancer, cancer, or metastatic stages, or to prevent disease. For example, the compositions described herein may be used to treat a viral disease such as HIV or hepatitis or for prevention or treatment of cancer. Within such methods, pharmaceutical compositions are typically administered to a patient. The patient may or may not be afflicted with the disease or disorder (e.g., a viral infection, a bacterial infection, or cancer). Accordingly, the above pharmaceutical compositions maybe used to prevent the development of a disease or disorder (e.g., a viral infection, a bacterial infection, or cancer)or to treat a patient afflicted with the disease or disorder (e.g., a viral infection, a bacterial infection, or cancer). The disease or disorder may be diagnosed using criteria generally accepted in the art. For example, viral infection may be diagnosed by the measurement of viral titer in a sample from the patient, bacterial infection may be diagnosed by detecting the bacteria in a sample from the patient, and cancer may be diagnosed by detecting the presence of a malignant tumor. Pharmaceutical compositions may be administered either prior to or following surgical removal of primary tumors and/or treatment such as administration of radiotherapy or conventional chemotherapeutic drugs.
[0080] Immunotherapy is typically active immunotherapy, in which treatment relies on the in vivo stimulation of the endogenous host immune system to react against, e.g., tumors or bacterially or virally infected cells, with the administration of immune response-modifying agents (compositions comprising nucleic acids encoding immunogenic polypeptides as provided herein).
[0081] Frequency of administration of the prophylactic or therapeutic compositions described herein, as well as dosage, will vary from individual to individual, and may be readily established using standard techniques. Often between 1 and 10 doses may be administered over a 52 week period. Typically 3 doses are administered, at intervals of 1 month, more typically, 2-3 doses are administered every 2-3 months. It is possible that the intervals will be more like once a year for certain therapies. Booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients and particular diseases and disorders. A suitable dose is an amount of a compound that, when administered as described above, is capable of promoting, e.g., an anti-tumor, an anti -viral, or an antibacterial, immune response, and is at least 10-50% above the basal (i.e., untreated) level. Such response can be monitored by measuring the anti-tumor antibodies in a patient or by vaccine-dependent generation of cytolytic T cells capable of killing, e.g., the patient's tumor cells, the patient's virally infected cells, or the patient's bacterially infected cells in vitro. Such vaccines should also be capable of causing an immune response that leads to an improved clinical outcome (e.g., more frequent remissions, complete or partial or longer disease-free survival) in vaccinated patients as compared to non-vaccinated patients. Typically, the amount of the viral titers will be between 1.0x104 pfu/animal and 1.0x1015 pfu/animal. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.01 ml to about 10 ml, more typically from about 0.025 to about 7.5 ml, most typically from about 0.05 to about 5 ml. Those of skill in the art will appreciate that the dose size may be adjusted based on the particular patient or the particular disease or disorder being treated. For oral administration, the chimeric adenoviral vector can conveniently be formulated in a pill.
[0082] In general, an appropriate dosage and treatment regimen provides the active compound(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit. Such a response can be monitored by establishing an improved clinical outcome {e.g., more frequent remissions, complete or partial, or longer disease-free survival) in treated patients as compared to non-treated patients. Such immune responses may generally be evaluated using standard proliferation, cytotoxicity or cytokine assays described above, which may be performed using samples obtained from a patient before and after treatment.
[0083] For example, detection of immunocomplexes formed between immunogenic polypeptides and antibodies in body fluid which are specific for immunogenic polypeptides may be used to monitor the effectiveness of therapy, which involves a particular immunogenic polypeptide, for a disease or disorder in which the immunogenic polypeptide is associated. Samples of body fluid taken from an individual prior to and subsequent to initiation of therapy may be analyzed for the immunocomplexes by the methodologies described above. Briefly, the number of immunocomplexes detected in both samples are compared. A substantial change in the number of immunocomplexes in the second sample (post-therapy initiation) relative to the first sample (pre-therapy) reflects successful therapy. A Administration of the Compositions of the Present Invention [0084] According to the composition for use in methods of the present invention, a composition comprising the chimeric adenoviral vector is administered orally, intranasally, or mucosally via, for example, the vagina, lungs, salivary glands, nasal cavities, small intestine, colon, rectum, tonsils, or Peyer's patches. The composition may be administered alone or with an adjuvant as described above. In some disclosures, the adjuvants are encoded by a nucleic acid sequence (e.g., a nucleic acid encoding IL-2, GM- CSF, IL- 12, of bacterial flagellin). In some disclosures, the adjuvant is administered at the same time as the composition. In other disclosures, the adjuvant is administered after the composition, e.g., 6, 12, 18, 24, 36, 48, 60, or 72 hours after administration of the composition. B. Detection of an Immune Response to Atigens of Interest [0085] An immune response to the heterologous polypeptide can be detected using any means know in the art including, for example detecting specific activation of CD4+ or CD8+ T cells or by detecting the presence of antibodies that specifically bind to the polypeptide.
[0086] Specific activation of CD4+ or CD8+ T cells associated with a mucosal, humoral, or cell-mediated immune response may be detected in a variety of ways. Methods for detecting specific T cell activation include, but are not limited to, detecting the proliferation of T cells, the production of cytokines (e.g., lymphokines), or the generation of cytolytic activity (i.e., generation of cytotoxic T cells specific for the immunogenic polypeptide). For CD4+ T cells, a preferred method for detecting specific T cell activation is the detection of the proliferation of T cells. For CD8+ T cells, a preferred method for detecting specific T cell activation is the detection of the generation of cytolytic activity using 51 Cr release assays (see, e.g., Brossart and Bevan, Blood 90(4): 1594-1599 (1997) and Lenzetal., J. Exp. Med. 192(8):1135-1142 (2000)).
[0087] Detection of the proliferation of T cells maybe accomplished by a variety of known techniques. For example, T cell proliferation can be detected by measuring the rate of DNA synthesis. T cells which have been stimulated to proliferate exhibit an increased rate of DNA synthesis. Atypical way to measure the rate of DNA synthesis is, for example, by pulse-labeling cultures of T cells with tritiated thymidine, a nucleoside precursor which is incorporated into newly synthesized DNA. The amount of tritiated thymidine incorporated can be determined using a liquid scintillation spectrophotometer. Other ways to detect T cell proliferation include measuring increases in interleukin-2 (IL-2) production, Ca2+ flux, or dye uptake, such as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium. Alternatively, synthesis of lymphokines (e.g., interferon-gamma) can be measured or the relative number of T cells that can respond to the immunogenic polypeptide may be quantified.
[0088] Antibody immune responses (aka Humoral immune responses or B cell responses), including mucosal antibody responses can be detected using immunoassays known in the art [Tucker et al., Mol Therapy, 8, 392-399 (2003); Tucker et al., Vaccine, 22, 2500-2504 (2004)]. Suitable immunoassays include the double monoclonal antibody sandwich immunoassay technique of David et al. (U.S. Pat. No. 4,376,110); monoclonal-polyclonal antibody sandwich assays (Wide et al., in Kirkham and Hunter, eds., Radioimmunoassay Methods, E. and S. Livingstone, Edinburgh (1970)); the "western blot" method of Gordon et al. (U.S. Pat. No. 4,452,901); immunoprecipitation of labeled ligand (Brown et al. (1980) J. Biol. Chem. 255:4980-4983); enzyme-linked immunosorbent assays (ELISA) as described, for example, by Raines et al. (1982) J. Biol. Chem. 257:5154-5160; immunocytochemical techniques, including the use of fluorochromes (Brooks et al. (1980) Clin. Exp. Immunol. 39:477); and neutralization of activity (Bowen-Pope et al. (1984) Proc. Natl. Acad. Sci. USA 81:2396-2400). In addition to the immunoassays described above, a number of other immunoassays are available, including those described in U.S. Pat. Nos. 3,817,827; 3,850,752; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; and 4,098,876.
EXAMPLES
[0089] The following examples are intended to illustrate, but not to limit the present invention.
Example 1: Construction of a Chimeric Adenoviral Vector <DS1> [0090] To demonstrate that TLR-3 agonists can improve adaptive immune responses to expressed antigens of interest, several different chimeric adenoviral vectors were constructed that comprise nucleic acid sequences encoding several different antigens of interest. In this example, the nucleic acid encoding gp120 (from the NIH AIDS Reagent and Reference Reagent Program) was placed under control of a CMV promoter with a small intron just upstream of the start codon in the shuttle vector (pShuttle, Qbiogene). A poly A tail from bGH was placed downstream of the nucleic acid encoding gp120. The vector sequence is set forth in SEQ ID NO: 1. Homologous recombination with the vector pAd (Qbiogene) was performed to generate a vector capable of producing recombinant Ad (E1/E3 deleted) that contained the nucleic acid encoding gp120. DS1 was generated by transfecting the newpAd-CMV-gp120 expression construct into 293 cells. Titers were measured by standard methods.
Example 2: DS1 fvector plus TLR-3 aaonistt is superior to standard rAd5 for inducing an antigen specific immune response [0091] To determine whether the addition of TLR-3 agonist could improve adaptive immune responses, 10x107 PFU of either rAd-CMV-gp120 plus 5 ug/ml poly l:C (DS1) or rAd-CMV-gp120 alone (rAd5) were administered to animals by oral gavage on weeks 0 and 3. Both vectors express HIV gp120 under control of the CMV promoter and use recombinant E1/E3 deleted adenovirus type 5. Antibody titers to gp120 were measured in the plasma 3 and 6 weeks after the initial administration by anti-gp120 IgG ELISA as described in Tucker, et a!., Mol Ther 8:392 (2004)). As shown in Figure 1, DS1 performed significantly better than rAd5 in eliciting antibody responses to the protein gp120 both at 3 and 6 weeks post initial oral administration. In particular, the average antibody titer to gp120 was 100 fold better with the DS1 group than with the rAd5 group at week 6. It also appears that the DS1 group was boosted by readministration at week 4 in that the average titer increased greater than 20 fold between weeks 3 and 6 whereas the rAd5 group showed only a slight increase in mean antibody titer. The results demonstrate that the addition of a TLR-3 agonist can greatly improve Ad5 mediated antibody responses to antigens of interest following oral administration of a chimeric adenoviral vector comprising a nucleic acid encoding the antigen of interest. As a positive control for the assay, sera from an animal injected subcutaneously with gp120 plus Complete Freund's Adjuvant was also measured in the anti-gp120 ELISA at week 3. Untreated animals and animals administered the dsRNA analog alone (dsRNA) served as negative and background controls respectively for the ELISA. Each group contained 6 animals.
Example 3: Construction of a Second Chimeric Adenoviral Vector (DS1b1 and a Third Chimeric Adenoviral Vector (DS1c1 [0092] A nucleic acid encoding green fluorescent protein (GFP) was inserted into pShuttle-CMV (Qbiogene) using standard restriction enzyme digests. The plasmid pShuttleCMV-GFP was combined by homologous recombination with the vector pAd (Qbiogene) as described before in order to generate a vector capable of producing recombinant Ad (E1/E3 deleted) comprising a nucleic acid sequence encoding GFP. A nucleic acid encoding hemagluttinin (HA) from influenza A/PR/8/34 was cloned and placed in the pShuttle-CMV vector (Qbiogene) (SEQ ID NO: 13). The plasmid pShuttleCMV-HA (PR/8) was combined by homologous recombination with the vector pAd (Qbiogene) as described before in order to generate a vector capable of producing recombinant Ad (E1/E3 deleted) comprising a nucleic acid sequence encoding HA. Recombinant Ad was generated by transfecting the new pAd-CMV-GFP and pAd-CMV-HA expression construct into 293 cells. Titers were measured by standard methods.
Example 4: DS1b (Ad-CMV-GFP plus TLR-3 agonist) and DS1c tAd-CMV-HAplus TLR-3 aaonistt is superior to standard rAd5 for inducing an antigen specific immune response.
[0093] 1.0x107 PFU of either Ad-CMV-GFP plus 5 ug/ml poly l:C (DS1b) or Ad-CMV-GFP (rAd5) were administered to animals by oral gavage on week 0. Both viruses express the GFP under control of the CMV promoter and use recombinant E1/E3 deleted adenovirus type 5. Antibody titers to GFP were measured in the plasma 3 weeks after the initial virus administration by anti-GFP
IgG ELISA. As shown in in Figure 2, the DS1b group performed significantly better than rAd5 in eliciting antibody responses to the protein GFP at 3 weeks post initial oral administration.
[0094] The CDe^T cell responses to GFP were measured by tetramer staining of splenocytes. Animals were vaccinated on weeks 0, 4, 8 and spleens were harvested on week 10. The splenocytes were stained with CD8-FITC and the tetramer which recognizes the immunodominant epitope to GFP in Balb/c mice. Results show that oral administration of the DS1b vector was statistically better than rAd alone in inducing tetramer positive CD8 cells (Figure 2b).
[0095] 1.0x107 PFU of either Ad-CMV-HA plus 5 ug/ml poly l:C (DS1c) or Ad-CMV-HA (rAd5) were administered to animals by oral gavage on week 0. Both viruses express HA under control of the CMV promoter and use recombinant E1/E3 deleted adenovirus type 5. Antibody titers to HA were measured in the plasma 3 weeks after the initial virus administration by anti-PR8/34 IgG ELISA. The procedure for measuring antibody responses is similar to that described before with the exception that the ELISA plates were coated with 5 ug/ml of whole A/PR8/34 lysate (Advanced Biotechnology Incorporated, Gaithersburg, MD). As shown in Figure 2C, the DS1c group performed significantly better (approximate 100 fold better) than rAd5 in eliciting antibody responses to influenza at 3 weeks post initial oral administration. The results of these studies also demonstrate that the approach of using TLR-3 agonist along with a chimeric recombinant adnoviral vector can be generally applied to mulitple different heterologous antigens, with a 100 fold improvement in antibody titer.
Example 5 Non-Parenteral Routes of Delivery Are Superior to Parenteral Routes [0096] Intramuscular delivery was tested by directly injecting 1.0x107 pfu of pAd-CMV-gp120 (DS10 +/- poly l:C at 5 ug/ml into the quadriceps of animals. Plasma serum IgG titers to GFP were measured as described before. Each group contained 6 animals. As shown in Figure 3A, significant antibody titers to gp120 were observed at 3 weeks post administration in the group with TLR-3 agonist (i.m. rAd+PI). (Figure 3a).
[0097] Intranasal administration was tested by administering 20 ul of 1.1x106 pfu of DS1c +/-5 ug/ml of poly l:C into the nasal cavity of mice. The mice were lightly anesthetized with isoflurane before administering the virus formulated in sterile saline. The results show that the rAd-CMV-HAplus poly l:C (DS1c) had slightly higher antibody titers compared to animals given the standard rAd-CMV-HA. Results are plotted as individual animals for the DS1c (N=6) and the rAd (N=5) groups. Untreated animals (N=4) are used for negative controls.
Example 6. Construction of an expressed TLR3 agonist.
[0098] A short 45 bp segment of DNA was synthesized by ordering of DNA oligos that when annealed together formed a 45 bp
seqment designed to make a hairpin of double-stranded RNA (GAAACGATATGGGCTGAATACGGATCCGTATTCAGCCCATATCGTTTC) (SEQ ID NO: 10). This short segment (called lud) was cloned into the plasmid pSK-containing the human beta actin promoter and a BGH poly A tail. This plasmid is called pSk-luc1.
Example 7. The pSK-Iuc 1 functions in dendritic cell cultures like polv l:C. the effects of polv l:C and rAd are additive.
[0099] To determine whether the expressed TLR-3 agonist of Example 6 above could function as an inducer of pro-inflammatory cytokines and dendritic cell maturation like the TLR-3 ligand poly l:C, an expressed dsRNATLR-3 agonist was tested in dendritic cell cultures. Bone marrow from the femurs of Balb/c mice were cultured with flt-3 ligand (200 ng/ml), 5% serum, in DMEM media in order to make primary dendritic cell cultures. Five days after primary bone marrow cultures were set-up, 293 cells were transfected with either pSk-luc1, pSK-beta2 (a long seqment of beta galactosidase that forms a 200 bp hairpin), or pcDNA3 (empty expression vector). On day 6, the transfected cells were treated by UV irradiation (20 seconds at 40 kJ/cm2) to cause apoptosis and these cells were given to the dendritic cells. Either poly l:C (1 ug/ml), rAd (1 pfu/cell), rAd + poly l:C, pSK-luc1 transfected cells, pSK-beta2 transfected cells, or pcDNA3 transfected cells were given to the dendritic cells and cultured overnight. As shown in Figure 4A, pSK-luc1 transfected cells can significantly improve dendritic cell activation as measured by the mouse IL-6 ELISA. The results of this experiment also show that the combination of rAd plus TLR3 ligand (poly l:C) together can greatly improve dendritic cell activity.
[0100] Additional ligands were also tested. The TLR-3 agonist set forth in SEQ ID NO: 11 (ml) also forms a dsRNA hairpin of approximately the same size as lud. These were made by overlapping oligonucleotides and annealing them together before cloning into the pSK-vector under control of the human beta actin promoter. The vectors were transfected into 293 cells and given to primary dendritic cells as described before. As shown in Figure 4B, these additional ligands can activate dendritic cells similar to that of the ligand lud (Figure 4B).
Example 8. Construction of a Fourth Chimeric Adenoviral Vector (DS21 and rapid cloning vectors (DS2beta-luc and DS2C-lucL
[0101] Anucleic acid encoding gp120 (from the NIH AIDS Research and Reference Reagent Program)) was placed under control of a CMV promoter with a small intran just upstream of the start codon in the shuttle vector (pShuttleCMV, Qbiogene). A poly A tail from bGH was placed downstream of the nucleic acid encoding gp120. The dsRNATLR-3 agonist lud under the control of the human beta actin promoter and poly A (described in example 5 above) was inserted into the gp120 pShuttle vector such that both the nucleic acid encoding gp120 and the nucleic acid encoding TLR-3 agonist were contained in a single vector under the control of two separate promoters. The orientation of the expression of the nucleic acid encoding the antigen of interest and the expression of the TLR-3 agonist is illustrated in Figure 5.
[0102] Two generic shuttle vectors called DS2beta-luc (SEQ ID NO: 14) and DS2C-luc (SEQ ID NO: 15) were also constructed such that a nucleic acid encoding any antigen of interest could be inserted under the CMV promoter and either the human beta actin promoter or the CMV promoter is used to drive expression of a dsRNATLR-3 agonist. In particular, the vector DS2C-luc has a unique Kpn 1 site that a nucleic acid encoding an antigen of interest can easily be cloned into. The purpose of these vectors is to make subsequent vector construction much easier because a nucleic acid encoding any antigen of interest could be inserted into the cloning site to rapidly manufacture a vector capable of eliciting antibody and T cells responses against the antigen of interest. Homologous recombination of DS2 with the vector pAd (Qbiogene) was performed as before in order to generate a vector capable of producing recombinant Ad (E1/E3 deleted) that contained a nucleic acid encoding GFP and a nucleic acid encoding the dsRNATLR-3 agonist lud. Recombinant Ad was generated by transfecting the newpAd-betaactin-luc1-CMV-gp120 expression construct into 293 cells. Titers were measured by standard methods.
Example 9: Induction of an antigen specfic immune response following oral delivery of DS2.
[0103] 1.0x107 PFU of either pAd-CMV-gp120 plus the TLR-3 agonist luc1(DS2) or pAd-CMV-gp120 (rAd5) were administered to animals by oral gavage on week. Both viruses express the gp120 under control of the CMV promoter and use recombinant E1/E3 deleted adenovirus type 5. Antibody titers to gp120 were measured in the plasma 3 weeks after virus administration by anti-gp120 IgG ELISA.The ELISA protcol has been described before (Tucker, et al, Mol Therapy 8:392 (2004)). Results demonstrate that DS2 can induce approximately a 2 log improvement in antibody titer to gp120, the heterologous antigen used in the experiment. The DS2 vector comprises a nucleic acid sequence encoding expressing gp120 and a nucleic acid sequence expressing a dsRNA TLR-3 agonist. As a positive control for the assay, sera from two animals injected subcutaneously with 10 micrograms gp120 protein plus Complete Freund's Adjuvant was also measured in the anti-gp120 ELISA. Untreated animals served as negative controls for the ELISA. Each group contained 6 animals. The results are illustrated in Figure 6.
Example 10: Induction of an antigen specfic immune response followin oral delivery of DS3.
[0104] 1.0x107 PFU of either pAd-CMV-influenza HA (from A/PR/8/34) plus the TLR7/8 ligand polyuridylic acid (DS3) or pAd-CMV-HA (rAd5) were administered to animals by oral gavage on week 0. Both viruses express influenza HA under control of the CMV promoter and use recombinant E1/E3 deleted adenovirus type 5. Antibody titers to HA were measured in the plasma 3 weeks after virus administration by anti-influenza HA IgG ELISA. Each group contained 6 animals. The results are illustrated in Figure 7.
Example 11: Construction of a fifth, sixth, and seventh chimeric adenoviral vector (DS2b. DS2b-for. and ND1.1 2141.
[0105] The gene influenza HA (A/lndo/5/2005) was synthesized by CelTek (Nashville, TN) and placed into the vector pShuttleCMV (Qbiogene) which has a CMV promoter with a small intran just upstream of the start codon in the shuttle vector. The lud DNA with human beta actin promoter and poly A (described in example 5) were placed into the vector downstream of the antigen, in the orientation shown in figure 5 for DS2b. The sequence of ludis (GAAACGATATGGGCTGAATACGGATCCGTATTCAGCCCATATCGTTTC) (SEQ ID NO: 10) and the completed pShuttle vector is set forth in SEQ ID NO: 6. An alternative orientation of lud with promoter in a shuttle vector is described as SEQ ID NO: 7 and is designated DS2b-for. We have also constructed another pShuttle vector (called DS2bC-HA) (SEQ ID NO: 16) that comprises two separate CMV promoters driving expression of the TLR-3 agonist lud and influenza HA described above. Homologous recombination with the vector pAd (Qbiogene) was performed as before in order to generate vectors capable of producing recombinant Ad (E1/E3 deleted) that contained the nucleic acid encoding HA and the TLR-3 agonist lud under separate promoters. Recombinant Ad was generated by transfecting the new pAd- constructs into 293 cells. Titers were measured by standard methods. The completed pAd vector containing DS2C-luc was named ND1.1 214 and deposited in the ATCC patent depository on Feb 22, 2007 (Manassus, VA). The nucleic acid sequence of this chimeric adenoviral vector is set forth in in SEQ ID NO: 17. The nucleic acid encoding the heterologous antigen is in bold text and is flanked by a Cla I recognition site on the 5' end and a Not 1 recognition site on the 3'end. The nucleic acid sequence encoding the TLR-3 agonists is in italic, with the linker sequence in bold. A nucleic acid sequence encoding any antigen of interest and a nucleic acid sequence encoding any suitable expressed TLR-3 agonist can be inserted into the chimeric adenoviral vector.
Example 12: Induction of an antigen specific immune response following oral delivery of DS2b.
[0106] 1.0x107 PFU of either pAd-CMV-HAplus the TLR-3 agonists lud in the reverse orientation (DS2b) or forward orientation (DS2b-for), or pAd-CMV-HA (rAd5) were administered to animals by oral gavage on week 0. These viruses express the antigen influenza HA under control of the CMV promoter and use recombinant E1/E3 deleted adenovirus type 5. Antibody titers to HA were measured in the plasma 3 weeks after virus administration by anti-HA IgG ELISA. Results demonstrate that the DS2b vector elicits an antibody responses to the protein HA greater than the standard rAd vector (rAd5). The DS2b vector contains rAd5 expressing HA as well as expresses a toll-like receptor 3 (TLR3) agonist, a hairpin of double-stranded RNA, demonstrating that the use of the encoded dsRNA ligand can improve adaptive immune responses to antigens of interest. As shown in Figure 8Aand Figure 6, expressed dsRNA can improve adaptive immune responses to multiple different heterologous antigens. Untreated animals served as negative control for the ELISA. Each group contained 6 animals.
[0107] Vectors in the opposite orientation (DS2for) were examined for antibody responses following either oral or intramuscular administration of 1.0x107 pfu virus per animal at 0 and 5 weeks. Antibody responses to HA were measured at 4 and 7 weeks post initial administation. As shown in Figure 8B, the opposite orientation vector can also induce substantial antibody responses to heterologous antigens. The DS1b and DS1b for vectors induced similar responses to HA at the 4 week time point. Significantly, the effect of boosting of the antibody response was demonstrated with the DS1b for vector and showed that multiple doses could be used to increase antibody responses to the heterologous antigen.
[0108] Another example of potential of the chimeric adenoviral vector approach was demonstrated as well. The vector ND1.1 214 was given to animals by oral (1.0x107 pfu) or intranasal administration (3x106 pfu) and the antibody responses to the heterologous antigen were measured at week 3. As shown in Figure 8C, substantial antibody responses to HA were measured following oral administration, well beyond the typical values from a single oral administration of rAd vector.
INFORMAL SEQUENCE USTING
[0109] SEQ ID NO: 1 (DS1) taacatcatc aataatatac cttattttgg attgaagcca atatgataat gagggggtgg agtttgtgac gtggcgcggg gcgtgggaac ggggcgggtg acgtagtagt gtggcggaag tgtgatgttg caagtgtggc ggaacacatg taagcgacgg atgtggcaaa agtgacgttt ttggtgtgcg ccggtgtaca caggaagtga caattttcgc gcggttttag gcggatgttg tagtaaattt gggcgtaacc gagtaagatt tggccatttt cgcgggaaaa ctgaataaga ggaagtgaaa tctgaataattttgtgttactcatagcgcgtaatactggtaccgcggccgcctcgagtctag
agatCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCC agtcacgacgttgtaaaacgacggccagtgaattgtaatacgactcactatagggcgaattg
GGTACTGGCCAcagagcttggcccattgcatacgttgtatccatatcataatatgtacattt atattggctcatgtccaacattaccgccatgttgacattgattattgactagttattaatag taatcaattacggggtcattagttcatagcccatatatggagttccgcgttacataacttac ggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataatgacgt atgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacgg taaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgt caatgacggtaaatggcccgcctggcattatgcccagtacatgaccttatgggactttccta cttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtac atcaatgggcgtggatagcggtttgactcacggggatttccaagtctccaccccattgacgt caatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtcgtaacaactccg ccccattgacgcaaatgggoggtaggcgtgtacggtgggaggtctatataagcagagctcgt ttagtgaaccgtcagatcgcctggagacgccatccacgctgttttgacctccatagaagaca ccgggaccgatccagcctgactctagCctAGCTCtgaagttggtggtgaggccctgggcagg ttggtatcaaggttacaagacaggtttaaggagaccaatagaaactgggcatgtggagacag agaagactcttgggtttctgataggcactgactctctctgcctattggtetattttcccacc cttaggctgctggtctgagcctagGAGATCTCTCGAGGTCGACGGTATAGCTTCTAGAGATC cctcgacctcgagatccattgtgctctaaaggagatacccggccagacaccctcacctgcgg
TGCCCAGCTGCCCAGGCTGAGGCAAGAGAAGGCCAGAAACCATGCCCATGGGGTCTCTGCAA ccgctggccaccttgtacctgctggggatgctggtcgcttccgtgctagctgtggagaagct gtgggtgactgtatactatggggtgcctgtgtggaaggaggccaccaccaccctgttctgtg cctctgatgccaaggcctatgacactgaggtccacaatgtctgggccacccatgcctgtgtg cccactgaccccaaccctcaggaggtggtgctggagaatgtgactgagcacttcaacatgtg gaagaacaacatggtggagcagatgcaggaggacatcatcagcctgtgggaccagagcctga agccctgtgtgaagctgacccccctgtgtgtgaccctgaactgcaaggatgtgaatgccacc aacaccaccaatgactctgagggcactatggagaggggtgagatcaagaactgcagcttcaa catcaccaccagcatcagggatgaggtgcagaaggagtatgccctgttctacaagctggatg tggtgcccattgacaacaacaacaccagctacaggctgatcagctgtgacacctctgtgatc acccaggcctgccccaagatcagctttgagcccatccccatccactactgtgcccctgctgg ctttgccatcctgaagtgcaatgacaagaccttcaatggcaaaggcccttgcaagaatgtga gcactgtgcagtgcactcatggcatcaggcctgtggtgagcacccagctgctgctgaatggc agcctggctgaggaggaggtggtgatcaggtctgacaacttcaccaacaatgccaagaccat
CATTGTGCAGC
TGAAGGAGTCTGTGGAGATCAACTGCACCAGGCCCAACAACAACACCAGGAAGAGCATTCAC
ATTGGCCCTGGCAGGGCCTTCTACACCACTGGGGAGATCATTGGGGACATCAGGCAGG
CCCACTGCAACATCAGCAGGGCCAAGTGGAATGACACCCTGAAGCAGATTGTGATCAAGCTG
AGGGAGCAGTTTGAGAACAAGACCATTGTGTTCAATCACAGCTCTGGTGGTGATCCTGAGAT
TGTGATGCACAGCTTCAACTGTGGTGGTGAGTTCTTCTACTGCAACAGCACCCAGCTGTTCA
ACAGCACCTGGAACAACAACACTGAGGGCAGCAACAACACTGAGGGCAACACCATCACCCTG CCTTGCAGGATCAAGCAGATCATCAACATGTGGCAGGAGGTGGGCAAGGCCATGTATGCTCC TCCCATCAGGGGCCAGATCAGGTGCAGCAGCAACATCACTGGCCTGCTGCTGACCAGGGATG GTGGCATCAATGAGAATGGCACTGAGATTTTCAGGCCTGGTGGTGGGGACATGAGGGACAAC TGGAGGTCTGAGCTGTACAAGTACAAGGTGGTGAAGATTGAGCCCCTTGGTGTGGCTCCCAC CAAGGCTAAGCGCAGGGTGGTGCAGAGGGAGAAGcgcgctgtgggctgaggatccCGAGGGT GAGTGCTCCTGCCTGGACGCATCCCGGCTATGCAGCCCCAGTCCAGGGCAGCAAGGCAGGCC CCGTCTGCCTCTTCACCCGGAGCCTCTGCCCGCCCCACTCATGCTCAGGGAGAGGGTCTTCT GGCTTTTTCCCAGGCTCTGGGCAGGCACAGGCTAGGTGCCCCTAACCCAGGCCCTGCACACA AAGGGGCAGGTGCTGGGCTCAGACCTGCCAAGAGCCATATCCGGGAGGACCCTGCCCCTGAC CTAAGCCCACCCCAAAGGCCAAACTCTCCACTCCCTCAGCTCGGACACCTTCTCTCCTCCCA GATTCCAGTAACTCCCAATCTTCTCTCTGCAGAGCCCAAATCTTGTGACAAAACTCACACAT GCCCACCGTGCCCAGGTAAGCCAGCCCAGGCCTCGCCCTCCAGCTCAAGGCGGGACAGGTGC CCTAGAGTAGCCTGCATCCAGGGACAGGCCCCAGCCGGGTGCTGACACGTCCACCTCCKTCT CTTCCTCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGA AGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAA AGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTCAGCGTCCTCACCGTCCTGCAC CAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCC CATCGAGAAAACCATCTCCAAAGCCAAAGGTGGGACCCGTGGGGTGCGAGGGCCACATGGAC AGAGGCCGGCTCGGCCCACCCTCTGCCCTGAGAGTGACCGCTGTACCAACCTCTGTCCTACA GGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAA CCAGGTCAGCCTGACCTGCCTGGTCAKAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGG AGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGC TCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTT CTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGT CTCCGGGTAAATGAGTGCGACGGCCGCAGGTAAGCCAGCCCAGGCCTCGCCCTCCAGCTCAA GGCGGGACAGGTGCCCTAGAGTAGCCTGCATCCAGGGACAGGCCCCAGCCGGGTGCTGACAC GTCCACCTCCATCTCTTCCTCAGGTCTGCCCGGGTGGCATCCCTGTGACCCCTCCCCAGTGC CTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGT TGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATG GAGCAAGGGGCCCAAGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAG CATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAAC TCATCAATGTATCTTATCATGTCTGgatctggg cgtggttaag 421 ggtgggaaag aatatataag gtgggggtct tatgtagttt tgtatctgtt ttgcagcagc 481 cgccgccgcc atgagcacca actcgtttga tggaagcatt gtgagctcat atttgacaac 541 gcgcatgccc ccatgggccg gggtgcgtca gaatgtgatg ggctccagca ttgatggtcg 601 ccccgtcctg cccgcaaact ctactacctt gacctacgag accgtgtctg gaacgccgtt 661 ggagactgca gcctccgccg ccgcttcagc cgctgcagcc accgcccgcg ggattgtgac 721 tgactttgct ttcctgagcc cgcttgcaag cagtgcagct tcccgttcat ccgcccgcga 781 tgacaagttg acggctcttt tggcacaatt ggattctttg acccgggaac ttaatgtcgt 841 ttctcagcag ctgttggatc tgcgccagca ggtttctgcc ctgaaggctt cctcccctcc 901 caatgcggtt taaaacataa ataaaaaacc agactctgtt tggatttgga tcaagcaagt 961 gtcttgctgt ctttatttag gggttttgcg cgcgcggtag gcccgggacc agcggtctcg 1021 gtcgttgagg gtcctgtgta ttttttocag gacgtggtaa aggtgactct ggatgttcag 1081 atacatgggc ataagcccgt ctctggggtg gaggtagcac cactgcagag cttcatgctg 1141 cggggtggtg ttgtagatga tccagtcgta gcaggagcgc tgggcgtggt gcctaaaaat 1201 gtctttcagt agcaagctga ttgccagggg caggcccttg gtgtaagtgt ttacaaagcg 1261 gttaagctgg gatgggtgca tacgtgggga tatgagatgc atcttggact gtatttttag 1321 gttggctatg ttcccagcca tatccctccg gggattcatg ttgtgcagaa ccaccagcac 1381 agtgtatccg gtgcacttgg gaaatttgtc atgtagctta gaaggaaatg cgtggaagaa 1441 cttggagacg cccttgtgac ctccaagatt ttccatgcat tcgtccataa tgatggcaat 1501 gggcccacgg gcggcggcct gggcgaagat atttctggga tcactaacgt catagttgtg 1561 ttccaggatg agatcgtcat aggccatttt tacaaagcgc gggcggaggg tgccagactg 1621 cggtataatg gttccatccg gcccaggggc gtagttaccc tcacagattt gcatttccca 1681 cgctttgagt tcagatgggg ggatcatgtc tacctgcggg gcgatgaaga aaacggtttc 1741 cggggtaggg gagatcagct gggaagaaag caggttcctg agcagctgcg acttaccgca 1801 gccggtgggc ccgtaaatca cacctattac cgggtgcaac tggtagttaa gagagctgca 1861 gctgccgtca tccctgagca ggggggccac ttcgttaagc atgtccctga ctcgcatgtt 1921 ttccctgacc aaatccgcca gaaggcgctc gccgcccagc gatagcagtt cttgcaagga 1981 agcaaagttt ttcaacggtt tgagaccgtc cgccgtaggc atgcttttga gcgtttgacc 2041 aagcagttcc aggcggtccc acagctcggt cacctgctct acggcatctc gatccagcat 2101 atctcctcgt ttcgcgggtt ggggcggctt tcgctgtacg gcagtagtcg gtgctcgtcc 2161 agacgggcca gggtcatgtc tttccacggg cgcagggtcc tcgtcagcgt agtctgggtc 2221 acggtgaagg ggtgcgctcc gggctgcgcg ctggccaggg tgcgcttgag gctggtcctg 2281 ctggtgctga agcijctgccg gtcttcgccc tgcgcgtcgg ccaggtagca tttgaccatg 2341 gtgtcatagt ccagcccctc cgcggcgtgg cccttggcgc gcagcttgcc cttggaggag 2401 gcgccgcacg aggggcagtg cagacttttg agggcgtaga gcttgggcgc gagaaatacc 2461 gattccgggg agtaggcatc cgcgccgcag gccccgcaga cggtctcgca ttccacgagc 2521 caggtgagct ctggccgttc ggggtcaaaa accaggtttc ccccatgctt tttgatgcgt 2581 ttcttacctc tggtttccat gagccggtgt ccacgctcgg tgacgaaaag gctgtccgtg 2641 tccccgtata cagacttgag agggagttta aacgaattca atagcttgtt gcatgggcgg 2701 cgatataaaa tgcaaggtgc tgctcaaaaa atcaggcaaa gcctcgcgca aaaaagaaag 2761 cacatcgtag tcatgctcat gcagataaag gcaggtaagc tccggaacca ccacagaaaa 2821 agacaccatt tttctctcaa acatgtctgc gggtttctgc ataaacacaa aataaaataa 2881 caaaaaaaca tttaaacatt agaagcctgt cttacaacag gaaaaacaac ccttataagc 2941 ataagacgga ctacggccat gccggcgtga ccgtaaaaaa actggtcacc gtgattaaaa 3001 agcaccaccg acagctcctc ggtcatgtcc ggagtcataa tgtaagactc ggtaaacaca 3061 tcaggttgat tcatcggtca gtgctaaaaa gcgaccgaaa tagcccgggg gaatacatac 3121 ccgcaggcgt agagacaaca ttacagcccc cataggaggt ataacaaaat taataggaga 3181 gaaaaacaca taaacacctg aaaaaccctc ctgcctaggc aaaatagcac cctcccgctc 3241 cagaacaaca tacagcgctt cacagcggca gcctaacagt cagccttacc agtaaaaaag 3301 aaaacctatt aaaaaaacac cactcgacac ggcaccagct caatcagtca cagtgtaaaa 3361 aagggccaag tgcagagcga gtatatatag gactaaaaaa tgacgtaacg gttaaagtcc 3421 acaaaaaaca cccagaaaac cgcacgcgaa cctacgccca gaaacgaaag ccaaaaaacc 3481 cacaacttcc tcaaatcgtc acttccgttt tcccacgtta cgtaacttcc cattttaaga 3541 aaactacaat tcccaacaca tacaagttac tccgccctaa aacctacgtc acccgccccg 3601 ttcccacgcc ccgcgccacg tcacaaactc caccccctca ttatcatatt ggcttcaatc 3661 caaaataagg tatattattg atgatgttaa ttaacatgca tggatccata tgcggtgtga 3721 aataccgcac agatgcgtaa ggagaaaata ccgcatcagg cgctcttccg cttcctcgct 3781 cactgactcg ctgcgctcgg tcgttcggct gcggcgagcg gtatcagctc actcaaaggc 3841 ggtaatacgg ttatccacag aatcagggga taacgcagga aagaacatgt gagcaaaagg 3901 ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg 3961 cccccctgac gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg 4021 actataaaga taccaggcgt ttccccctgg aagctccctc gtgcgctctc ctgttccgac 4081 cctgccgctt accggatacc tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca 4141 tagctcacgc tgtaggtatc tcagttcggt gtaggtcgtt cgctccaagc tgggctgtgt 4201 gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc 4261 caacccggta agacacgact tatcgccact ggcagcagcc actggtaaca ggattagcag 4321 agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg tggcctaact acggctacac 4381 tagaaggaca gtatttggta tctgcgctct gctgaagcca gttaccttcg gaaaaagagt 4441 tggtagctct tgatccggca aacaaaccac cgctggtagc ggtggttttt ttgtttgcaa 4501 gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct tttctacggg 4561 gtctgacgct cagtggaacg aaaactcacg ttaagggatt ttggtcatga gattatcaaa 4621 aaggatcttc acctagatcc ttttaaatta aaaatgaagt tttaaatcaa tctaaagtat 4681 atatgagtaa acttggtctg acagttacca atgcttaatc agtgaggcac ctatctcagc 4741 gatctgtcta tttcgttcat ccatagttgc ctgactcccc gtcgtgtaga taactacgat 4801 acgggagggc ttaccatctg gccccagtgc tgcaatgata ccgcgagacc cacgctcacc 4861 ggctccagat ttatcagcaa taaaccagcc agccggaagg gccgagcgca gaagtggtcc 4921 tgcaacttta tccgcctcca tccagtctat taattgttgc cgggaagcta gagtaagtag 4981 ttcgccagtt aatagtttgc gcaacgttgt tgccattgct gcagccatga gattatcaaa 5041 aaggatcttc acctagatcc ttttcacgta gaaagccagt ccgcagaaac ggtgctgacc 5101 ccggatgaat gtcagctact gggctatctg gacaagggaa aacgcaagcg caaagagaaa 5161 gcaggtagct tgcagtgggc ttacatggcg atagctagac tgggcggttt tatggacagc 5221 aagcgaaccg gaattgccag ctggggcgcc ctctggtaag gttgggaagc cctgcaaagt 5281 aaactggatg gctttctcgc cgccaaggat ctgatggcgc é^gggatcaa gctctgatca 5341 agagacagga tgaggatcgt ttcgcatgat tgaacaagat ggattgcacg caggttctcc 5401 ggccgcttgg gtggagaggc tattcggcta tgactgggca caacagacaa tcggctgctc 5461 tgatgccgcc gtgttccggc tgtcagcgca ggggcgcccg gttctttttg tcaagaccga 5521 cctgtccggt gccctgaatg aactgcaaga cgaggcagcg cggctatcgt ggctggccac 5581 gacgggcgtt ccttgcgcag ctgtgctcga cgttgtcact gaagcgggaa gggactggct 5641 gctattgggc gaagtgccgg ggcaggatct cctgtcatct caccttgctc ctgccgagaa 5701 agtatccatc atggctgatg caatgcggcg gctgcatacg cttgatccgg ctacctgccc 5761 attcgaccac caagcgaaac atcgcatcga gcgagcacgt actcggatgg aagccggtct 5821 tgtcgatcag gatgatctgg acgaagagca tcaggggctc gcgccagccg aactgttcgc 5881 caggctcaag gcgagcatgc ccgacggcga ggatctcgtc gtgacccatg gcgatgcctg 5941 cttgccgaat atcatggtgg aaaatggccg cttttctgga ttcatcgact gtggccggct 6001 gggtgtggc'g gaccgctatc aggacatagc gttggctacc cgtgatattg ctgaagagct 6061 tggcggcgaa tgggctgacc gcttcctcgt gctttacggt atcgccgctc ccgattcgca 6121 gcgcatcgcc ttctatcgcc ttcttgacga gttcttctga attttgttaa aatttttgtt 6181 aaatcagctc attttttaac caataggccg aaatcggcaa catcccttat aaatcaaaag 6241 aatagaccgc gatagggttg agtgttgttc cagtttggaa caagagtcca ctattaaaga 6301 acgtggactc caacgtcaaa gggcgaaaaa ccgtctatca QQQcgatggc ccactacgtg 6361 aaccatcacc caaatcaagt tttttgcggt cgaggtgccg taaagctcta aatcggaacc 6421 ctaaagggag cccccgattt agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg 6481 aagggaagaa agcgaaagga gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc 6541 gcgtaaccac cacacccgcg cgcttaatgc gccgctacag ggcgcgtcca ttcgccattc 6601 aggatcgaat taattcttaa t SEQ ID:2 (Vector Sequence DS2) taacatcatc aataatatac cttattttgg attgaagcca atatgataat gagggggtgg agtttgtgac gtggcgcggg gcgtgggaac ggggcgggtg acgtagtagt gtggcggaag tgtgatgttg caagtgtggc ggaacacatg taagcgacgg atgtggcaaa agtgacgttt ttggtgtgcg ccggtgtaca caggaagtga caattttcgc gcggttttag gcggatgttg tagtaaattt gggcgtaacc gagtaagatt tggccatttt cgcgggaaaa ctgaataaga ggaagtgaaa tctgaataat tttgtgttac tcatagcgcg
taatactGCTAGAgafcCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGC
CAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAATTGTAATACGACTCACTA TAGGGCGAATTGGGTACTGGCCAcagagcttggcccattgcatacgttgtatccatatcata atatgtacatttatattggctcatgtccaacattaccgccatgttgacattgattattgact agttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgt tacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcocattgacgt caataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtg gagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgcc ccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgaccttat gggactttcctacttggcagtaaatctacgfca-fctagteeatogcfcafcfcaocatggtgatgcgg ttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctcca ccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtc gtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatata agcagagctcgtttagtgaaccgtcagatcgcctggagacgccatccacgctgttttgacct ccatagaagacaccgggaccgatccagcctgactctagCctAGCTCtgaagttggtggtgag gccctgggcaggttggtatcaaggttacaagacaggtttaaggagaccaatagaaactgggc atgtggagacagagaagactcttgggtttctgataggcactgactctctctgcctattggtc
tattttcccacccttaggctgctggtctgagcctagGAGATCI’CTCGAGGTCGA.CGGTATCG
ATCGSæaCAGCTTCTAGAGATCCCTCGACCTCGAGATCCATTGTGCTCTAAAGGAGATACCC
GGCCAGACACCCTCACCTGCGGTGCCCAGCTGCCCAGGCTGAGGCAAGAGAAGGCCAGAAAC
CATGCCCATGGGGTCTCTGCAACCGCTGGCCACCTTGTACCTGCTGGGGATGCTGGTCGCTT
CCGTGCTAGCTGTGGAGAAGCTGTGGGTGACTGTATACTATGGGGTGCCTGTGTGGAAGGAG
GCCACCACCACCCTGTTCTGTGCCTCTGATGCCAAGGCCTATGACACTGAGGTCCACAATGT
CTGGGCCACCCATGCCTGTGTGCCCACTGACCCCAACCCTCAGGAGGTGGTGCTGGAGAATG
TGACTGAGCACTTCAACATGTGGAAGAACAACATGGTGGAGCAGATGCAGGAGGACATCATC
AGCCTGTGGGACCAGAGCCTGAAGCCCTGTGTGAAGCTGACCCCCCTGTGTGTGACCCTGAA
CTGCAAGGATGTGAATGCCACCAACACCACCAATGACTCTGAGGGCACTATGGAGAGGGGTG
AGATCAAGAACTGCAGCTTCAACATCACCACCAGCATCAGGGATGAGGTGCAGAAGGAGTAT
GCCCTGTTCTACAAGCTGGATGTGGTGCCCATTGACAACAACAACACCAGCTACAGGCTGAT
CAGCTGTGACACCTCTGTGATCACCCAGGCCTGCCCCAAGATCAGCTTTGAGCCCATCCCCA
TCCACTACTGTGCCCCTGCTGGCTTTGCCATCCTGAAGTGCAATGACAAGACCTTCAATGGC
AAAGGCCCTTGCAAGAATGTGAGCACTGTGCAGTGCACTCATGGCATCAGGCCTGTGGTGAG
CACCCAGCTGCTGCTGAATGGCAGCCTGGCTGAGGAGGAGGTGGTGATCAGGTCTGACAACT
TCACCAACAATGCCAAGACCATCATTGTGCAGC
TGAAGGAGTCTGTGGAGATCAACTGCACCAGGCCCAACAACAACACCAGGAAGAGCATTCAC
ATTGGCCCTGGCAGGGCCTTCTACACCACTGGGGAGATCATTGGGGACATCAGGCAGG
CCCACTGCAACATCAGCAGGGCCAAGTGGAATGACACCCTGAAGCAGATTGTGATCAAGCTG
AGGGAGCAGTTTGAGAACAAGACCATTGTGTTCAATCACAGCTCTGGTGGTGATCCTGAGAT tgtgatgcacagcttcaactgtggtggtgagttcttctactgcaacagcacccagctgttca
ACAGCACCTGGAACAACAACACTGAGGGCAGCAACAACACTGAGGGCAACACCATCACCCTG
CCTTGCAGGATCAAGCAGATCATCAACATGTGGCAGGAGGTGGGCAAGGCCATGTATGCTCC
TCCCATCAGGGGCCAGATCAGGTGCAGCAGCAACATCACTGGCCTGCTGCTGACCAGGGATG
GTGGCATCAATGAGAATGGCACTGAGATTTTCAGGCCTGGTGGTGGGGACATGAGGGACAAC
TGGAGGTCTGAGCTGTACAAGTACAAGGTGGTGAAGATTGAGCCCCTTGGTGTGGCTCCCAC
CAAGGCTAAGCGCAGGGTGGTGCAGAGGGAGAAGcgcgctgtgggctgaggatccCGAGGGT
GAGTGCTCCTGCCTGGACGCATCCCGGCTATGCAGCCCCAGTCCAGGGCAGCAAGGCAGGCC
CCGTCTGCCTCTTCACCCGGAGCCTCTGCCCGCCCCACTCATGCTCAGGGAGAGGGTCTTCT
GGCTTTTTCCCAGGCTCTGGGCAGGCACAGGCTAGGTGCCCCTAACCCAGGCCCTGCACACA
AAGGGGCAGGTGCTGGGCTCAGACCTGCCAAGAGCCATATCCGGGAGGACCCTGCCCCTGAC
CTAAGCCCACCCCAAAGGCCAAACTCTCCACTCCCTCAGCTCGGACACCTTCTCTCCTCCCA
GATTCCAGTAACTCCCAATCTTCTCTCTGCAGAGCCCAAATCTTGTGACAAAACTCACACAT
GCCCACCGTGCCCAGGTAAGCCAGCCCAGGCCTCGCCCTCCAGCTCAAGGCGGGACAGGTGC
CCTAGAGTAGCCTGCAT CCAGGGACAGGCCCCAGCCGGGTGCTGACACGT CCACCT CCATCT CTTCCTCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAG GACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGA AGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAA agccgcgggaggagcagtacaacagcacgtaccgggtggtcagcgtcctcaccgtcctgcac caggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccc catcgagaaaaccatctccaaagccaaaggtgggacccgtggggtgcgagggccacatggac AGAGGCCGGCTCGGCCCACCCTCTGCCCTGAGAGTGACCGCTGTACCAACCTCTGTCCTACA GGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAA CCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGG AGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGC TCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTT CTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGT CTCCGGGTAAATGAGTGCGACGGCCGCAGGTAAGCCAGCCCAGGCCTCGCCCTCCAGCTCAA GGCGGGACAGGTGCCCTAGAGTAGCCTGCATCCAGGGACAGGCCCCAGCCGGGTGCTGACAC GTCCACCTCCATCTCTTCCTCAGGTCTGCCCGGGTGGCATCCCTGTGACCCCTCCCCAGTGC CTCTCCTGGCCCTGGAAGXTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGT TGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATG GAGCAAGGGGCCCAAGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAG CATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAAC TCATCAATGTATCTTATCATGTCTGgatctggg cgtggttaag 421 ggtgggaaag aatatataag gtgggggtct tatgtagttt tgtatctgtt ttgcagoagc 481 cgccgccgcc atgagcacca actcgtttga tggaagcatt gtgagctcat
OGGCGGCCGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTG
TGCCTT
CTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCC
ACTCCCAC
TGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTC
TGGGGGGT
GGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGC
GGTGGGCT CTATGGCTTCTGAGGCGGAAAGAACCTATGGCTTCTGAGGCGGAAAGAACCAACCACCGCGG TGGCGGCCGCCACACAAAAAACCAACACACAGATGTAATGAAAATAAAGATATTTTATTTCT AGAGAAACGATATGGGCTGAATACGGATCCGTATTCAGCCCATATCG1TTCCTGCAGGAATT CGCCCTTTAGATATCATCGATGTCTCGGCGGTGGTGGCGCGTCGCGCCGCTGGGTTTTATAG GGCGCCGCCGCGGCCGCTCGAGCCATAAAAGGCAACTTTCGGAACGGCGCACGCTGATTGGC CCCGCGCCGCTCACTCACCGGCTTCGCCGCACAGTGCAGCATTTTTTTACCCCCTCTCCCCT CCTTTTGCGAAAAAAAAAAAGAGCGAGAGCGAGATTGAGGAAGAGGAGGAGGGAGAGTTTTG GCGTTGGCCGCCTTGGGGTGCTGGGCGTCGACGATATCTAAGGGCGAATTCGATATCAagct agctTgtegactcg aagatctggg cgtggttaag 421 ggtgggaaag aatatataag gtgggggtct tatgtagttt tgtatctgtt ttgcagcagc 481 cgccgccgcc atgagcacca actcgtttga tggaagcatt gtgagctcat atttgacaac 541 gcgcatgccc ccatgggccg gggtgcgtca gaatgtgatg ggctccagca ttgatggtcg 601 ccccgtcctg cccgcaaact ctactacctt gacctacgag accgtgtctg gaacgccgtt 661 ggagactgca gcctccgccg ccgcttcagc cgctgcagcc accgcccgcg ggattgtgac 721 tgactttgct ttcctgagcc cgcttgcaag cagtgcagct tcccgttcat ccgcccgcga 781 tgacaagttg acggctcttt tggcacaatt ggattctttg acccgggaac ttaatgtcgt 841 ttctcagcag ctgttggatc tgcgccagca ggtttctgcc ctgaaggctt cctcccctcc 901 caatgcggtt taaaacataa ataaaaaacc agactctgtt tggatttgga tcaagcaagt 961 gtcttgctgt ctttatttag gggttttgcg cgcgcggtag gcccgggacc agcggtctcg 1021 gtcgttgagg gtcctgtgta ttttttccag gacgtggtaa aggtgactct ggatgttcag 1081 atacatgggc ataagcccgt ctctggggtg gaggtagcac cactgcagag cttcatgctg 1141 cggggtggtg ttgtagatga tccagtcgta gcaggagcgc tgggcgtggt gcctaaaaat 1201 gtctttcagt agcaagctga ttgccagggg caggcccttg gtgtaagtgt ttacaaagcg 1261 gttaagctgg gatgggtgca tacgtgggga tatgagatgc atcttggact gtatttttag 1321 gttggctatg ttcccagcca tatccctccg gggattcatg ttgtgcagaa ccaccagcac 1381 agtgtatccg gtgcacttgg gaaatttgtc atgtagctta gaaggaaatg cgtggaagaa 1441 cttggagacg cccttgtgac ctccaagatt ttccatgcat tcgtccataa tgatggcaat 1501 gggcccacgg gcggcggcct gggcgaagat atttctggga tcactaacgt catagttgtg 1561 ttccaggatg agatcgtcat aggccatttt tacaaagcgc gggcggaggg tgccagactg 1621 cggtataatg gttccatccg gcccaggggc gtagttaccc tcacagattt gcatttccca 1681 cgctttgagt tcagatgggg ggatcatgtc tacctgcggg gcgatgaaga aaacggtttc 1741 cggggtaggg gagatcagct gggaagaaag caggttcctg agcagctgcg acttaccgca 1801 gccggtgggc ccgtaaatca cacctattac cgggtgcaac tggtagttaa gagagctgca 1861 gctgccgtca tccctgagca ggggggccac ttcgttaagc atgtccctga ctcgcatgtt 1921 ttccctgacc aaatccgcca gaaggcgctc gccgcccagc gatagcagtt cttgcaagga 1981 agcaaagttt ttcaacggtt tgagaccgtc cgccgtaggc atgcttttga gcgtttgacc 2041 aagcagttcc aggcggtccc acagctcggt cacctgctct acggcatctc gatccagcat 2101 atctcctcgt ttcgcgggtt ggggcggctt tcgctgtacg gcagtagtcg gtgctcgtcc 2161 agacgggcca gggtcatgtc tttccacggg cgcagggtcc tcgtcagcgt agtctgggtc 2221 acggtgaagg ggtgcgctcc gggctgcgcg ctggccaggg tgcgcttgag gctggtcctg 2281 ctggtgctga agcgctgccg gtcttcgccc tgcgcgtcgg ccaggtagca tttgaccatg 2341 gtgtcatagt ccagcccctc cgcggcgtgg cccttggcgc gcagcttgcc cttggaggag 2401 gcgccgcacg aggggcagtg cagacttttg agggcgtaga gcttgggcgc gagaaatacc 2461 gattccgggg agtaggcatc cgcgccgcag gccccgcaga cggtctcgca ttccacgagc 2521 caggtgagct ctggccgttc ggggtcaaaa accaggtttc ccccatgctt tttgatgcgt 2581 ttcttacctc tggtttccat gagccggtgt ccacgctcgg tgacgaaaag gctgtccgtg 2641 tccccgtata cagacttgag agggagttta aacgaattca atagcttgtt gcatgggcgg 2701 cgatataaaa tgcaaggtgc tgctcaaaaa atcaggcaaa gcctcgcgca aaaaagaaag 2761 cacatcgtag tcatgctcat gcagataaag gcaggtaagc tccggaacca ccacagaaaa 2821 agacaccatt tttctctcaa acatgtctgc gggtttctgc ataaacacaa aataaaataa 2881 caaaaaaaca tttaaacatt agaagcctgt cttacaacag gaaaaacaac ccttataagc 2941 ataagacgga ctacggccat gccggcgtga ccgtaaaaaa actggtcacc gtgattaaaa 3001 agcaccaccg aoagctcctc ggtcatgtcc ggagtcataa tgtaagactc ggtaaacaca 3061 tcaggttgat tcatcggtca gtgctaaaaa gcgaccgaaa tagcccgggg gaatacatac 3121 ccgcaggcgt agagacaaca ttacagcccc cataggaggt ataacaaaat taataggaga 3181 gaaaaacaca taaacacctg aaaaaccctc ctgcctaggc aaaatagcac cctcccgctc 3241 cagaacaaca tacagcgctt cacagcggca gcctaacagt cagccttacc agtaaaaaag 3301 aaaacctatt aaaaaaacac cactcgacac ggcaccagct caatcagtca cagtgtaaaa 3361 aagggccaag tgcagagcga gtatatatag gactaaaaaa tgacgtaacg gttaaagtcc 3421 acaaaaaaca cccagaaaac cgcacgcgaa cctacgccca gaaacgaaag ccaaaaaacc 3481 cacaacttcc tcaaatcgtc acttccgttt tcccacgtta cgtaacttcc cattttaaga 3541 aaactacaat tcccaacaca tacaagttac tccgccctaa aacctacgtc acccgccccg 3601 ttcccacgcc ccgcgccacg tcacaaactc caccccctca ttatcatatt ggcttcaatc 3661 caaaataagg tatattattg atgatgttaa ttaacatgca tggatccata tgcggtgtga 3721 aataccgcac agatgcgtaa ggagaaaata ccgcatcagg cgctcttccg cttcctcgct 3781 cactgactcg ctgcgctcgg tcgttcggct gcggcgagcg gtatcagctc actcaaaggc 3841 ggtaatacgg ttatccacag aatcagggga taacgcagga aagaacatgt gagcaaaagg 3901 ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg 3961 cccccctgac gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg 4021 actataaaga taccaggcgt ttocccctgg aagctccctc gtgcgctctc ctgttccgac 4081 cctgccgctt accggatacc tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca 4141 tagctcacgc tgtaggtatc tcagttcggt gtaggtcgtt cgctccaagc tgggctgtgt 4201 gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc 4261 caacccggta agacacgact tatcgccact ggcagcagcc actggtaaoa ggattagcag 4321 agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg tggcctaact acggctacac 4381 tagaaggaca gtatttggta tctgcgctct gctgaagcca gttaccttcg gaaaaagagt 4441 tggtagctct tgatccggca aacaaaccac cgctggtagc ggtggttttt ttgtttgcaa 4501 gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct tttctacggg 4561 gtctgacgct cagtggaacg aaaactcacg ttaagggatt ttggtcatga gattatcaaa 4621 aaggatcttc acctagatcc ttttaaatta aaaatgaagt tttaaatcaa tctaaagtat 4681 atatgagtaa acttggtctg acagttacca atgcttaatc agtgaggcac ctatctcagc 4741 gatctgtcta tttcgttcat ccatagttgc ctgactcccc gtcgtgtaga taactacgat 4801 acgggagggc ttaccatctg gccccagtgc tgcaatgata ccgcgagacc cacgctcacc 4861 ggctccagat ttatcagcaa taaaccagcc agccggaagg gccgagcgca gaagtggtcc 4921 tgcaacttta tccgcctcca tccagtctat taattgttgc cgggaagcta gagtaagtag 4981 ttcgccagtt aatagtttgc gcaacgttgt tgccattgct gcagccatga gattatcaaa 5041 aaggatcttc acctagatcc ttttcacgta gaaagccagt ccgcagaaac ggtgctgacc 5101 ccggatgaat gtcagctact gggctatctg gacaagggaa aacgcaagcg caaagagaaa 5161 gcaggtagct tgcagtgggc ttacatggcg atagctagac tgggcggttt tatggacagc 5221 aagcgaaccg gaattgccag ctggggcgcc ctctggtaag gttgggaagc cctgcaaagt 5281 aaactggatg gctttctcgc cgccaaggat ctgatggcgc aggggatcaa gctctgatca 5341 agagacagga tgaggatcgt ttcgcatgat tgaacaagat ggattgcacg caggttctcc 5401 ggccgcttgg gtggagaggc tattcggcta tgactgggca caacagacaa tcggctgctc 5461 tgatgccgcc gtgttccggc tgtcagcgca ggggcgcccg gttctttttg tcaagaccga 5521 cctgtccggt gccctgaatg aactgcaaga cgaggcagcg cggctatcgt ggctggccac 5581 gacgggcgtt ccttgcgcag ctgtgctcga cgttgtcact gaagcgggaa gggåctggct 5641 gctattgggc gaagtgccgg ggcaggatct cctgtcatct caccttgctc ctgccgagaa 5701 agtatccatc atggctgatg caatgcggcg gctgcatacg cttgatccgg ctacctgccc • 5761 attcgaccac caagcgaaac atcgcatcga gcgagcacgt actcggatgg aagccggtct 5821 tgtcgatcag gatgatctgg acgaagagca tcaggggctc gcgccagccg aactgttcgc 5881 caggctcaag gcgagcatgc ccgacggcga ggatctcgtc gtgacocatg gcgatgcctg 5941 cttgccgaat atcatggtgg aaaatggccg cttttctgga ttcatcgact gtggccggct 6001 gggtgtggcg gaccgctatc aggacatagc gttggctacc cgtgatattg ctgaagagct 6061 tggcggcgaa tgggctgacc gcttcctcgt gctttacggt atcgccgctc ccgattcgca 6121 gcgcatcgcc ttctatcgcc ttcttgacga gttcttctga attttgttaa aatttttgtt 6181 aaatcagctc attttttaac caataggccg aaatcggcaa catcccttat aaatcaaaag 6241 aatagaccgc gatagggttg agtgttgttc cagtttggaa caagagtcca ctattaaaga 6301 acgtggactc caacgtcaaa gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg 6361 aaccatcacc caaatcaagt tttttgcggt cgaggtgccg taaagctcta aatcggaaoc 6421 ctaaagggag cccccgattt agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg 6481 aagggaagaa agcgaaagga gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc 6541 gcgtaaccac cacacccgcg cgcttaatgc gccgctacag ggcgcgtcca ttcgccattc 6601 aggatcgaat taattcttaa t SEQ ID No:3 GAAACGATATGGGCTGAATACTTAAGTATTCAGCCCATATCGTTTC.
Seq id no:4
CGGGCCCCCCCTCGAGGTCGACGGTATCGATAAGCTTGATATCGAATTCGCCCTTAGATATC
GTCGACGCCCAGCACCCCAAGGCGGCCAACGCCAAAACTCTCCCTCCTCCTCTTCCTCAATC tcgctctcgctctttttttttttcgcaaaaggaggggagagggggtaaaaaaatgctgcact
GTGCGGCGAAGCCGGTGAGTGAGCGGCGCGGGGCCAATCAGCGTGCGCCGTTCCGAAAGTTG
CCTTTTATGGCTCGAGCGGCCGCGGCGGCGCCCTATAAAACCCAGCGGCGCGACGCGCCACC
ACCGCCGAGACATCGATGATATCTA
AAGGGCGAATTCCTGCAGCCCGGGGGATCCACTAGTCTAGATGCATGCTCGAGCGGCCGCCA
GTGTGATGGATATCTGCAGAATTCGCCCTTCAGCTGCGGATCCATTCGCCATTCAGGCTGCG
CAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGG
GATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAA
ACGACGGCCAGTGAATTGTAATACGACTCACTATAGGGCGAATTGGGTACCGGGCCCCCCCT
CGAGGTCGACGGTATCGATAAGCTTGATATCGAATTCCTGCAGCCCGGGGGATCCACTAGTT
TCTAGAAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGGCGGCCG
CCACCGCGGTGGAGCT
Atcgaattcaagcttgtcgactc gaagatc CT AG ACTAGTGGAT CCCCCGGGCTGCAGGAATT
CGCCCTTTAGATATCATCGATGTCTCGGCGGTGGTGGCGCGTCGCGCCGCTGGGTTTTATAG GGCGCCGCCGCGGCCGCTCGAGCCATAAAAGGCAACTTTCGGAACGGCGCACGCTGATTGGC CCCGCGCCGCTCACTCACCGGCTTCGCCGCACAGTGCAGCATTTTTTTACCCCCTCTCCCCT CCTTTTGCGAAAAAAAAAAAGAGCGAGAGCGAGATTGAGGAAGAGGAGGAGGGAGAGTTTTG GCGTTGGCCGCCTTGGGGTGCTGGGCGTCGACGATATCTAAGGGCGAATT C GATATCAAGC TTATCGATAC CGTCGACCTC GAGGGGGGGC CCG SEQ NO: 5
CGGGCCCCCCCTCGAGGTCGACGGTATCGATAAGCTTGATATC gaattcgcccttagatatcgtcgacgcccagcaccccaaggcggcca
ACGCCAAAACTCTCCCTCCTCCTCTTCCTCAATCTCGCTCTCGCTCTTTTTTTTTTTCGCAA
AAGGAGGGGAGAGGGGGTAAAAAAATGCTGCACTGTGCGGCGAAGCCGGTGAGTGAGCGGCG
CGGGGCCAATCAGCGTGCGCCGTTCCGAAAGTTGCCTTTTATGGCTCGAGCGGCCGCGGCGG
CGCCCTATAAAACCCAGCGGCGCGACGCGCCACCACCGCCGAGACATCGATGATATCTA
AAGGGCGAATTCCTGCAGCCCGGGGGATCCACTAGTCTAGATGCATGCTCGAGCGGCCGCCA
GTGTGATGGATATCTGCAGAATTCGCCCTT
CAGCTGCGGATCCATTCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGC
GATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGI
GCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACG
TTGTAAAACGACGGCCAGTGAATTGTAATACGACTCACTATAGGGCGAAT
TGGGTACCGGGCCCCCCCTCGAGGTCGACGGTATCGATAAGCTTGATATC
GAATTCCTGCAGCCCGGGGGATCCACTAGTT
TCTAGAAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGGCGGCCG
CCACCGCGGTGGAGCTA
Tcgaattcaagcttgtcgactc gaagatcgtaca caggaagtgacaattttcgcgcggttttaggcggatgttg tagtaaatttgggcgtaaccgagtaagatttggccattttcgcgggaaaactgaataaga ggaagtgaaatctgaataattttgtgttactcatagcgcgtaatactggtac
CGGGCCCCCCCTCGAGGTCGACGGTATCGATAAGCTTGATATC
GAATTCGCCCTTAGATATCGTCGACGCCCAGCACCCCAAGGCGGCCA
ACGCCAAAACTCTCCCTCCTCCTCTTCCTCAATCTCGCTCTCGCTCTTTTTTTTTTTCGCAA
AAGGAGGGGAGAGGGGGTAAAAAAATGCTGCACTGTGCGGCGAAGCCGGTGAGTGAGCGGCG
CGGGGCCAATCAGCGTGCGCCGTTCCGAAAGTTGCCTTTTATGGCTCGAGCGGCCGCGGCGG
CGCCCTATAAAACCCAGCGGCGCGACGCGCCACCACCGCCGAGACATCGATGATATCTA
AAGGGCGAATTCCTGCAGCCCGGGGGATCCACTAGTCTAGAACTAGTGGATCCCCCGGGCTG
CAGGAATTC
GATATCAAGCTTATCGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCA
ATTCGCCCTATAGTGAGTCGTATTACAATTCACTGGCCGTCGTTTTACAA
CGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGC
ACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATC
GCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGATCCGCAGCTG
AAGGGCGAATTCTGCAGATATCCATCACACTGGCGGCCGCTCGAGCATGCA
TCTAGAAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGGCGGCCG
CCACCGCGGTGGAGCTA SEQ ID:6 taacatcatc aataatatac cttattttgg attgaagcca atatgataat gagggggtgg agtttgtgac gtggcgcggg gcgtgggaac ggggcgggtg acgtagtagt gtggcggaag tgtgatgttg caagtgtggc ggaacacatg taagcgacgg atgtggoaaa agtgacgttt ttggtgtgcg ccggtgtaca caggaagtga caattttcgc gcggttttag gcggatgttg tagtaaattt gggcgtaacc gagtaagatt tggccatttt cgcgggaaaa ctgaataaga ggaagtgaaa tctgaataat tttgtgttac tcatagcgcg
taatactGCTAGAgatCTSGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGC CAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAATTGTAATACGACTCACTA TAGGGCGAATTGGGTACTGGCCAcagagcttggcccattgcatacgttgtatccatatcata atatgtacatttatattggctcatgtccaaoattaccgccatgttgacattgattattgact agttattaatagtaatoaattacggggtcattagttcatagcccatatatggagttccgcgt tacataacttacggtaaatggoccgcctggctgaccgcccaacgacccccgcccattgacgt caataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtg gagtatttacggtaaactgcccacttggoagtacatcaagtgtatcatatgccaagtacgcc ccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgaccttat gggactttcctacttggcagtacatctaegtattagtaatcgotattaecatggtgatgcgg ttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctcca ccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtc gtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatata agcagagctogtttagtgaaccgtcagatcgcctggagacgccatccacgctgttttgacct ccatagaagacaccgggaccgatccagcctgactctagCctAGCTCtgaagttggtggtgag gccctgggcaggttggtatcaaggttacaagacaggtttaaggagaccaatagaaactggga atgtggagacagagaagaetcttgggtttctgataggcactgactctctctgcctattggtc tattttcccacccttaggctgctggtctgagootagGAGArCTCTCSAGGTCGACGGTArcg atgcca ccATGGAGAA AATCGTCCTG TTGCTCGCTA TTGTGTCTCT
51 AGTGAAGAGC GATCAAATTT GTATCGGCTA CCATGCCAAT AACTCAACAG 101 AGCAGGTCGA TACTATCATG GAGAAAAACG TAACAGTTAC TCATGCCCAA 151 GACATCTTGG AAAAGACCCA CAACGGCAAA CTTTGCGACC TGGATGGAGT 201 GAAGCCCCTG ATCCTCCGGG ACTGTTCAGT CGCTGGTTGG CTGCTCGGGA 251 ACCCTATGTG TGATGAGTTT ATCAACGTGC CTGAATGGTC TTACATTGTG 301 GAGAAGGCTA ACCCTACCAA TGACCTCTGC TATCCTGGGT CATTTAACGA 351 TTACGAGGAA CTGAAACACC TGTTGTCTAG AATTAACCAC TTTGAAAAGA 401 TACAGATTAT ACCCAAGTCT AGTTGGAGTG ATCACGAAGC CTCCTCAGGC 451 GTTAGCTCAG CGTGTCCCTA TCTGGGCTCT CCATCCTTCT TTAGAAATGT 501 GGTCTGGTTA ATCAAAAAGA ACAGTACCTA CCCAACCATC AAAAAGTCTT 551 ATAACAATAC CAATCAGGAG GACCTGCTCG TGTTGTGGGG.TATCCATCAC 601 CCGAACGACG CCGCTGAACA GACTAGGCTG TATCAGAACC CCACTACATA 651 CATCAGTATT GGCACGAGTA CTCTGAACCA GCGATTAGTG CCAAAGATTG 701 CAACACGGAG CAAHGTAAAT GGGCAATCTG GCAGGATGGA GTTTTTCTGG 751 ACAATCTTAA AACCCAACGA TGCGATAAAT TTCGAGTCCA ATGGCAATTT 801 CATCGCCCCT GAATACGCCT ATAAGATCGT GAAAAAGGGG GACTCTGCAA 8 51 TTATGAAGTC CGAATTAGAG TATGGCAATT GCAACACGAA GTGCCAGACA 901 CCAATGGGAG CCATTAATAG CTCAATGCCC TTCCATAATA TTCATCCATT 951 GACCATTGGG GAGTGCCCAA AGTACGTGAA GTCCAACCGC CTGGTCCXCG 1001 CAACCGGTCT AAGAAATAGC CCGCAGAGAG AATCGCGGAG GAAGAAACGT 1051 GGCCTGTTTG GCGCGATTGC CGGATTCATC GAGGGAGGCT GGCAGGGTAT 1101 GGTCGATGGT TGGTACGGAT ACCACCATAG CAACGAACAG GGGTCCGGCT 1151 ATGCAGCAGA TAAGGAGAGC ACTCAGAAAG CTATTGACGG AGTTACAAAC 12 01 AAGGTTAATA GTATTATAGA TAAAATGAAC ACGCAATTCG AGGCCGTTGG 1251 GAGGGAGTTT AACAATCTGG AACGCCGGAT C G AAAAT CT G AATAAGAAAA 1301 TGGAAGACGG CTTCCTTGAC GTGTGGACTT ATAATGCAGA GCTGCTTGTA 1351 CTCATGGAGA ACGAGAGGAC CCTGGATTTC CACGATAGCA ACGTGAAGAA 1401 CCTTTACGAC AAGGTGAGAC TTCAGCTCCG AGACAACGCC AAGGAGCTGG 14 51 GGAATGGATG CTTCGAGTTT TACCACAAAT GTGACAATGA GTGCATGGAA 1501 AGTATACGCA ACGGGACCTA CAATTACCCT CAGTATAGCG AAGAGGCTCG 1551 GCTCAAACGC GAAGAGATAA GCGGGGTGAA ATTGGAATCA ATCGGEACAT 1601 ATCAAATCCT GTCCATCTAT TCCACCGTCG CCTCTTCGCT GGCCCTCGCT 1651 ATCATGATGG CTGGTCTGTC CCTATGGATG TGTTCCAATG GAAGCCTTCA 1701 GTGCCGTATT TGTATATGAg c
GGCCGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTGTGCC
TT
CTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCC
ACTCCCAC
TGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTC
TGGGGGGT
GGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGC
GGTGGGCT
CTATGGCTTCTGAGGCGGAAAGAACCAA
CCACCGCGGTGGCGGCCGCCACACAAAAAACCAACACACAGATGTAATGAAAATAAAGATAT
TTTATTTCTAGAGAAACGATATGGGCTGAATACGGATCCGTATTCAGCCCATATCGTTTCCT
GCAGGAATTCGCCCTTTAGATATCATCGATGTCTCGGCGGTGGTGGCGCGTCGCGCCGCTGG
GTTTTATAGGGCGCCGCCGCGGCCGCTCGAGCCATAAAAGGCAACTTTCGGAACGGCGCACG
CTGATTGGCCCCGCGCCGCTCACTCACCGGCTTCGCCGCACAGTGCAGCATTTTTTTACCCC
CTCTCCCCTCCTTTTGCGAAAAAAAAAAAGAGCGAGAGCGAGATTGAGGAAGAGGAGGAGGG
AGAGTTTTGGCGTTGGCCGCCTTGGGGTGCTGGGCGTCGACGATATCTAAGGGCGAATTCGA
TATCA AGCTAGCT Tgtegactcg aagatctggg cgtggttaag 421 ggtgggaaag aatatataag gtgggggtct tatgtagttt tgtatctgtt ttgcagcagc 481 cgccgccgcc atgagcacca actcgtttga tggaagoatt gtgagctcat atttgacaac 541 gcgcatgccc ccatgggccg gggtgcgtca gaatgtgatg ggctccagca ttgatggtcg 601 ccccgtcctg cccgcaaact ctactacctt gacctacgag accgtgtctg gaacgccgtt 661 ggagactgca gcctccgccg ccgcttcagc cgctgcagcc accgcccgcg ggattgtgac 721 tgactttgct ttcctgagcc cgcttgcaag cagtgcagct tcccgttcat ccgcccgcga 781 tgacaagttg acggctcttt tggcacaatt ggattctttg acccgggaac ttaatgtcgt 841 ttctcagcag ctgttggatc tgcgccagca ggtttctgcc ctgaaggctt cctcccctcc 901 caatgcggtt taaaacataa ataaaaaacc agactctgtt tggatttgga tcaagcaagt 961 gtcttgctgt ctttatttag gggttttgcg egcgcggtag gcccgggacc agcggtctcg 1021 gtcgttgagg gtcctgtgta ttttttccag gacgtggtaa aggtgactct ggatgttcag 1081 atacatgggc ataagcccgt ctctggggtg gaggtagcac cactgcagag cttcatgctg 1141 cggggtggtg ttgtagatga tccagtcgta gcaggagcgc tgggcgtggt gcctaaaaat 1201 gtctttcagt agcaagctga ttgccagggg caggcccttg gtgtaagtgt ttacaaagcg 1261 gttaagctgg gatgggtgca tacgtgggga tatgagatgc atcttggact gtatttttag 1321 gttggctatg ttcccagcca tatccctccg gggattcatg ttgtgcagaa ccaccagcac 1381 agtgtatccg gtgcacttgg gaaatttgtc atgtagctta gaaggaaatg cgtggaagaa 1441 cttggagacg cccttgtgac ctccaagatt ttccatgcat tcgtccataa tgatggcaat 1501 gggcccacgg gcggcggcct gggcgaagat atttctggga tcactaacgt catagttgtg 1561 ttccaggatg agatcgtcat aggccatttt tacaaagcgc gggcggaggg tgccagactg 1621 cggtataatg gttccatccg gcccaggggc gtagttaccc tcacagattt gcatttccca 1681 cgctttgagt tcagatgggg ggatcatgtc tacctgcggg gcgatgaaga aaacggtttc 1741 cggggtaggg gagatcagct gggaagaaag caggttcctg agcagctgcg acttaccgca 1801 gccggtgggc ccgtaaatca cacctattac cgggtgcaac tggtagttaa gagagctgca 1861 gctgccgtca tccctgagca ggggggccac ttcgttaagc atgtccctga ctcgcatgtt 1921 ttccctgacc aaatccgcca gaaggcgctc gccgcccagc gatagcagtt cttgcaagga 1981 agcaaagttt ttcaacggtt tgagaccgtc cgccgtaggc atgcttttga gcgtttgacc 2041 aagcagttcc aggcggtccc acagctcggt cacctgctct acggcatctc gatccagcat 2101 atctcctcgt ttcgcgggtt ggggcggctt tcgctgtacg gcagtagtcg gtgctcgtcc 2161 agacgggcca gggtcatgtc tttccacggg cgcagggtcc tcgtcagcgt agtctgggtc 2221 acggtgaagg ggtgcgctcc gggctgcgcg ctggccaggg tgcgcttgag gctggtcctg 2281 ctggtgctga agcgctgccg gtcttcgccc tgcgcgtcgg ccaggtagca tttgaccatg 2341 gtgtcatagt ccagcccctc cgcggcgtgg cccttggcgc gcagcttgcc cttggaggag 2401 gcgccgcacg aggggcagtg cagacttttg agggcgtaga gcttgggcgc gagaaatacc 2461 gattccgggg agtaggcatc cgcgccgcag gccccgcaga cggtctcgca ttccacgagc 2521 caggtgagct ctggccgttc ggggtcaaaa accaggtttc ccccatgctt tttgatgcgt 2581 ttcttacctc tggtttccat gagccggtgt ccacgctcgg tgacgaaaag gctgtccgtg 2641 tccccgtata cagacttgag agggagttta aacgaattca atagcttgtt gcatgggcgg 2701 cgatataaaa tgcaaggtgc tgctcaaaaa atcaggcaaa gcctcgcgca aaaaagaaag 2761 cacatcgtag tcatgctcat gcagataaag gcaggtaagc tccggaacca ccacagaaaa 2821 agacaccatt tttctctcaa acatgtctgc gggtttctgc ataaacacaa aataaaataa 2881 caaaaaaaca tttaaacatt agaagcctgt cttacaacag gaaaaacaac ccttataagc 2941 ataagacgga ctacggccat gccggcgtga ccgtaaaaaa actggtcacc gtgattaaaa 3001 agcaccaccg acagctcctc ggtcatgtcc ggagtcataa tgtaagactc ggtaaacaca 3061 tcaggttgat tcatcggtca gtgctaaaaa gcgaccgaaa tagcccgggg gaatacatac 3121 ccgcaggcgt agagacaaca ttacagcccc cataggaggt ataacaaaat taataggaga 3181 gaaaaacaca taaacacctg aaaaaccctc ctgcctaggc aaaatagcac cctcccgctc 3241 cagaacaaca tacagcgctt cacagcggca gcctaacagt cagccttacc agtaaaaaag 3301 aaaacctatt aaaaaaacac cactcgacac ggcaccagct caatcagtca cagtgtaaaa 3361 aagggccaag tgcagagcga gtatatatag gactaaaaaa tgacgtaacg gttaaagtcc 3421 acaaaaaaca cccagaaaac cgcacgcgaa cctacgccca gaaacgaaag ccaaaaaacc 3481 cacaacttcc tcaaatcgtc acttccgttt tcccacgtta cgtaacttcc cattttaaga 3541 aaactacaat tcccaacaca tacaagttac tccgccctaa aacctacgtc acccgccccg 3601 ttcccacgcc ccgcgccacg tcacaaactc caccccctca ttatcatatt ggcttcaatc 3661 caaaataagg tatattattg atgatgttaa ttaacatgca tggatccata tgcggtgtga 3721 aataccgcac agatgcgtaa ggagaaaata ccgcatcagg cgctcttccg cttcctcgct 3781 cactgactcg ctgcgctcgg tcgttcggct gcggcgagcg gtatcagctc actcaaaggc 3841 ggtaatacgg ttatccacag aatcagggga taacgcagga aagaacatgt gagcaaaagg 3901 ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg 3961 cc.cccctgac gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg 4021 actataaaga taccaggcgt ttccccctgg aagctccctc gtgcgctctc ctgttccgac 4081 cctgccgctt accggatacc tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca 4141 tagctcacgc tgtaggtatc tcagttcggt gtaggtcgtt cgctccaagc tgggctgtgt 4201 gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc 4261 caacccggta agacacgact tatcgccact ggcagcagcc actggtaaca ggattagcag 4321 agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg tggcctaact acggctacac 4381 tagaaggaca gtatttggta tctgcgctct gctgaagcca gttaccttcg gaaaaagagt 4441 tggtagctct tgatccggca aacaaaccac cgctggtagc ggtggttttt ttgtttgcaa 4501 gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct tttctacggg 4561 gtctgacgct cagtggaacg aaaactcacg ttaagggatt ttggtcatga gattatcaaa 4621 aaggatcttc acctagatcc ttttaaatta aaaatgaagt tttaaatcaa tctaaagtat 4681 atatgagtaa acttggtctg acagttacca atgcttaatc agtgaggcac ctatctcagc 4741 gatctgtcta tttcgttcat ccatagttgc ctgactcccc gtcgtgtaga taactacgat 4801 acgggagggc ttaccatctg gccccagtgc tgcaatgata ccgcgagacc cacgctcacc 4861 ggctccagat ttatcagoaa taaaccagcc agccggaagg gccgagcgca gaagtggtcc 4921 tgcaacttta tccgcctcca tccagtctat taattgttgc cgggaagcta gagtaagtag 4981 ttcgccagtt aatagtttgc gcaacgttgt tgccattgct gcagccatga gattatcaaa 5041 aaggatcttc acctagatcc ttttcacgta gaaagccagt ccgcagaaac ggtgctgacc 5101 ccggatgaat gtcagctact gggctatctg gacaagggaa aacgcaagcg caaagagaaa 5161 gcaggtagct tgcagtgggc ttacatggcg atagctagac tgggcggttt tatggacagc 5221 aagcgaaccg gaattgccag ctggggcgcc ctctggtaag gttgggaagc cctgcaaagt 5281 aaactggatg gctttctcgc cgccaaggat ctgatggcgc aggggatcaa gctctgatca 5341 agagacagga tgaggatcgt ttcgcatgat tgaacaagat ggattgcacg caggttctcc 5401 ggccgcttgg gtggagaggc tattcggcta tgactgggca caacagacaa tcggctgctc 5461 tgatgccgcc gtgttccggc tgtcagcgca ggggcgcccg gttctttttg tcaagaccga 5521 cctgtccggt gccctgaatg aactgcaaga cgaggcagcg cggctatcgt ggctggccac 5.581 gacgggcgtt ccttgcgcag ctgtgctcga cgttgtcact gaagcgggaa gggactggct 5641 gctattgggc gaagtgccgg ggcaggatct cctgtcatct caccttgctc ctgccgagaa 5701 agtatccatc atggctgatg caatgcggcg gctgcatacg cttgatccgg ctacctgccc 5761 attcgaccac caagcgaaac atcgcatcga gcgagcacgt actcggatgg aagccggtct 5821 tgtcgatcag gatgatctgg acgaagagca tcaggggctc gcgccagccg aactgttcgc 5881 caggctcaag gcgagcatgc ccgacggcga ggatctcgtc gtgacccatg gcgatgcctg 5941 cttgccgaat atcatggtgg aaaatggccg cttttctgga ttcatcgact gtggccggct 6001 gggtgtggcg gac.cgctatc aggacatagc gttggctacc cgtgatattg ctgaagagct 6061 tggcggcgaa tgggctgacc gcttcctcgt gctttacggt atcgccgctc ccgattcgca 6121 gcgcatcgcc ttctatcgcc ttcttgacga gttcttctga attttgttaa aatttttgtt 6181 aaatcagctc attttttaac caataggccg aaatcggcaa catcccttat aaatcaaaag 6241 aatagaccgc gatagggttg agtgttgttc cagtttggaa caagagtcca ctattaaaga 6301 acgtggactc caacgtcaaa gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg 6361 aaccatcacc caaatcaagt tttttgcggt cgaggtgccg taaagctcta aatcggaacc 6421 ctaaagggag cccccgattt agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg 6481 aagggaagaa agcgaaagga gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc 6541 gcgtaaccac cacacccgcg cgcttaatge gccgctacag ggcgcgtcca ttcgccattc 6601 aggatcgaat taattcttaa t SEQ ID:7 taacatcatc aataatatac cttattttgg attgaagcca atatgataat gagggggtgg agtttgtgac gtggcgcggg gcgtgggaac ggggcgggtg acgtagtagt gtggcggaag tgtgatgttg caagtgtggc ggaacacatg taagcgacgg atgtggcaaa agtgacgttt ttggtgtgcg ccggtgtaca caggaagtga caattttcgc gcggttttag gcggatgttg tagtaaattt gggcgtaacc gagtaagatt tggccatttt cgcgggaaaa ctgaataaga ggaagtgaaa tctgaataat tttgtgttac tcatagcgcg
taatactGCTAGAgatCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGC CAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAATTGTAATACGACTCACTA TAGGGCGAATTGGGTACTGGCCAcagagcttggcccattgcatacgttgtatccatatcata atatgtacatttatattggctcatgtccaacattaccgccatgttgacattgattattgact agttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgt tacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgt caataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtg gagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgcc ccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgaccttat gggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcgg ttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctcca ccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtc gtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatata agcagagctcgtttagtgaaccgtcagatcgcctggagacgccatccacgctgttttgacct ccatagaagacaccgggaccgatccagcctgactctagCctAGCTCtgaagttggtggtgag gccctgggcaggttggtatcaaggttacaagacaggtttaaggagaccaatagaaactgggc atgtggagacagagaagactcttgggtttctgataggcactgactctctctgcctattggtc tattttcccacccttaggctgctggtctgagcctagGAGArcrCTCGAGGTCGACGGTATcg atgcca ccATGGAGAA AATCGTCCTG TTGCTCGCTA TTGTGTCTCT
51 AGTGAAGAGC GATCAAATTT GTATCGGCTA CCATGCCAAT AACTCAACAG 101 AGCAGGTCGA TACTATCATG GAGAAAAACG TAACAGTTAC TCATGCCCAA 151 GACATCTTGG AAAAGACCCA CAACGGCAAA CTTTGCGACC TGGATGGAGT 201 GAAGCCCCTG ATCCTCCGGG ACTGTTCAGT CGCTGGTTGG CTGCTCGGGA 251 ACCCTATGTG T GAT GAGT TT ATCAACGTGC CTGAATGGTC TTACATTGTG 301 GAGAAGGCTA ACCCTACCAA TGACCTCTGC TATCCTGGGT CATTTAACGA 351 TTACGAGGAA CTGAAACACC TGTTGTCTAG AATTAACCAC TTTGAAAAGA 401 TACAGATTAT ACCCAAGTCT AGTTGGAGTG ATCACGAAGC CTCCTCAGGC 451 GTTAGCTCAG CGTGTCCCTA TCTGGGCTCT CCATCCTTCT TTAGAAATGT 501 GGTCTGGTTA AT C AAAAAGA ACAGTACCTA CCCAACCATC AAAAAGTCTT 551 ATAACAATAC CAATCAGGAG GACCTGCTCG TGTTGTGGGG TATCCATCAC 601 CCGAACGACG CCGCTGAACA GACTAGGCTG TATCAGAACC CCACTACATA 651 CATCAGTATT GGCACGAGTA CTCTGAACCA GCGATTAGTG CCAAAGATTG 701 CAACACGGAG CAAAGTAAAT GGGCAATCTG GCAGGATGGA GTTTTTCTGG
7 51 ACAATCTTAA AACCCAACGA TGCGATAAAT TTCGAGTCCA ATGGCAATTT 801 CATCGCCCCT GAATACGCCT ATAAGATCGT GAAAAAGGGG GACTCTGCAA
8 51 TTATGAAGTC CGAATTAGAG TATGGCAATT GCAACACGAA GTGCCAGACA 901 CCAATGGGAG CCATTAATAG CTCAATGCCC TTCCATAATA TTCATCCATT 951 GACCATTGGG GAGTGCCCAA AGTACGTGAA GTCCAACCGC CTGGTCCTCG 1001 CAACCGGTCT AAGAAATAGC CCGCAGAGAG AATCGCGGAG GAAGAAACGT 1051 GGCCTGTTTG GCGCGATTGC CGGATTCATC GAGGGAGGCT GGCAGGGTAT 1101 GGTCGATGGT TGGTACGGAT ACCACCATAG CAACGAACAG GGGTCCGGCT 1151 ATGCAGCAGA TAAGGAGAGC ACTCAGAAAG CTATTGACGG AGTTACAAAC 1201 AAGGTTAATA GTATTATAGA TAAAATGAAC ACGCAATTCG AGGCCGTTGG 1251 GAGGGAGTTT AACAATCTGG AACGCCGGAT CGAAAATCTG AATAAGAAAA 1301 TGGAAGACGG CTTCCTTGAC GTGTGGACTT ATAATGCAGA GCTGCTTGTA 1351 CTCATGGAGA ACGAGAGGAC CCTGGATTTC CACGATAGCA ACGTGAAGAA 1401 CCTTTACGAC AAGGTGAGAC TTCAGCTCCG AGACAACGCC AAGGAGCTGG 14 51 GGAATGGATG CTTCGAGTTT TACCACAAAT GTGACAATGA GTGCATGGAA 1501 AGTATACGCA ACGGGACCTA CAATTACCCT CAGTATAGCG AAGAGGCTCG 1551 GCTCAAACGC GAAGAGATAA GCGGGGTGAA ATTGGAATCA ATCGGAACAT 1601 ATCAAATCCT GTCCATCTAT TCCACCGTCG CCTCTTCGCT GGCCCTCGCT 1651 ATCATGATGG CTGGTCTGTC CCTATGGATG TGTTCCAATG GAAGCCTTCA 1701 GTGCCGTATT TGTATATGAg c
GGCCGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTGTGCC tt ctagttgccagccatctgttgtttgcccctcccccgtgccttccttgaccctggaaggtgcc
ACTCCCAC tgtcctttcctaataaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattc
TGGGGGGT
GGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGC
GGTGGGCT
CTATGGCTTCTGAGGCGGAAAGAACCAA
TGATATCGAATTCGCCCTTAGATATCGTCGACecCCAGCACCCCAAGGCGGCCAACGCCAAA
ACTCTCCCTCCTCCTCTTCCTCAATCTCGCTCTCGCTCTTTTTTTTTTTCGCAAAAGGAGGG
GAGAGGGGGTAAAAAAATGCTGCACTGTGCGGCGAAGCCGGTGAGTGAGCGGCGCGGGGCCA
ATCAGCGTGCGCCGTTCCGAAAGTTGCCTTTTATGGCTCGAGCGGCCGCGGCGGCGCCCTAT
AAAACCCAGCGGCGCGACGCGCCACCACCGCCGAGACATCGATGATATCTAAAGGGCGAATT
CCTGCAGgaaacgatatgggctgaatacggatccgtattcagcccatatcgtttcTCTAGAA
ATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGGCGGCCGCCACCGC
GGTGG agctTgtegactcg aagatctggg cgtggttaag 421 ggtgggaaag aatatataag gtgggggtct tatgtagttt tgtatctgtt ttgcagcagc 481 cgccgccgcc atgagcacca actcgtttga tggaagcatt gtgagctcat atttgacaac 541 gcgcatgccc ccatgggccg gggtgcgtca gaatgtgatg ggctccagca ttgatggtcg 601 ccccgtcctg cccgcaaact ctactacctt gacctacgag accgtgtctg gaacgccgtt 661 ggagactgca gcctccgccg ccgcttcagc cgctgcagcc accgcccgcg ggattgtgac 721 tgactttgct ttcctgagcc cgcttgcaag cagtgcagct tcccgttcat ccgcccgcga 781 tgacaagttg acggctcttt tggcacaatt ggattctttg acccgggaac ttaatgtcgt 841 ttctcagcag ctgttggatc tgcgccagca ggtttctgcc ctgaaggctt cctcccctcc 901 caatgcggtt taaaacataa ataaaaaacc agactctgtt tggatttgga tcaagcaagt 961 gtcttgctgt ctttatttag gggttttgcg cgcgcggtag gcccgggacc agcggtctcg 1021 gtcgttgagg gtcctgtgta ttttttccag gacgtggtaa aggtgactct ggatgttcag 1081 atacatgggc ataagcccgt ctctggggtg gaggtagcac cactgcagag cttcatgctg 1141 cggggtggtg ttgtagatga tccagtcgta gcaggagcgc tgggcgtggt gcctaaaaat 1201 gtctttcagt agcaagctga ttgccagggg caggcccttg gtgtaagtgt ttacaaagcg 1261 gttaagctgg gatgggtgca tacgtgggga tatgagatgc atcttggact gtatttttag 1321 gttggctatg ttcccagcca tatccctccg gggattcatg ttgtgcagaa ccaccagcac 1381 agtgtatccg gtgcacttgg gaaatttgtc atgtagctta gaaggaaatg cgtggaagaa 1441 cttggagacg cccttgtgac ctccaagatt ttcoatgcat tcgtccataa tgatggcaat 1501 gggcccacgg gcggcggcct gggcgaagat atttctggga tcactaacgt catagttgtg 1561 ttccaggatg agatcgtcat aggccatttt tacaaagcgc gggcggaggg tgccagactg 1621 cggtataatg gttccatccg gcccaggggc gtagttaccc tcacagattt gcatttccca 1681 cgctttgagt tcagatgggg ggatcatgtc tacctgcggg gcgatgaaga aaacggtttc 1741 cggggtaggg gagatcagct gggaagaaag caggttcctg agcagctgcg acttaccgca 1801 gccggtgggc ccgtaaatca cacctattac cgggtgcaac tggtagttaa gagagctgca 1861 gctgccgtca tccctgagca ggggggccac ttcgttaagc atgtccctga ctcgcatgtt 1921 ttccctgacc aaatccgcca gaaggcgctc gccgcccagc gatagcagtt cttgcaagga 1981 agcaaagttt ttcaacggtt tgagaccgtc cgccgtaggc atgcttttga gcgtttgacc 2041 aagcagttcc aggcggtccc acagctcggt cacctgctct acggcatctc gatccagcat 2101 atctcctcgt ttcgcgggtt ggggcggctt tcgctgtacg gcagtagtcg gtgctcgtcc 2161 agacgggcca gggtcatgtc tttccacggg cgcagggtcc tcgtcagcgt agtctgggtc 2221 acggtgaagg ggtgcgctcc gggctgcgcg ctggccaggg tgcgcttgag gctggtcctg 2281 ctggtgctga agcgctgccg gtcttcgccc tgcgcgt.cgg ccaggtagca tttgaccatg 2341 gtgtcatagt ccagcccctc cgcggcgtgg cccttggcgc gcagcttgcc cttggaggag 2401 gcgccgcacg aggggcagtg cagacttttg agggcgtaga gcttgggcgc gagaaatacc 2461 gattccgggg agtaggcatc cgcgccgcag gccccgcaga cggtctcgca ttccacgagc 2521 caggtgagct ctggccgttc ggggtcaaaa accaggtttc ccccatgctt tttgatgcgt 2581 ttcttacctc tggtttccat gagccggtgt ccacgctcgg tgacgaaaag gctgtccgtg 2641 tccccgtata cagacttgag agggagttta aacgaattca atagcttgtt gcatgggcgg 2701 cgatataaaa tgcaaggtgc tgctcaaaaa atcaggcaaa gcctcgcgca aaaaagaaag 2761 cacatcgtag tcatgctcat gcagataaag gcaggtaagc tccggaacca ccacagaaaa 2821 agacaccatt tttctctcaa acatgtctgc gggtttctgc ataaacacaa aataaaataa 2881 caaaaaaaca tttaaacatt agaagcctgt cttacaacag gaaaaacaac ccttataagc 2941 ataagacgga ctacggccat gccggcgtga ccgtaaaaaa actggtcacc gtgattaaaa 3001 agcaccaccg acagctcctc ggtcatgtcc ggagtcataa tgtaagactc ggtaaacaca 3061 tcaggttgat tcatcggtca gtgctaaaaa gcgaccgaaa tagcccgggg gaatacatac 3121 ccgcaggcgt agagacaaca ttacagcccc cataggaggt ataacaaaat taataggaga 3181 gaaaaacaca taaacacctg aaaaaccctc ctgcctaggc aaaatagcac cctcccgctc 3241 cagaacaaca tacagcgctt cacagcggca gcctaacagt cagccttacc agtaaaaaag 3301 aaaacctatt aaaaaaacac cactcgacac ggcaccagct caatcagtca cagtgtaaaa 3361 aagggccaag tgcagagcga gtatatatag gactaaaaaa tgacgtaacg gttaaagtcc 3421 acaaaaaaca cccagaaaac cgcacgcgaa cctacgccca gaaacgaaag ccaaaaaacc 3481 cacaacttcc tcaaatcgtc acttccgttt tcccacgtta cgtaacttcc cattttaaga 3541 aaactacaat tcccaacaca tacaagttac tccgccctaa aacctacgtc acccgccccg 3601 ttcccacgcc ccgcgceacg tcacaaactc caccccctca ttatcatatt ggcttcaatc 3661 caaaataagg tatattattg atgatgttaa ttaacatgca tggatccata tgcggtgtga 3721 aataccgcac agatgcgtaa ggagaaaata ccgcatcagg cgctcttccg cttcctcgct 3781 cactgactcg ctgcgctcgg tcgttcggct gcggcgagcg gtatcagctc actcaaaggc 3841 ggtaatacgg ttatccacag aatcagggga taacgcagga aagaacatgt gagcaaaagg 3901 ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg 3961 cccccctgac gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg 4021 actataaaga taccaggcgt ttccccctgg aagctccctc gtgcgctctc ctgttccgac 4081 cctgccgctt accggatacc tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca 4141 tagctcacgc tgtaggtatc tcagttcggt gtaggtcgtt cgctccaagc tgggctgtgt 4201 gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc 4261 caacccggta agacacgact tatcgccact ggcagcagcc actggtaaca ggattagcag 4321 agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg tggcctaact acggctacac 4381 tagaaggaca gtatttggta tctgcgctct gctgaagcca gttaccttcg gaaaaagagt 4441 tggtagctct tgatccggca aacaaaccac cgctggtagc ggtggttttt ttgtttgcaa 4501 gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct tttctacggg 4561 gtctgacgct cagtggaacg aaaactcacg ttaagggatt ttggtcatga gattatcaaa 4621 aaggatcttc acctagatcc ttttaaatta aaaatgaagt tttaaatcaa tctaaagtat 4681 atatgagtaa acttggtctg acagttacca atgcttaatc agtgaggcac ctatctcagc 4741 gatctgtcta tttcgttcat ccatagttgc ctgactcccc gtcgtgtaga taactacgat 4801 acgggagggc ttaccatctg gccccagtgc tgcaatgata ccgcgagacc cacgctcacc 4861 ggctccagat ttatcagcaa taaaccagcc agccggaagg gccgagcgca gaagtggtcc 4921 tgcaacttta tccgcctcca tccagtctat taattgttgc cgggaagcta gagtaagtag 4981 ttcgccagtt aatagtttgc gcaacgttgt tgccattgct gcagccatga gattatcaaa 5041 aaggatcttc acctagatcc ttttcacgta gaaagccagt ccgcagaaac ggtgctgacc 5101 ccggatgaat gtcagctact gggctatctg gacaagggaa aacgcaagcg caaagagaaa 5161 gcaggtagct tgcagtgggc ttacatggcg atagctagac tgggcggttt tatggacagc 5221 aagcgaaccg gaattgccag ctggggcgcc ctctggtaag gttgggaagc cctgcaaagt 5281 aaactggatg gctttctcgc cgccaaggat ctgatggcgc aggggatcaa gctctgatca 5331 agagacagga tgaggatcgt ttcgcatgat tgaacaagat ggattgcacg caggttctcc 5401 ggccgcttgg gtggagaggc tattcggcta tgactgggca caacagacaa tcggctgctc 5461 tgatgccgcc gtgttccggc tgtcagcgca ggggcgcccg gttctttttg tcaagaccga 5521 cctgtccggt gccctgaatg aactgcaaga cgaggcagcg cggctatcgt ggctggccac 5581 gacgggcgtt ccttgcgcag ctgtgctcga cgttgtcact gaagcgggaa gggactggct 5641 gctattgggc gaagtgccgg ggcaggatct cctgtcatct caccttgctc ctgccgagaa 5701 agtatccatc atggctgatg caatgcggcg gctgcatacg cttgatccgg ctacctgccc 5761 attcgaccac caagcgaaac atcgcatcga gcgagcacgt actcggatgg aagccggtct 5821 tgtcgatcag gatgatctgg acgaagagca tcaggggctc gcgccagccg aactgttcgc 5881 caggctcaag gcgagcatgc ccgacggcga ggatctcgtc gtgacccatg gcgatgcctg 5941 cttgccgaat atcatggtgg aaaatggccg cttttctgga ttcatcgact gtggccggct 6001 gggtgtggcg gaccgctatc aggacatagc gttggctacc cgtgatattg ctgaagagct 6061 tggcggcgaa tgggctgacc gcttcctcgt gctttacggt atcgccgctc ccgattcgca 6121 gcgcatcgcc ttctatcgcc ttcttgacga gttcttctga attttgttaa aatttttgtt 6181 aaatcagctc attttttaac caataggccg aaatcggcaa catcccttat aaatcaaaag 6241 aatagaccgc gatagggttg agtgttgttc cagtttggaa caagagtcca ctattaaaga 6301 acgtggactc caacgtcaaa gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg 6361 aaccatcacc caaatcaagt tttttgcggt cgaggtgccg taaagctcta aatcggaacc 6421 ctaaagggag cccccgattt agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg 6481 aagggaagaa agcgaaagga gcgggcgcta.gggcgctggc aagtgtagcg gtcacgctgc 6541 gcgtaaccac cacacccgcg cgcttaatgc gccgctacag ggcgcgtcca ttcgccattc 6601 aggatcgaat taattcttaa t SEQ ID:8 GATGGTGCTTCAAGCTAGTACttaaGTACTAGCTTGAAGCACCATC SEQ ID: 9 GATGGTGCTTCAAGCTAGTACggatccGTACTAGCTTGAAGCACCATC SEQ ID: 10 GAAACGATATGGGCTGAATACggatccGTATTCAGCCCATATCGTTTC SEQ ID: 11 CCTAATAATTAT CAAAAT GT ggatccACATTTT GAT AATT ATT AG G SEQ ID: 12 CCTAATAATTAT CAAAAT GT aattACATTTT GAT AATT ATTAG G SEQ ID: 13 (DS1c) 1 taacatcatc aataatatac cttattttgg attgaagcca atatgataat gagggggtgg 61 agtttgtgac gtggcgcggg gcgtgggaac ggggcgggtg acgtagtagt gtggcggaag 121 tgtgatgttg caagtgtggc ggaacacatg taagcgacgg atgtggcaaa agtgacgttt 181 ttggtgtgcg ccggtgtaca caggaagtga caattttcgc gcggttttag gcggatgttg 241 tagtaaattt gggcgtaacc gagtaagatt tggccatttt cgcgggaaaa ctgaataaga 301 ggaagtgaaa tctgaataat tttgtgttac tcatagcgcg taatactgta atagtaatca 361 attacggggt cattagttca tagcccatat atggagttcc gcgttacata acttacggta 421 aatggcccgc ctggctgacc gcccaacgac ccccgcccat tgacgtcaat aatgacgtat 481 gttcccatag taacgccaat agggactttc cattgacgtc aatgggtgga gtatttacgg 541 taaactgccc acttggcagt acatcaagtg tatcatatgc caagtacgcc ccctattgac 601 gtcaatgacg gtaaatggcc cgcctggcat tatgcccagt acatgacctt atgggacttt 661 cctacttggc agtacatcta cgtattagtc atcgctatta ccatggtgat gcggttttgg 721 cagtacatca atgggcgtgg atagcggttt gactcacggg gatttccaag tctccacccc 781 at.tgacgt.ca atgggagttt gttttggcac caaaatcaac gggactttcc aaaatgtcgt 841 aacaactccg ccccattgac gcaaatgggc ggtaggcgtg tacggtggga ggtctatata 901 agcagagctg gtttagtgaa ccgtcagatc cgctagagat CtGGTACCGAGCTCGGATCCGCCACCATGGAGGCAAACCTACTGGTCCTGTTATGTGCACTT GCAGCTGCAGATGCAGACACAATATGTATAGGCTACCATGCGAACAATTCAACCGACACTGG TGACACAGTActcgagaaga atgtgacagt gacacactct gttaacctgc 181 tcgaagacag ccacaacgga aaactatgta gattaaaagg aatagcccca ctacaattgg 241 ggaaatgtaa catcgccgga tggctcttgg gaaacccaga atgcgaccca ctgcttccag 301 tgagatcatg gtcctaca.tt gtagaaacac caaactctga gaatggaata tgttatccag 361 gagatttcat cgactatgag gagctgaggg agcaattgag ctcagtgtca tcattcgaaa 421 gattcgaaat atttcccaaa gaaagctcat ggcccaacca caacacaacc aaaggagtaa 481 cggcagcatg ctcccatgcg gggaaaagca gtttttacag aaatttgcta tggctgacgg 541 agaaggaggg ctcataccca aagctgaaaa attcttatgt gaacaagaaa gggaaagaag 601 tccttgtact gtggggtatt catcacccgt ctaacagtaa ggatcaacag aatatctatc 661 agaatgaaaa tgcttatgtc tctgtagtga cttcaaatta taacaggaga tttaccccgg 721 aaatagcaga aagacccaaa gtaagagatc aagctgggag gatgaactat tactggacct 781 tgctaaaacc cggagacaca ataatatttg aggcaaatgg aaatctaata gcaccaaggt 841 atgctttcgc actgagtaga ggctttgggt ccggcatcat cacctcaaac gcatcaatgc 901 atgagtgtaa cacgaagtgt caaacacccc tgggagctat aaacagcagt ctccctttcc 961 agaatataca cccagtcaca ataggagagt gcccaaaata ogtcaggagt gccaaattga. 1021 ggatggttac aggactaagg aacattccgt ccattcaatc cagaggtcta tttggagcca 1081 ttgccggttt tattgaaggg ggatggactg gaatgataga tggatggtac ggttatcatc 1141 atcagaatga acagggatca ggctatgcag cggatcaaaa aagcacacaa aatgccatta 1201 acgggattac aaacaaggtg aactctgtta tcgagaaaat gaacattcaa ttcacagctg 1261 tgggtaaaga attcaacaaa ttagaaaaaa ggatggaaaa tttaaataaa aaagttgatg 1321 atggatttct ggacatttgg acatataatg cagaattgtt agttctactg gaaaatgaaa 1381 ggactctgga tttccatgac tcaaatgtga agaatctgta tgagaaagta aaaagccaat 1441 taaagaataa tgccaaagaa atcggaaatg gatgttttga gttctaccac aagtgtgaca 1501 atgaatgcat ggaaagtgta agaaatggga cttatgatta tcccaaatat tcagaagagt 1561 caaagttgaa cagggaaaag gtagatggag tgaaattgga atcaatgggg atctatcaga 1621 ttctggcgat ctactcaact gtcgccagtt cactggtgct tttggtctcc ctgggggcaa 1681 tcagtttctg gatgtgttct aatggatctt tgcagtgcag aatatgcatc tgagattaga
1741 atttcagaga tatgaggaaa aacacccttg tttctact CCCAAGCTTTAATGCGGTAGTTTATCACAGTTAA&TTGCTAA CGCAGTCAGGCACCGTGTATGAAATCTAACAATGCGCTCATCGTCATCCTCGGCACCGTCAC CCTGGATGCTGTAGGCATAGGCTTGGTTATGCCGGTACTGCCGGGCCTCTTGCGGGATGG GCGGCCGCtcgagcct aagcttctag ataagatatc cgatccaccg gatctagata actgatcata 1021 atcagccata ccacatttgt agaggtttta cttgctttaa aaaacctccc acacctcccc 1081 ctgaacctga aacataaaat gaatgcaatt gttgttgtta acttgtttat tgcagcttat 1141 aatggttaca aataaagcaa tagcatcaca aatttcacaa ataaagcatt tttttcactg 1201 cattctagtt gtggtttgtc caaactcatc aatgtatctt aacgcggatc tgggcgtggt 1261 taagggtggg aaagaatata taaggtgggg gtcttatgta gttttgtatc tgttttgcag 1321 cagccgccgc cgccatgagc accaactcgt ttgatggaag cattgtgagc tcatatttga 1381 caacgcgcat gcccccatgg gccggggtgc gtcagaatgt gatgggctcc agcattgatg 1441 gtcgccccgt cctgcccgca aactctacta ccttgaccta cgagaccgtg tctggaacgc 1501 cgttggagac tgcagcctcc gccgccgctt cagccgctgc agccaccgcc cgcgggattg 1561 tgactgactt tgctttcctg agcccgcttg caagcagtgc agcttcccgt tcatccgccc 1621 gcgatgacaa gttgacggct cttttggcac aattggattc tttgacccgg gaacttaatg 1681 tcgtttctca gcagctgttg gatctgcgcc agcaggtttc tgccctgaag gcttcctccc 1741 ctcccaatgc ggtttaaaac ataaataaaa aaccagactc tgtttggatt tggatcaagc 1801 aagtgtcttg ctgtctttat ttaggggttt tgcgcgcgcg gtaggcccgg gaccagcggt 1861 ctcggtcgtt gagggtcctg tgtatttttt ccaggacgtg gtaaaggtga ctctggatgt 1921 tcagatacat gggcataagc ccgtctctgg ggtggaggta gcaccactgc agagcttcat 1981 gctgcggggt ggtgttgtag atgatccagt cgtagcagga gcgctgggcg tggtgcctaa 2041 aaatgtcttt cagtagcaag ctgattgcca ggggcaggcc cttggtgtaa gtgtttacaa 2101 agcggttaag ctgggatggg tgcatacgtg gggatatgag atgcatcttg gactgtattt 2161 ttaggttggc tatgttccca gccatatccc tccggggatt catgttgtgc agaaccacca 2221 gcacagtgta tccggtgcac ttgggaaatt tgtcatgtag cttagaagga aatgcgtgga 2281 agaacttgga gacgcccttg tgacctccaa gattttccat gcattcgtcc ataatgatgg 2341 caatgggccc acgggcggcg gcctgggcga agatatttct gggatcacta acgtcatagt 2401 tgtgttccag gatgagatcg tcataggcca tttttacaaa gcgcgggcgg agggtgccag 2461 actgcggtat aatggttcca tccggcccag gggcgtagtt accctcacag atttgcattt 2521 cccacgcttt gagttcagat ggggggatca tgtctacctg oggggcqat.g aagaaaacgg 2581 tttccggggt aggggagatc agctgggaag aaagcaggtt cctgagcagc tgcgacttac 2641 cgcagccggt gggcccgtaa atcacaccta ttaccgggtg caactggtag ttaagagagc 2701 tgcagctgcc gtcatccctg agcagggggg ccacttcgtt aagcatgtcc ctgactcgca 2761 tgttttccct gaccaaatcc gccagaaggc gctcgccgcc cagcgatagc agttcttgca 2821 aggaagcaaa gtttttcaac ggtttgagac cgtccgccgt aggcatgctt ttgagcgttt 2881 gaccaagcag ttccaggcgg tcccacagct cggtcacctg ctctacggca tctcgatcca 2941 gcatatctcc tcgtttcgcg ggttggggcg gctttcgctg tacggcagta gtcggtgctc 3001 gtccagacgg gccagggtca tgtctttcca cgggcgcagg gtcctcgtca gcgtagtctg 3061 ggtcacggtg aaggggtgcg ctccgggctg cgcgctggcc agggtgcgct tgaggctggt 3121 cctgctggtg ctgaagcgct gccggtcttc gccctgcgcg tcggccaggt agcatttgac 3181 catggtgtca tagtccagcc cctccgcggc gtggcccttg gcgcgcagct tgcccttgga 3241 ggaggcgccg cacgaggggc agtgcagact tttgagggcg tagagcttgg gcgcgagaaa 3301 taccgattcc ggggagtagg catccgcgcc gcaggccccg cagacggtct cgcattccac 3361 gagccaggtg agctctggcc gttcggggtc aaaaaccagg tttcccccat gctttttgat 3421 gcgtttctta cctctggttt ccatgagccg gtgtccacgc tcggtgacga aaaggctgtc 3481 cgtgtccccg tatacagact tgagagggag tttaaacgaa ttcaatagct tgttgcatgg 3541 gcggcgatat aaaatgcaag gtgctgctca aaaaatcagg caaagcctcg cgcaaaaaag 3601 aaagcacatc gtagtcatgc tcatgcagat aaaggcaggt aagctccgga accaccacag 3661 aaaaagacac catttttctc tcaaacatgt ctgcgggttt ctgcataaac acaaaataaa 3721 ataacaaaaa aacatttaaa cattagaagc ctgtcttaca acaggaaaaa caacccttat 3781 aagcataaga cggactacgg ccatgccggc gtgaccgtaa aaaaactggt caccgtgatt 3841 aaaaagcacc accgacagct cctcggtcat gtccggagtc ataatgtaag actcggtaaa 3901 cacatcaggt tgattcatcg gtcagtgcta aaaagcgacc gaaatagccc gggggaatac 3961 atacccgcag gcgtagagac aacattacag cccccatagg aggtataaca aaattaatag 4021 gagagaaaaa cacataaaca cctgaaaaac cctcctgcct aggcaaaata gcaccctccc 4081 g.ctccagaac aacatacagc gcttcacagc ggcagcctaa cagtcagcct taccagtaaa 4141 aaagaaaaoc tattaaaaaa acaccactcg acacggcacc agctcaatca gtcacagtgt 4201 aaaaaagggc caagtgcaga gcgagtatat ataggactaa aaaatgacgt aacggttaaa 4261 gtccacaaaa aacacccaga aaaccgcacg cgaacctacg cccagaaacg aaagccaaaa 4321 aacccacaac ttcctcaaat cgtcacttcc gttttcccac gttacgtaac ttcccatttt 4381 aagaaaacta caattcccaa cacatacaag ttactccgcc ctaaaaccta cgtcacccgc 4441 cccgttccca cgccccgcgc cacgtcacaa actccacccc ctcattatca tattggcttc 4501 aatccaaaat aaggtatatt attgatgatg ttaattaaca tgcatggatc catatgcggt 4561 gtgaaatacc gcacagatgc gtaaggagaa aataccgcat caggcgctct tccgcttcct 4621 cgctcactga ctcgctgcgc tcggtcgttc ggctgcggcg agcggtatca gctcactcaa 4681 aggcggtaat acggttatcc acagaatcag gggataacgc aggaaagaac atgtgagcaa 4741 aaggccagca aaaggccagg aaccgtaaaa aggccgcgtt gctggcgttt ttccataggc 4801 tccgcccccc tgacgagcat cacaaaaatc gacgctcaag tcagaggtgg cgaaacccga 4861 caggactata aagataccag gcgtttcccc ctggaagctc cctcgtgcgc tctcctgttc 4921 cgaccctgcc gcttaccgga tacctgtccg cctttctccc ttcgggaagc gtggcgcttt 4981 ctcatagctc acgctgtagg tatctcagtt cggtgtaggt cgttcgctcc aagctgggct 5041 gtgtgcacga accccccgtt cagcccgacc gctgcgcctt atccggtaac tatcgtcttg 5101 agtccaaccc ggtaagacac gacttatcgc cactggcagc agccactggt aacaggatta 5161 gcagagcgag gtatgtaggc ggtgctacag agttcttgaa gtggtggcct aactacggct 5221 acactagaag gacagtattt ggtatctgcg ctctgctgaa gccagttacc ttcggaaaaa 5281 gagttggtag ctcttgatcc ggcaaacaaa ccaccgctgg tagcggtggt ttttttgttt 5341 gcaagcagca gattacgcgc agaaaaaaag gatctcaaga agatcctttg atcttttcta 5401 cggggtctga cgctcagtgg aacgaaaact cacgttaagg gattttggtc atgagattat 5461 caaaaaggat cttcacctag atccttttaa attaaaaatg aagttttaaa tcaatctaaa 5521 gtatatatga gtaaacttgg tctgacagtt accaatgctt aatcagtgag gcacctatct 5581 cagcgatctg tctatttcgt tcatccatag ttgcctgact ccccgtcgtg tagataacta 5641 cgatacggga gggcttacca tctggcccca gtgctgcaat gataccgcga gacccacgct 5701 caccggctcc agatttatca gcaataaacc agccagccgg aagggccgag cgcagaagtg 5761 gtcctgcaac tttatccgcc tccatccagt ctattaattg ttgccgggaa gctagagtaa 5821 gtagttcgcc agttaatagt ttgcgcaacg ttgttgccat tgctgcagcc atgagattat 5881 caaaaaggat cttcacctag atccttttca cgtagaaagc cagtccgcag aaacggtgct 5941 gaccccggat gaatgtcagc tactgggcta tctggacaag ggaaaacgca agcgcaaaga 6001 gaaagcaggt agcttgcagt gggcttacat ggcgatagct agactgggcg gttttatgga 6061 cagcaagcga accggaattg ccagctgggg cgccctctgg taaggttggg aagccctgca 6121 aagtaaactg gatggctttc tcgccgccaa ggatctgatg gcgcagggga tcaagctctg 6181 atcaagagac aggatgagga tcgtttcgca tgattgaaca agatggattg cacgcaggtt 6241 ctccggccgc ttgggtggag aggctattcg gctatgactg ggcacaacag acaatcggct 6301 gctctgatgc cgccgtgttc cggctgtcag cgcaggggcg cccggttctt tttgtcaaga 6361 ccgacctgtc cggtgccctg aatgaactgc aagacgaggc agcgcggcta tcgtggctgg 6421 ccacgacggg cgttccttgc gcagctgtgc tcgacgttgt cactgaagcg ggaagggact 6481 ggctgctatt gggcgaagtg ccggggcagg atctcctgtc atctcacctt gctcctgccg 6541 agaaagtatc catcatggct gatgcaatgc ggcggctgca tacgcttgat ccggctacct 6601 gcccattcga ccaccaagcg aaacatcgca tcgagcgagc acgtactcgg atggaagccg 6661 gtcttgtcga tcaggatgat ctggacgaag agcatcaggg gctcgcgcca gccgaactgt 6721 tcgccaggct caaggcgagc atgcccgacg gcgaggatct cgtcgtgacc catggcgatg 6781 cctgcttgcc gaatatcatg gtggaaaatg gccgcttttc tggattcatc gactgtggcc 6841 ggctgggtgt ggcggaccgc tatcaggaca tagcgttggc tacccgtgat attgctgaag 6901 agcttggcgg cgaatgggct gaccgcttcc tcgtgcttta cggtatcgcc gctcccgatt 6961 cgcagcgcat cgccttctat. cgccttcttg acgagttctt ctgaattttg ttaaaatttt 7021 tgttaaatca gctcattttt taaccaatag gccgaaatcg gcaacatccc ttataaatca 7081 aaagaataga ccgcgatagg gttgagtgtt gttccagttt ggaacaagag tccactatta 7141 aagaacgtgg actccaacgt caaagggcga aaaaccgtct atcagggcga tggcccacta 7201 cgtgaaccat cacccaaatc aagttttttg cggtcgaggt gccgtaaagc tctaaatcgg 7261 aaccctaaag ggagcccccg atttagagct tgacggggaa agccggcgaa cgtggcgaga 7321 aaggaaggga agaaagcgaa aggagcgggc gctagggcgc tggcaagtgt agcggtcacg 7381 ctgcgcgtaa ccaccacacc cgcgcgctta atgcgccgct acagggcgcg tccattcgcc 7441 attcaggatc gaattaattc ttaat SEQ ID:14 DS2beta-luc taacatcatc aataatatac cttattttgg attgaagcca atatgataat gagggggtgg agtttgtgac gtggcgcggg gcgtgggaac ggggcgggtg acgtagtagt gtggcggaag tgtgatgttg caagtgtggc ggaacacatg taagcgacgg atgtggcaaa agtgacgttt ttggtgtgcg ccggtgtaca caggaagtga caattttcgc gcggttttag gcggatgttg tagtaaattt gggcgtaacc gagtaagatt tggccatttt cgcgggaaaa ctgaataaga ggaagtgaaa tctgaataat tttgtgttac tcatagcgcg
taatactGCTAGAgatCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGC
CAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAATTGTAATACGACTCACTA TAGGGCGAATTGGGTACTGGCCAcagagcttggcccattgcatacgttgtatccatatcata atatgtacatttatattggctcatgtccaacattaccgccatgttgacattgattattgact agttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgt tacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgt caataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtg gagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgcc ccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgaccttat gggactttcctacttggcagtacatctaegfcattagtcatcgcfca-tfcaccatggtgatgcgg ttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctcca ccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtc gtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatata agcagagctcgtttagtgaaccgtcagatcgcctggagacgccatccacgctgttttgacct ccatagaagacaccgggaccgatccagcctgactctagCctAGCTCtgaagttggtggtgag gccctgggcaggttggtatcaaggttacaagacaggtttaaggagaccaatagaaactgggc atgtggagacagagaagactcttgggtttctgataggcactgactctctctgcctattggtc
cattttcccacccttaggctgctggtctgagcctagGAGATCTCTCGAGGTCGACGGTATCG
ATGGGTACCGGCGGCCGeCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCTGATCAGC
CTCGACTGTGCCTT
CTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCC
ACTCCCAC
TGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTC
TGGGGGGT
GGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGC
GGTGGGCT
CTATGGCTTCTGAGGCGGAAAGAACCTATGGCTTCTGAGGCGGAAAGAACCAACCACCGCGG
TGGCGGCCGCCACACAAAAAACCAACACACAGATGTAATGAAAATAAAGATATTTTATTTCT
AGAGAAACGATATGGGCTGAATACGGATCCGTATTCAGCCCATATCGTTTCCTGCAGGAATT
CGCCCTTTAGATATCATCGATGTCTCGGCGGTGGTGGCGCGTCGCGCCGCTGGGTTTTATAG
GGCGCCGCCGCGGCCGCTCGAGCCATAAAAGGCAACTTTCGGAACGGCGCACGCTGATTGGC cccgcgccgctcactcaccggcttcgccGcacagtgcagcatttttttaccccctctcccot CCTTTTGCGAAAAAAAAAAAGAGCGAGAGCGAGATTGAGGAAGAGGAGGAGGGAGAGTTTTG GCGTTGGCCGCCTTGGGGTGCTGGGCGTCGACGATATCTAAGGGCGAATTCGATATCAagct agctTgtcgaotcg aagatctggg cgtggttaag 421 ggtgggaaag aatatataag gtgggggtct tatgtagttt tgtatctgtt ttgcagcagc 481 cgccgccgcc atgagcacca actcgtttga tggaagcatt gtgagctcat atttgacaac 541 gcgcatgocc ccatgggccg gggtgcgtca gaatgtgatg ggctccagca ttgatggtcg 601 ccccgtcctg cccgcaaact ctactacctt gacctacgag accgtgtctg gaacgccgtt 661 ggagactgca gcctccgccg ccgcttcagc cgctgcagcc accgcccgcg ggattgtgac 721 tgactttgct ttcctgagcc cgcttgcaag cagtgcagct tcccgttcat ccgcccgcga 781 tgacaagttg acggctcttt tggcacaatt ggattctttg acccgggaac ttaatgtcgt 841 ttctcagcag ctgttggatc tgcgccagca ggtttctgcc ctgaaggctt cctcccctcc 901 caatgcggtt taaaacataa ataaaaaacc agactctgtt tggatttgga tcaagcaagt 961 gtcttgctgt ctttatttag gggttttgcg cgcgcggtag gcccgggacc agcggtctcg 1021 gtcgttgagg gtcctgtgta ttttttccag gacgtggtaa aggtgactct ggatgttcag 1081 atacatgggc ataagcccgt ctctggggtg gaggtagcac cactgcagag cttcatgctg 1141 cggggtggtg ttgtagatga tccagtcgta gcaggagcgc tgggcgtggt gcctaaaaat 1201 gtctttcagt agcaagctga ttgccagggg caggcccttg gtgtaagtgt ttacaaagcg 1261 gttaagctgg gatgggtgca tacgtgggga tatgagatgc atcttggact gtatttttag 1321 gttggctatg ttcccagcca tatccctccg gggattcatg ttgtgcagaa ccaccagcac 1381 agtgtatccg gtgcacttgg gaaatttgtc atgtagctta gaaggaaatg cgtggaagaa 1441 cttggagacg cccttgtgac ctccaagatt ttccatgcat tcgtccataa tgatggcaat 1501 gggcccacgg gcggcggcct gggcgaagat atttctggga tcactaacgt catagttgtg 1561 ttccaggatg agatcgtcat aggccatttt tacaaagcgc gggcggaggg tgccagactg 1621 cggtataatg gttccatccg gcccaggggc gtagttaccc tcacagattt gcatttccca 1681 cgctttgagt tcagatgggg ggatcatgtc tacctgcggg gcgatgaaga aaacggt'ttc 1741 cggggtaggg gagatcagct gggaagaaag caggttcctg agcagctgcg acttaccgca 1801 gccggtgggc ccgtaaatca cacctattac cgggtgcaac tggtagttaa gagagctgca 1861 gctgccgtca tccctgagca ggggggccac ttcgttaagc atgtccctga ctcgcatgtt 1921 ttccctgacc aaatccgcca gaaggcgctc gccgcccagc gatagcagtt cttgcaagga 1981 agcaaagttt ttcaacggtt tgagaccgtc cgccgtaggc atgcttttga gcgtttgacc 2041 aagcagttcc aggcggtccc acagctcgg€ cacctgctct acggcatctc gatccagcat 2101 atctcctcgt ttcgcgggtt ggggcggctt tcgctgtacg gcagtagtcg gtgctcgtcc 2161 agacgggcca gggtcatgtc tttccacggg cgcagggtcc tcgtcagcgt agtctgggtc 2221 acggtgaagg ggtgcgctcc gggctgcgcg ctggccaggg tgcgcttgag gctggtcctg 2281 ctggtgctga agcgctgccg gtcttcgccc tgcgcgtcgg ccaggtagca tttgaccatg 2341 gtgtcatagt ccagcccctc cgcggcgtgg cccttggcgc gcagcttgcc cttggaggag 2401 gcgccgcacg aggggcagtg cagacttttg agggcgtaga gottgggcgc gagaaatacc 2461 gattccgggg agtaggcatc cgcgccgcag gccccgcaga cggtctcgca ttccacgagc 2521 caggtgagct ctggccgttc ggggtcaaaa accaggtttc ccccatgctt tttgatgcgt 2581 ttcttacctc tggtttccat gagccggtgt ccacgctcgg tgacgaaaag gctgtccgtg 2641 tccccgtata cagacttg'ag agggagttta aacgaattca atagcttgtt gcatgggcgg 2701 cgatataaaa tgcaaggtgc tgctcaaaaa atcaggcaaa gcctcgcgca aaaaagaaag 2761 cacatcgtag tcatgctcat gcagataaag gcaggtaagc tccggaacca ccacagaaaa 2821 agacaccatt tttctctcaa acatgtctgc gggtttctgc ataaacacaa aataaaataa 2881 caaaaaaaca tttaaacatt agaagcctgt cttacaacag gaaaaacaac ccttataagc 2941 ataagacgga ctacggccat gccggcgtga ccgtaaaaaa actggtcacc gtgattaaaa 3001 agcaccaccg acagctcctc ggtcatgtcc ggagtcataa tgtaagactc ggtaaacaca 3061 tcaggttgat tcatcggtca gtgctaaaaa gcgaccgaaa tagcccgggg gaatacatac 3121 ccgcaggcgt agagacaaca ttacagcccc cataggaggt ataacaaaat taataggaga 3181 gaaaaacaca taaacacctg aaaaaccctc ctgcctaggc aaaatagcac cctcccgctc 3241 cagaacaaca tacagcgctt cacagcggca gcctaacagt cagccttacc agtaaaaaag 3301 aaaacctatt aaaaaaacac cactcgacac ggcaccagct caatcagtca cagtgtaaaa 3361 aagggccaag tgcagagcga gtatatatag gactaaaaaa tgacgtaacg gttaaagtcc 3421 acaaaaaaca cccagaaaac cgcacgcgaa cctacgccca gaaacgaaag ccaaaaaacc 3481 cacaacttcc tcaaatcgtc acttccgttt tcccacgtta cgtaacttcc cattttaaga 3541 aaactacaat tcccaacaca tacaagttac tccgccctaa aacctacgtc acccgccocg 3601 ttcccacgcc ccgcgccacg tcacaaactc caccccctca ttatcatatt ggcttcaatc 3661 caaaataagg tatattattg atgatgttaa ttaacatgca tggatccata tgcggtgtga 3721 aataccgcac agatgcgtaa ggagaaaata ccgcatcagg cgctcttccg cttcctcgct 3781 cactgactcg ctgcgctcgg tcgttcggct gcggcgagcg gtatcagctc actcaaaggc 3841 ggtaatacgg ttatccacag aatcagggga taacgcagga aagaacatgt gagcaaaagg 3901 ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg 3961 cccccctgac gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg 4021 actataaaga taccaggcgt ttccccctgg aagctccctc gtgcgctctc ctgttccgac 4081 cctgccgctt accggatacc tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca 4141 tagctcacgc tgtaggtatc tcagttcggt gtaggtcgtt cgctccaagc tgggctgtgt 4201 gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc 4261 caacccggta agacacgact tatcgccact ggcagcagcc actggtaaca ggattagcag 4321 agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg tggcctaact acggctacac 4381 tagaaggaca gtatttggta tctgcgctct gctgaagcca gttaccttcg gaaaaagagt 4441 tggtagctct tgatccggca aacaaaccac cgctggtagc ggtggttttt ttgtttgcaa 4501 gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct tttctacggg 4561 gtctgacgct cagtggaacg aaaactcacg ttaagggatt ttggtcatga gattatcaaa 4621 aaggatcttc acctagatcc ttttaaatta aaaatgaagt tttaaatcaa tctaaagtat 4681 atatgagtaa acttggtctg acagttacca atgcttaatc agtgaggcac ctatctcagc 4741 gatctgtcta tttcgttcat ccatagttgc ctgactcccc gtcgtgtaga taactacgat 4801 acgggagggc ttaccatctg gccccagtgc tgcaatgata ccgcgagacc cacgctcacc 4861 ggctccagat ttatcagcaa taaaccagcc agccggaagg gccgagcgca gaagtggtcc 4921 tgcaacttta tccgcctcca tccagtctat taattgttgc cgggaagcta gagtaagtag 4981 ttcgccagtt aatagtttgc gcaacgttgt tgccattgct gcagccatga gattatcaaa 5041 aaggatcttc acctagatcc ttttcacgta gaaagccagt ccgcagaaac ggtgctgacc 5101 ccggatgaat gtcagctact gggctatctg gacaagggaa aacgcaagcg caaagagaaa 5161 gcaggtagct tgcagtgggc ttacatggcg atagctagac tgggcggttt tatggacagc 5221 aagcgaaccg gaattgccag ctggggcgcc ctctggtaag gttgggaagc cctgcaaagt 5281 aaactggatg gctttctcgc cgccaaggat ctgatggcgc aggggatcaa gctctgatca 5341 agagacagga tgaggatcgt ttcgcatgat tgaacaagat ggattgcacg caggttctcc 5401 ggccgcttgg gtggagaggc tattcggcta tgactgggca caacagacaa tcggctgctc 5461 tgatgccgcc gtgttccggc tgtcagcgca ggggcgcccg gttctttttg tcaagaccga 5521 cctgtccggt gccctgaatg aactgcaaga cgaggcagcg cggctatcgt ggctggccac 5581 gacgggcgtt ccttgcgcag ctgtgctcga cgttgtcact gaagcgggaa gggactggct 5641 gctattgggc gaagtgccgg ggcaggatct cctgtcatct caccttgctc ctgccgagaa 5701 agtatccato atggctgatg caatgcggcg gctgcatacg cttgatccgg ctacctgccc 5761 attcgaccac caagcgaaac atcgeatcga gcgagcacgt aotcggatgg aagccggtct 5821 tgtcgatcag gatgatctgg acgaagagca tcaggggctc gcgccagccg aactgttcgc 5881 caggctcaag gcgagcatgc ccgacggcga ggatctcgtc gtgacccatg gcgatgcctg 5941 cttgccgaat atcatggtgg aaaatggccg cttttctgga ttcatcgact gtggccggct . 6001 gggtgtggcg gaccgctatc aggacatagc gttggctacc cgtgatattg ctgaagagct 6061 tggcggcgaa tgggctgacc gcttcctcgt gctttacggt atcgccgctc ccgattcgca 6121 gcgcatcgcc ttctatcgcc ttcttgacga gttcttctga attttgttaa aatttttgtt 6181 aaatcagctc attttttaac caataggccg aaatcggcaa catcccttat aaatcaaaag 6241 aatagaccgc gatagggttg agtgttgttc cagtttggaa caagagtcca ctattaaaga 6301 acgtggactc caacgtcaaa gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg 6361 aaccatcacc caaatcaagt tttttgcggt cgaggtgccg taaagctcta aatcggaacc 6421 ctaaagggag cccccgattt agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg 6481 aagggaagaa agcgaaagga gcgggcgota gggcgctggc aagtgtagcg gtcacgctgc 6541 gcgtaaccac cacacccgcg cgcttaatgc gccgctacag ggcgcgtcca ttcgccattc 6601 aggatcgaat taattcttaa t SEQ ID: 15 taacatcatc aataatatac cttattttgg attgaagcca atatgataat gagggggtgg agtttgtgac gtggcgcggg gcgtgggaac ggggcgggtg acgtagtagt gtggcggaag tgtgatgttg caagtgtggc ggaacacatg taagcgacgg atgtggcaaa agtgacgttt ttggtgtgcg ccggtgtaca caggaagtga caattttcgc gcggttttag gcggatgttg tagtaaattt gggcgtaacc gagtaagatt tggccatttt cgcgggaaaa ctgaataaga ggaagtgaaa tctgaataat tttgtgttac tcatagcgcg
taatactGCTAGAgatCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGC
CAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAATTGTAATACGACTCACTA TAGGGCGAATTGGGTACT.GGCCAcagagcttggcccattgcatacgttgtatccatatcata atatgtacatttatattggctcatgtccaacattaccgccatgttgacattgattattgact agttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgt tacataacttacggtaaatggcccgoctggctgaccgcccaacgacccccgcccattgacgt caataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtg gagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgcc ccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgaccttat gggactttcctacttggcagtacatctacgtattagtcatcgctattaccatgqtgatgcgg ttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctcca ccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtc gtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatata agcagagctcgtttagtgaaccgtcagatcgcctggagacgccatccacgctgttttgacct ccatagaagacaccgggaccgatccagcctgactctagCctAGCTCtgaagttggtggtgag gccctgggcaggttggtatcaaggttacaagacaggtttaaggagaccaatagaaactggge atgtggagaoagagaagactcttgggtttctgataggcactgactctctctgcctattggtc
tattttcccacccttaggotgctggtctgagoctagGAGATCTCTCGAGGTCGACGGTATCG
ATCGGEACCGGCGGCCGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCraGCTGATCAGC
CTCGACTGTGCCTT
CTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCC
ACTCCCAC
TGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTC
TGGGGGGT
GGGGIGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGC
GGTGGGCT
CTATGGCTTCTGAGGCGGAAAGAACCA
AAGCTTAGGCTCGAGCGGCC
GCCACACAAAAAACCAACACACAGATGTAATGAAAATAAAGATATTTTATTTCTAGAGAAAC gatatgggctgaatacggatccgtattcagcccatatcgtttcccagatctctagcggatCt gacggttcactaaaccagctctgct
TATATAGACCTCCCACCGTACACGCCTACCGCCCATTTGCGTCAATGGGGCGGAGTTGTT
ACGACATTTTGGAAAGTCCCGTTGATTTTGGTGCCAAAACAAACTCCCATTGACGTCAAT
GGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTACTG
CCAAAACCGCATCACCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGG
AAAGTCCCATAAGGTCATGTACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGAC
GTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGCAGTTTA
CCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCGXTACTATGGGAAC
ATACGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATT
TACCGTAAGTTATGTAACGCGGAACTCCATATATGGGCTATGAACTAATGACCCCGTAAT
TGATTACTATTACAGTATTACGCGCTATGAGTAACACAAAATTATTCAGATTTCACTTCC
TCTTATTCAGTTTTCCCGCGAAAATGGCCAAATCTTACTCGGTTACGCCCAAATTTACTA
CAACATCCGCCTAAAACCGCGCGAAAATTGTCACTTCCTGTGTACACCGGCGCACACCAA
AAACGTCACTTTTGCCACATCCGTCGCTTACATGTGTTCCGCCACACTTGCAACATCACA
CTTCCGCCACACTACTACGTCACCCGCCCCGTTCCCACGCCCCGCGCCACGTCACAAACT
CCACCCCCTCATTATCATATTGGCTTCAATCCAAAATAAGGTATATTATTGATGATGTTAAG
CTT gtcgactcg aagatctggg cgtggttaag 421 ggtgggaaag aatatataag gtgggggtct tatgtagttt tgtatctgtt ttgcagcagc 481 cgccgccgcc atgagcacca actcgtttga tggaagcatt gtgagctcat atttgacaac 541 gcgcatgccc ccatgggccg gggtgcgtca gaatgtgatg ggctccagca ttgatggtcg 601 ccccgtcctg cccgcaaact ctactacctt gacctacgag accgtgtctg gaacgccgtt 661 ggagactgca gcctccgccg cogcttcagc cgctgcagcc accgcccgcg ggattgtgac 721 tgactttgct ttcctgagcc cgcttgcaag cagtgcagct tcccgttcat ccgcccgcga 781 tgacaagttg acggctcttt tggcacaatt ggattctttg acccgggaac ttaatgtcgt 841 ttctcagcag ctgttggatc tgcgccagca ggtttctgcc ctgaaggctt cctcccctcc 901 caatgcggtt taaaacataa ataaaaaacc agactctgtt tggatttgga tcaagcaagt 961 gtcttgctgt ctttatttag gggttttgcg cgcgcggtag gcccgggacc agcggtctcg 1021 gtcgttgagg gtcctgtgta ttttttccag gacgtggtaa aggtgactct ggatgttcag 1081 atacatgggc ataagcccgt ctctggggtg gaggtagcac cactgcagag cttcatgctg 1141 cggggtggtg ttgtagatga tccagtcgta gcaggagcgc tgggcgtggt gcctaaaaat 1201 gtctttcagt agcaagctga ttgccagggg caggcccttg gtgtaagtgt ttacaaagcg 1261 gttaagctgg gatgggtgca tacgtgggga tatgagatgc atcttggact gtatttttag 1321 gttggctatg ttcccagcca tatccctccg gggattcatg ttgtgcagaa ccaccagcac 1381 agtgtatccg gtgcacttgg gaaatttgtc atgtagctta gaaggaaatg cgtggaagaa 1441 cttggagacg cccttgtgac ctccaagatt ttccatgcat tcgtccataa tgatggcaat 1501 gggcccacgg gcggcggcct gggcgaagat atttctggga tcactaacgt catagttgtg 1561 ttccaggatg agatcgtcat aggccatttt tacaaagcgc gggcggaggg tgccagactg 1621 cggtataatg gttccatccg gcccaggggc gtagttaccc tcacagattt gcatttccca 1681 cgctttgagt tcagatgggg ggatcatgtc tacctgcggg gcgatgaaga aaacggtttc 1741 cggggtaggg gagatcagct gggaagaaag caggttcctg agcagctgcg acttaccgca 1801 gccggtgggc ccgtaaatca cacctattac cgggtgcaac tggtagttaa gagagctgca 1861 gctgccgtca tccctgagca ggggggccac ttcgttaagc atgtccctga ctcgcatgtt 1921 ttccctgacc aaatccgcca gaaggcgctc gccgcccagc gatagcagtt cttgcaagga 1981 agcaaagttt ttcaacggtt tgagaccgtc cgccgtaggc , atgcttttga gcgtttgacc 2041 aagcagttcc aggcggtccc acagctcggt cacctgctct acggcatctc gatccagcat 2101 atctcctcgt ttcgcgggtt ggggcggctt tcgctgtacg gcagtagtcg gtgctcgtcc 2161 agacgggcca gggtcatgtc tttccacggg cgcagggtcc tcgtcagcgt agtctgggtc 2221 acggtgaagg ggtgcgctcc gggctgcgcg ctggccaggg tgcgcttgag gctggtcctg 2281 ctggtgctga agcgctgccg gtcttcgccc tgcgcgtcgg ccaggtagca tttgaccatg 2341 gtgtcatagt ccagcccctc cgcggcgtgg cccttggcgc gcagcttgcc cttggaggag 2401 gcgccgcacg aggggcagtg cagacttttg agggcgtaga gcttgggcgc gagaaatacc 2461 gattccgggg agtaggcatc cgcgccgcag gccccgcaga cggtctcgca ttccacgagc 2521 caggtgagct ctggccgttc ggggtcaaaa accaggtttc ccccatgctt tttgatgcgt 2581 ttcttacctc tggtttccat gagccggtgt ccacgctcgg tgacgaaaag gctgtccgtg 2641 tccccgtata cagacttgag agggagttta aacgaattca atagcttgtt gcatgggcgg 2701 cgatataaaa tgcaaggtgc tgctcaaaaa atcaggcaaa gcctcgcgca aaaaagaaag 2761 cacatcgtag tcatgctcat gcagataaag gcaggtaagc tccggaacca ccacagaaaa 2821 agacaccatt tttctctcaa acatgtctgc gggtttctgc ataaacacaa aat.aaaat.aa 2881 caaaaaaaca tttaaacatt agaagcctgt cttacaacag gaaaaacaac ccttataagc 2941 ataagacgga ctacggccat gccggcgtga ccgtaaaaaa actggtcacc gtgattaaaa 3001 agcaccaccg acagctcctc ggtcatgtcc ggagtcataa tgtaagactc ggtaaacaca 3061 tcaggttgat tcatcggtca gtgctaaaaa gcgaccgaaa tagcccgggg gaatacatac 3121 ccgcaggcgt agagacaaca ttacagcccc cataggaggt ataacaaaat taataggaga 3181 gaaaaacaca taaacacctg aaaaaccctc ctgcctaggc aaaatagcac cctcccgctc 3241 cagaacaaca tacagcgctt cacagcggca gcctaacagt cagccttacc agtaaaaaag 3301 aaaacctatt aaaaaaacac cactcgacac ggcaccagct caatcagtca cagtgtaaaa 3361 aagggccaag tgcagagcga gtatatatag gactaaaaaa tgacgtaacg gttaaagtcc 3421 acaaaaaaca cccagaaaac cgcacgcgaa cctacgccca gaaacgaaag ccaaaaaacc 3481 cacaacttcc tcaaatcgtc acttccgttt tcccacgtta cgtaacttcc cattttaaga 3541 aaactacaat tcccaacaca tacaagttac tccgccctaa aacctacgtc acccgccccg 3601 ttcccacgcc ccgcgccacg tcacaaactc caccccctca ttatcatatt ggcttcaatc 3661 caaaataagg tatattattg atgatgttaa ttaacatgca tggatccata tgcggtgtga 3721 aataccgcac agatgcgtaa ggagaaaata ccgcatcagg cgctcttccg cttcctcgct 3781 cactgactcg ctgcgctcgg tcgttcggct gcggcgagcg gtatcagctc actcaaaggc 3841 ggtaatacgg ttatccacag aatcagggga taacgcagga aagaacatgt gagcaaaagg 3901 ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg 3961 cccccctgac gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg 4021 actataaaga taccaggcgt ttccccctgg aagctccctc gtgcgctctc ctgttccgac 4081 cctgccgctt accggatacc tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca 4141 tagctcacgc tgtaggtatc tcagttcggt gtaggtcgtt cgctccaagc tgggctgtgt 4201 gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc 4261 caacccggta agacacgact tatcgccact ggcagcagcc actggtaaca ggattagcag 4321 agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg tggcctaact acggctacac 4381 tagaaggaca gtatttggta tctgcgctct gctgaagcca gttaccttcg gaaaaagagt 4441 tggtagctct tgatccggca aacaaaccac cgctggtagc ggtggttttt ttgtttgcaa 4501 gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct tttctacggg 4561 gtctgacgct cagtggaacg aaaactcacg ttaagggatt ttggtcatga gattatcaaa 4621 aaggatcttc acctagatcc ttttaaatta aaaatgaagt tttaaatcaa tctaaagtat 4681 atatgagtaa acttggtctg acagttacca atgcttaatc agtgaggcac ctatctcagc 4741 gatctgtcta tttcgttcat ccatagttgc ctgactcccc gtcgtgtaga taactacgat 4801 acgggagggc ttaccatctg gccccagtgc tgcaatgata ccgcgagacc cacgctcacc 4861 ggctccagat ttatcagcaa taaaccagcc agccggaagg gccgagcgca gaagtggtcc 4921 tgcaacttta tccgcctcca tccagtctat taattgttgc cgggaagcta gagtaagtag 4981 ttcgccagtt aatagtttgc gcaacgttgt tgccattgct gcagccatga gattatcaaa 5041 aaggatcttc acctagatcc ttttcacgta gaaagccagt ccgcagaaac ggtgctgacc 5101 ccggatgaat gtcagctact gggctatctg gacaagggaa aacgcaagcg caaagagaaa 5161 gcaggtagct tgcagtgggc ttacatggcg atagctagac tgggcggttt tatggacagc 5221 aagcgaaccg gaattgccag ctggggcgcc ctctggtaag gttgggaagc cctgcaaagt 5281 aaactggatg gctttctcgc cgccaaggat ctgatggcgc aggggatcaa gctctgatca 5341 agagacagga tgaggatcgt ttcgcatgat tgaacaagat ggattgcacg caggttctcc 5401 ggccgcttgg gtggagaggc tattcggcta tgactgggca caacagacaa tcggctgctc 5461 tgatgccgcc gtgttccggc tgtcagcgca ggggcgcccg gttctttttg tcaagaccga 5521 cctgtccggt gccctgaatg aactgcaaga cgaggcagcg cggctatcgt ggctggccac 5581 gacgggcgtt ccttgcgcag ctgtgctcga cgttgtcact gaagcgggaa gggactggct 5641 gctattgggc gaagtgccgg ggcaggatct cctgtcatct caccttgctc ctgccgagaa 5701 agtatccatc atggctgatg caatgcggcg gctgcatacg cttgatccgg ctacctgccc 5761 attcgaccac caagcgaaac atcgcatcga gcgagcacgt actcggatgg aagccggtct 5821 tgtcgatcag gatgatctgg acgaagagca tcaggggctc gcgccagccg aactgttcgc 5881 caggctcaag gcgagcatgc ccgacggcga ggatctcgtc gtgacccatg gcgatgcctg 5941 cttgccgaat atcatggtgg aaaatggccg cttttctgga ttcatcgact gtggccggct 6001 gggtgtggcg gaccgctatc aggacatagc gttggctacc cgtgatattg ctgaagagct 6061 tggcggcgaa tgggctgacc gcttcctcgt gctttacggt atcgccgctc ccgattcgca 6121 gcgcatcgcc ttctatcgcc ttcttgacga gttcttctga attttgttaa aatttttgtt 6181 aaatcagctc attttttaac caataggccg aaatcggcaa catcccttat aaatcaaaag 6241 aatagaccgc gatagggttg agtgttgttc cagtttggaa caagagtcca ctattaaaga 6301 acgtggactc caacgtcaaa gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg 6361 aaccatcacc caaatcaagt tttttgcggt cgaggtgccg taaagctcta aatcggaacc 6421 ctaaagggag cccccgattt agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg 6481 aagggaagaa agcgaaagga gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc 6541 gcgtaaccac cacacccgcg cgcttaatgc gccgctacag ggcgcgtcca ttcgccattc 6601 aggatcgaat taattcttaa t SEQ ID: 16 shuttle Vector HA, CMV-luc taacatcatc aataatatac cttattttgg attgaagcca atatgataat gagggggtgg agtttgtgac gtggcgcggg gcgtgggaac ggggcgggtg acgtagtagt gtggcggaag tgtgatgttg caagtgtggc ggaacacatg taagcgacgg atgtggcaaa agtgacgttt ttggtgtgcg ccggtgtaca caggaagtga caattttcgc gcggttttag gcggatgttg tagtaaattt gggcgtaaco gagtaagatt tggccatttt cgcgggaaaa ctgaataaga ggaagtgaaa tctgaataat tttgtgttac tcatagcgcg
taatactGCTAGAga-tCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGC
CAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAATTGTAATACGACTCACTA TAGGGCGAATTGGGTACTGGCCAcagagcttggcccattgcatacgttgtatccatatcata atatgtacatttatattggctcatgtccaacattaccgccatgttgacattgattattgac-t agttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgt tacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgt caataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtg gagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgcc ccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgaccttat gggactttcctacttggcagtacatctacgtafcfcagtcafccgctattaccatggtgatgcgg ttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctcca ccccattgacgtcaatgggagtttgttttggcaccåaaatcaacgggactttccaaaatgtc gtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatata agcagagctcgtttagtgaaccgtcagatcgcctggagacgccatccacgctgttttgacct ccatagaagacaccgggaccgatccagcctgactctagCctAGCTCtgaagttggtggtgag gccctgggcaggttggtatcaaggttacaagacaggtttaaggagaccaatagaaactgggc atgfcggagacagagaagactcttgggtttctgataggcactgactctctctgcctattggtc
tattttcccacccttaggctgctggtctgagcctagGAGArC2iCTCGAGGTCGACGGTA2fcg atgcca ccATGGAGAA AATCGTCCTG TTGCTCGCTA TTGTGTCTCT 51 AGTGAAGAGC GATCAAATTT GTATCGGCTA CCATGCCAAT AACTCAACAG 101 AGCAGGTCGA TACTATCATG GAGAAAAACG TAACAGTTAC TCATGCCCAA 151 GACATCTTGG AAAAGACCCA CAACGGCAAA CTTTGCGACC TGGATGGAGT 201 GAAGCCCCTG ATCCTCCGGG ACTGTTCAGT CGCTGGTTGG CTGCTCGGGA 251 ACCCTATGTG TGATGAGTTT ATCAACGTGC CTGAATGGTC TTACATTGTG 301 GAGAAGGCTA ACCCTACCAA TGACCTCTGC TATCCTGGGT CATTTAACGA 351 TTACGAGGAA CTGAAACACC TGTTGTCTAG AATTAACCAC TTTGAAAAGA 4 01 TACAGATTAT ACCCAAGTCT AGTTGGAGTG ATCACGAAGC CTCCTCAGGC 451 GTTAGCTCAG CGTGTCCCTA TCTGGGCTCT CCATCCTTCT TTAGAAATGT 501 GGTCTGGTTA ATCAAAAAGA ACAGTACCTA CCCAACCATC AAAAAGTCTT 551 ATAACAATAC C AAT C AG GAG GACCTGCTCG TGTTGTGGGG TATCCATCAC 601 CCGAACGACG CCGCTGAACA GACTAGGCTG TATCAGAACC CCACTACATA 651 CATCAGTATT GGCACGAGTA CTCTGAACCA GCGATTAGTG CCAAAGATTG 7 01 CAACACGGAG CAAAGTAAAT GGGCAATCTG GCAGGATGGA GTTTTTCTGG 751 AC AAT C T T AA AACCCAACGA TGCGATAAAT TTCGAGTCCA ATGGCAATTT 801 CATCGCCCCT GAATACGCCT ATAAGATCGT GAAAAAGGGG GACTCTGCAA 851 TTATGAAGTC CGAATTAGAG TATGGCAATT GCAACACGAA GTGCCAGACA 901 CCAATGGGAG CCATTAATAG CTCAATGCCC TTCCATAATA TTCATCCATT 951 GACCATTGGG GAGTGCCCAA AGTACGTGAA GTCCAACCGC CTGGTCCTCG 1001 CAACCGGTCT AAGAAATAGC CCGCAGAGAG AATCGCGGAG GAAGAAACGT 1051 GGCCTGTTTG GCGCGATTGC CGGATTCATC GAGGGAGGCT GGCAGGGTAT 1101 GGTCGATGGT TGGTACGGAT ACCACCATAG CAACGAACAG GGGTCCGGCT 1151 ATGCAGCAGA TAAGGAGAGC ACTCAGAAAG CTATTGACGG AGTTACAAAC 1201 AAGGTTAATA GTATTATAGA TAAAATGAAC ACGCAATTCG AGGCCGTTGG 1251 GAGGGAGTTT AACAATCTGG AACGCCGGAT CGAAAATCTG AATAAGAAAA 1301 TGGAAGACGG CTTCCTTGAC GTGTGGACTT ATAATGCAGA GCTGCTTGTA 1351 CTCATGGAGA ACGAGAGGAC CCTGGATTTC CACGATAGCA ACGTGAAGAA 1401 CCTTTACGAC AAGGTGAGAC TTCAGCTCCG AGACAACGCC AAGGAGCTGG 1451 GGAATGGATG CTTCGAGTTT TACCACAAAT GTGACAATGA GTGCATGGAA 1501 AGTATACGCA ACGGGACCTA CAATTACCCT CAGTATAGCG AAGAGGCTCG 1551 GCTCAAACGC GAAGAGATAA GCGGGGTGAA ATTGGAATCA ATCGGAACAT 1601 ATCAAATCCT GTCCATCTAT TCCACCGTCG CCTCTTCGCT GGCCCTCGCT 1651 ATCATGATGG CTGGTCTGTC CCTATGGATG TGTTCCAATG GAAGCCTTCA 1701 GTGCCGTATT TGTATATGAg c
GGCCOCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTGTGCC
TT
CTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCC
ACTCCCAC
TGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTC
TGGGGGGT
GGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGC
GGTGGGCT CTATGGCTTCTGAGGCGGAAAGAACCAAAGCTtaacatcatc aataatatac cttattttgg attgaagcca atatgataat gagggggtgg 61 agtttgtgac gtggcgcggg gcgtgggaac ggggcgggtg acgtagtagt gtggcggaag 121 tgtgatgttg caagtgtggc ggaacacatg taagcgacgg atgtggcaaa agtgacgttt 181 ttggtgtgcg ccggtgtaca caggaagtga caattttcgc gcggttttag gcggatgttg 241 tagtaaattt gggcgtaacc gagtaagatt tggccatttt cgcgggaaaa ctgaataaga 301 ggaagtgaaa tctgaataat tttgtgttac tcatagcgcg taatactgta atagtaatca 361 attacggggt cattagttca tagcccatat atggagttcc gcgttacata acttacggta 421 aatggcccgc ctggctgacc gcccaacgac ccccgcccat tgacgtcaat aatgacgtat 481 gttcccatag taacgccaat agggactttc cattgacgtc aatgggtgga gtatttacgg 541 taaactgccc acttggcagt acatcaagtg tatcatatgc caagtacgcc ccctattgac 601 gtcaatgacg gtaaatggcc cgcctggcat tatgcccagt acatgacctt atgggacttt 661 cctacttggc agtacatcta cgtattagtc atcgctatta ccatggtgat gcggttttgg 721 cagtacatca atgggcgtgg atagcggttt gactcacggg gatttccaag tctccacccc 781 attgacgtca atgggagttt gttttggcac caaaatcaac gggactttcc aaaatgtcgt 841 aacaactccg ccccattgac gcaaatgggc ggtaggcgtg tacggtggga ggtctatata
901 agcagagctg gtttagtgaa ccgtcagatc cgctagAGAiTCTGGgaaacgatatgggctgaatacggatccgtattcagcccatatcgtttc T CT AGA AAT AAA ATA TCT TTA TTT TCA TTA CAT CTG TGT GTT GGT TTT TTG TGT GGC GG CCGCfccgagcct AAGCTTctag ataagatatc cgatccaccg gatctagata actgatcata 1021 atcagccata ccacatttgt agaggtttta cttgctttaa aaaacctccc acacctcccc 1081 ctgaacctga aacataaaat gaatgcaatt gttgttgtta acttgtttat tgcagcttat 1141 aatggttaca aataaagcaa tagcatcaca aatttcacaa ataaagcatt tttttcactg 1201 cattctagtt gtggtttgtc caaactcatc aatgtatctt aacgcggatc tgggcgtggt 1261 taagggtggg aaagaatata taaggtgggg gtcttatgta gttttgtatc tgttttgcag 1321 cagccgccgc cgccatgagc accaactcgt ttgatggaag cattgtg AGCTTg-tcgactcg aagatctggg cgtggttaag 421 ggtgggaaag aatatataag gtgggggtct tatgtagttt tgtatctgtt ttgcagcagc 481 cgccgccgcc atgagcacca actcgtttga tggaagcatt gtgagctcat atttgacaac 541 gcgcatgccc ccatgggccg gggtgcgtca gaatgtgatg ggctccagca ttgatggtcg 601 ccccgtcctg cccgcaaact ctactacctt gacctacgag accgtgtctg gaacgccgtt 661 ggagactgca gcctccgccg ccgcttcagc cgctgcagcc accgcccgcg ggattgtgac 721 tgactttgct ttcctgagcc cgcttgcaag cagtgcagct tcccgttcat ccgcccgcga 781 tgacaagttg acggctcttt tggcacaatt ggattctttg acccgggaac ttaatgtcgt 841 ttctcagcag ctgttggatc tgcgccagca ggtttctgcc ctgaaggctt cctcccctcc 901 caatgcggtt taaaacataa ataaaaaacc agactctgtt tggatttgga tcaagcaagt 961 gtcttgctgt ctttatttag gggttttgcg cgcgcggtag gcccgggacc agcggtctcg 1021 gtcgttgagg gtcctgtgta ttttttccag gacgtggtaa aggtgactct ggatgttcag 1081 atacatgggc ataagcccgt ctctggggtg gaggtagcac cactgcagag cttcatgctg 1141 cggggtggtg ttgtagatga tccagtcgta gcaggagcgc tgggcgtggt gcctaaaaat 1201 gtctttcagt agcaagctga ttgccagggg caggcccttg gtgtaagtgt ttacaaagcg 1261 gttaagctgg gatgggtgca tacgtgggga tatgagatgc atcttggact gtatttttag 1321 gttggctatg ttcccagcca tatccctccg gggattcatg ttgtgcagaa ccaccagcac 1381 agtgtatccg gtgcacttgg gaaatttgtc atgtagctta gaaggaaatg cgtggaagaa 1441 cttggagacg cccttgtgac ctccaaga'tt ttccatgcat tcgtccataa tgatggcaat 1501 gggcccacgg gcggcggcct gggcgaagat atttctggga tcactaacgt catagttgtg 1561 ttccaggatg agatcgtcat aggccatttt tacaaagcgc gggcggaggg tgccagactg 1621 cggtataatg gttccatccg gcccaggggc gtagttaccc tcacagattt gcatttccca 1681 cgctttgagt tcagatgggg ggatcatgtc tacctgcggg gcgatgaaga aaacggtttc 1741 cggggtaggg gagatcagct gggaagaaag caggttcctg agcagctgcg acttaccgca 1801 gccggtgggc ccgtaaatca cacctattac cgggtgcaac tggtagttaa gagagctgca 1861 gctgccgtca tccctgagca ggggggccac ttcgttaagc atgtccctga ctcgcatgtt 1921 ttccctgacc aaatccgcca gaaggcgctc gccgcccagc gatagcagtt cttgcaagga 1981 agcaaagttt ttcaacggtt tgagaccgtc cgccgtaggc atgcttttga gcgtttgacc 2041 aagcagttcc aggcggtccc acagctcggt cacctgctct acggcatctc gatccagcat 2101 atctcctcgt ttcgcgggtt ggggcggctt tcgctgtacg gcagtagtcg gtgctcgtcc 2161 agacgggcca gggtcatgto tttccacggg cgcagggtcc tcgtcagcgt agtctgggtc 2221 acggtgaagg ggtgcgctcc gggctgcgcg ctggccaggg tgcgcttgag gctggtcctg 2281 ctggtgctga agcgctgccg gtcttcgcoc tgcgcgtcgg ccaggtagca tttgaccatg 2341 gtgtcatagt ccagcccctc cgcggcgtgg cccttggcgc gcagcttgcc cttggaggag 2401 gcgccgcacg aggggcagtg cagacttttg agggcgtaga gcttgggcgc gagaaatacc 2461 gattccgggg agtaggcatc cgcgccgcag gccccgcaga cggtctcgca ttccacgagc 2521 caggtgagct ctggccgttc ggggtcaaaa accaggtttc ccccatgctt tttgatgcgt 2581 ttcttacctc tggtttccat gagccggtgt ccacgctcgg tgacgaaaag gctgtccgtg 2641 tccccgtata cagacttgag agggagttta aacgaattca atagcttgtt gcatgggcgg 2701 cgatataaaa tgcaaggtgc tgctcaaaaa atcaggcaaa gcctcgcgca aaaaagaaag 2761 cacatcgtag tcatgctcat gcagataaag gcaggtaagc tccggaacca ccacagaaaa 2821 agacaccatt tttctctcaa acatgtctgc gggtttctgc ataaacacaa aataaaataa 2881 caaaaaaaca tttaaacatt agaagcctgt cttacaacag gaaaaacaac ccttataagc 2941 ataagacgga ctacggccat gccggcgtga ccgtaaaaaa actggtcacc gtgattaaaa 3001 agcaccaccg acagctcctc ggtcatgtcc ggagtcataa tgtaagactc ggtaaacaca 3061 tcaggttgat tcatcggtca gtgctaaaaa gcgaccgaaa tagcccgggg gaatacatac 3121 ccgcaggcgt agagacaaca ttacagcccc cataggaggt ataacaaaat taataggaga 3181 gaaaaacaca taaacacctg aaaaaccctc ctgcctaggc aaaatagcac cctcccgctc 3241 cagaacaaca tacagcgctt cacagcggca gcctaacagt cagccttacc agtaaaaaag 3301 aaaacctatt aaaaaaacac cactcgacac ggcaccagct caatcagtca cagtgtaaaa 3361 aagggccaag tgcagagcga gtatatatag gactaaaaaa tgacgtaacg gttaaagtcc 3421 acaaaaaaca cccagaaaac cgcacgcgaa cctacgccca gaaacgaaag ccaaaaaacc 3481 cacaacttcc tcaaatcgtc acttccgttt tcccacgtta cgtaacttcc cattttaaga 3541 aaactacaat tcccaacaca tacaagttac tccgccctaa aacctacgtc acccgccccg 3601 ttcccacgcc ccgcgccacg tcacaaactc caccccctca ttatcatatt ggcttcaatc 3661 caaaataagg tatattattg atgatgttaa ttaacatgca tggatccata tgcggtgtga 3721 aataccgcac agatgcgtaa ggagaaaata ccgcatcagg cgctcttccg cttcctcgct 3781 cactgactcg ctgcgctcgg tcgttcggct gcggcgagcg gtatcagctc actcaaaggc 3841 ggtaatacgg ttatccacag aatcagggga taacgcagga aagaacatgt gagcaaaagg 3901 ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg 3961 ccccoctgac'gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg 4021 actataaaga taccaggcgt ttccccctgg aagctccctc gtgcgctctc ctgttccgac 4081 cctgccgctt accggatacc tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca 4141 tagctcacgc tgtaggtatc tcagttcggt gtaggtcgtt cgctccaagc tgggctgtgt 4201 gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc 4261 caacccggta agacacgact tatcgccact ggcagcagcc actggtaaoa ggattagcag 4321 agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg tggcctaact acggctacac 4381 tagaaggaca gtatttggta tctgcgctct gctgaagcca gttaccttcg gaaaaagagt 4441 tggtagctct tgatccggca aacaaaccac cgctggtagc ggtggttttt ttgtttgcaa 4501 gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct tttctacggg 4561 gtctgacgct cagtggaacg aaaactcacg ttaagggatt ttggtcatga gattatcaaa 4621 aaggatcttc acctagatcc ttttaaatta aaaatgaagt tttaaatcaa tctaaagtat 4681 atatgagtaa acttggtctg acagttacca atgcttaatc agtgaggcac ctatctcagc 4741 gatctgtcta tttcgttcat ccatagttgc ctgactcccc gtcgtgtaga taactacgat 4801 acgggagggc ttaccatctg gccccagtgc tgcaatgata ccgcgagacc cacgctcacc 4861 ggctccagat ttatcagcaa taaaccagcc agccggaagg gccgagcgca gaagtggtcc 4921 tgcaacttta tccgcctcca tccagtctat taattgttgc cgggaagcta gagtaagtag 4981 ttcgccagtt aatagtttgc gcaacgttgt tgccattgct gcagccatga gattatcaaa 5041 aaggatcttc acctagatcc ttttcacgta gaaagccagt ccgcagaaac ggtgctgacc 5101 ccggatgaat gtcagctact gggctatctg gacaagggaa aacgcaagcg caaagagaaa 5161 gcaggtagct tgcagtgggc ttacatggcg atagctagac tgggcggttt tatggacagc 5221 aagcgaaccg gaattgccag ctggggcgcc ctctggtaag gttgggaagc cctgcaaagt 5281 aaactggatg gctttctcgc cgccaaggat ctgatggcgc aggggatcaa gctctgatca 5341 agagacagga tgaggatcgt ttcgcatgat tgaacaagat ggattgcacg caggttctcc 5401 ggccgcttgg gtggagaggc tattcggcta tgactgggca caacagacaa tcggctgctc 5461 tgatgccgcc gtgttccggc tgtcagcgca ggggcgcccg gttctttttg tcaagaccga 5521 cctgtccggt gccctgaatg aactgcaaga cgaggcagcg cggctatcgt ggctggccac 5581 gacgggcgtt ccttgcgcag ctgtgctcga cgttgtcact gaagcgggaa gggactggct 5641 gctattgggc gaagtgccgg ggcaggatct cctgtcatct caccttgctc ctgccgagaa 5701 agtatccatc atggctgatg caatgcggcg gctgcatacg cttgatccgg ctacctgccc 5761 attcgaccac caagcgaaac atcgcatcga gcgagcacgt actcggatgg aagccggtct 5821 tgtcgatcag gatgatctgg acgaagagca tcaggggctc gcgccagccg aactgttcgc 5881 caggctcaag gcgagcatgc ccgacggcga ggatctcgtc gtgacccatg gcgatgcctg 5941 cttgccgaat atcatggtgg aaaatggccg cttttctgga ttcatcgact gtggccggct 6001 gggtgtggcg gaccgctatc aggacatagc gttggctacc cgtgatattg ctgaagagct 6061 tggcggcgaa tgggctgacc gcttcctcgt gctttacggt atcgccgctc ccgattcgca 6121 gcgcatcgcc ttctatcgcc ttcttgacga gttcttctga attttgttaa aatttttgtt 6181 aaatcagctc attttttaac caataggccg aaatcggcaa catcccttat aaatcaaaag 6241 aatagaccgc gatagggttg agtgttgttc cagtttggaa caagagtcca ctattaaaga 6301 acgtggactc caacgtcaaa gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg 6361 aaccatcacc caaatcaagt tttttgcggt cgaggtgccg taaagctcta aatcggaacc 6421 ctaaagggag cccccgattt agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg 6481 aagggaagaa agcgaaagga gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc 6541 gcgtaaccac cacacccgcg cgcttaatgc gccgctacag ggcgcgtcca ttcgccattc 6601 aggatcgaat taattcttaa t 1 taaggatccn nncctgtcct cgaccgatgc ccttgagagc cttcaaccca gtcagctcct 61 tccggtgggc gcggggcatg actatcgtcg ccgcacttat gactgtcttc tttatcatgc 121 aactcgtagg acaggtgccg gcagcgctct gggtcatttt cggcgaggac cgctttcgct 181 ggagcgcgac gatgatcggc ctgtcgcttg cggtattcgg aatcttgcac gccctcgctc 241 aagccttcgt cactggtccc gccaccaaac gtttcggcga gaagcaggcc attatcgccg 301 gcatggcggc cgacgcgctg ggctacgtct tgctggcgtt cgcgacgcga ggctggatgg 361 ccttccccat tatgattctt ctcgcttccg gcggcatcgg gatgcccgcg ttgcaggcca 421 tgctgtccag gcaggtagat gacgaccatc agggacagct tcaaggatcg ctcgcggctc 481 ttaccagcct aacttcgatc actggaccgc tgatcgtcac ggcgatttat gccgcctcgg 541 cgagcacatg gaacgggttg gcatggattg taggcgccgc cctatacctt gtctgcctcc 601 ccgcgttgcg tcgcggtgca tggagccggg ccacctcgac ctgaatggaa gccggcggca 661 cctcgctaac ggattcacca ctccaagaat tggagccaat caattcttgc ggagaactgt 721 gaatgcgcaa accaaccctt ggcagaacat atccatcgcg tccgccatct ccagcagccg 781 cacgcggcgc atctcgggca gcgttgggtc ctggccacgg gtgcgcatga tcgtgctcct 841 gtcgttgagg acccggctag gctggcgggg ttgccttact ggttagcaga atgaatcacc 901 gatacgcgag cgaacgtgaa gcgactgctg ctgcaaaacg tctgcgacct gagcaacaac 961 atgaatggtc ttcggtttcc gtgtttcgta aagtctggaa acgcggaagt cagcgccctg 1021 caccattatg ttccggatct gcatcgcagg atgctgctgg ctaccctgtg gaacacctac 1081 atctgtatta acgaagcgct ggcattgacc ctgagtgatt tttctctggt cccgccgcat 1141 ccataccgcc agttgtttac cctcacaacg ttccagtaac cgggcatgtt catcatcagt 1201 aacccgtatc gtgagcatcc tctctcgttt catcggtatc attaccccca tgaacagaaa 1261 ttccccctta cacggaggca tcaagtgacc aaacaggaaa aaaccgccct taacatggcc 1321 cgctttatca gaagccagac attaacgctt ctggagaaac tcaacgaget ggaegeggat 1381 gaacaggcag acatctgtga atcgcttcac gaccacgctg atgagettta ccgcagctgc 1441 ctcgcgcgtt teggtgatga cggtgaaaac ctctgacaca tgcagctccc ggagaeggte 1501 acagcttgtc tgtaagcgga tgccgggagc agacaagccc gtcagggcgc gtcagcgggt 1561 gttggcgggt gtcggggcgc agccatgacc cagtcacgta gcgatagcgg agtgtatact 1621 ggcttaacta tgcggcatca gagcagattg tactgagagt gcaccatatg cggtgtgaaa 1681 taccgcacag atgcgtaagg agaaaatacc gcatcaggcg ctcttccgct tcctcgctca 1741 ctgactcgct gcgctcggtc gttcggctgc ggcgagcggt atcagctcac tcaaaggcgg 1801 taatacggtt atccacagaa tcaggggata acgcaggaaa gaacatgtga gcaaaaggcc 1861 agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc gtttttccat aggctccgcc 1921 cccctgacga gcatcacaaa aatcgacgct caagtcagag gtggcgaaac ccgacaggac 1981 tataaagata ccaggcgttt ccccctggaa gctccctcgt gcgctctcct gttccgaccc 2041 tgccgcttac cggatacctg tccgcctttc tcccttcggg aagcgtggcg ctttctcaat 2101 gctcacgctg taggtatctc agttcggtgt aggtcgttcg ctccaagctg ggctgtgtgc 2161 acgaaccccc cgttcagccc gaccgctgcg ccttatccgg taactatcgt cttgagtcca 2221 acccggtaag acacgactta tcgccactgg cagcagccac tggtaacagg attagcagag 2281 cgaggtatgt aggcggtgct acagagttct tgaagtggtg gcctaactac ggctacacta 2341 gaaggacagt atttggtatc tgcgctctgc tgaagccagt taccttcgga aaaagagttg 2401 gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tggttttttt gtttgcaagc 2461 agcagattac gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt tctacggggt 2521 ctgacgctca gtggaacgaa aactcacgtt aagggatttt ggtcatgaga ttatcaaaaa 2581 ggatcttcac ctagatcctt ttaaattaaa aatgaagttt taaatcaatc taaagtatat 2641 atgagtaaac ttggtctgac agttaccaat gcttaatcag tgaggcacct atctcagcga 2701 tctgtctatt tcgttcatcc atagttgcct gactccccgt cgtgtagata actacgatac 2761 gggagggctt accatctggc cccagtgctg caatgatacc gcgagaccca cgctcaccgg 2821 ctccagattt atcagcaata aaccagccag ccggaagggc cgagcgcaga agtggtcctg 2881 caactttatc cgcctccatc cagtctatta attgttggcg ggaagctaga gtaagtagtt 2941 cgccagttaa tagtttgcgc aacgttgttg ccattgctgc agccatga gattatcaaa aaggatcttc acctagatcc ttttcacgta gaaagccagt ccgcagaaac ggtgctgacc ccggatgaat gtcagctact gggctatctg gacaagggaa aacgcaagcg caaagagaaa gcaggtagct tgcagtgggc ttacatggcg atagctagac tgggcggttt tatggacagc aagcgaaccg gaattgccag ctggggcgcc ctctggtaag gttgggaagc cctgcaaagt aaactggatg gctttctcgc ogccaaggat ctgatggcgc aggggatcaa gctctgatca agagacagga tgaggatcgt ttcgcatgat tgaacaagat ggattgcacg caggttctcc ggccgcttgg gtggagaggc tattcggcta tgactgggca caacagacaa tcggctgctc tgatgccgcc gtgttccggc tgtcagcgca ggggcgcccg gttctttttg tcaagaccga cctgtccggt gccctgaatg aactgcaaga cgaggcagcg cggctatcgt ggctggccac gacgggcgtt ccttgcgcag ctgtgctcga cgttgtcact gaagcgggaa gggactggct gctattgggc gaagtgccgg ggcaggatct cctgtcatct caccttgctc ctgccgagaa agtatccatc atggctgatg caatgcggcg gctgcatacg cttgatccgg ctacctgccc attcgaccac caagcgaaac atcgcatcga gcgagcacgt actcggatgg aagccggtct tgtcgatcag gatgatctgg acgaagagca tcaggggctc gcgccagccg aactgttcgc caggctcaag gcgagcatgc ccgacggcga ggatctcgtc gtgacccatg gcgatgcctg cttgccgaat atcatggtgg aaaatggccg cttttctgga ttcatcgact gtggccggct gggtgtggcg gaccgctatc aggacatagc gttggctacc cgtgatattg ctgaagagct tggcggcgaa tgggctgacc gcttcctcgt gctttacggt atcgccgctc ccgattcgca gcgcatcgcc ttctatcgcc ttcttgacga gttcttctga attttgttaa aatttttgtt aaatcagctc attttttaac caataggccg aaatcggcaa catcccttat aaatcaaaag aatagaccgc gatagggttg agtgttgttc cagtttggaa caagagtcca ctattaaaga acgtggactc caacgtcaaa gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg aaccatcacc caaatcaagt tttttgcggt cgaggtgccg taaagctcta aatcggaacc ctaaagggag cccccgattt agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg aagggaagaa agcgaaagga gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc gcgtaaccac cacacccgcg cgcttaatgc gccgctacag ggcgcgtcca ttcgccattc aggatcgaat taattcttaa ttaacatcatc aataatatac cttattttgg attgaagcca atatgataat gagggggtgg agtttgtgac gtggcgcggg gcgtgggaao ggggcgggtg acgtagtagt gtggcggaag tgtgatgttg caagtgtggc ggaacacatg taagcgacgg atgtggcaaa agtgacgttt ttggtgtgcg ccggtgtaca caggaagtga caattttcgc gcggttttag gcggatgttg tagtaaattt gggcgtaacc gagtaagatt tggccatttt cgcgggaaaa ctgaataaga ggaagtgaaa tctgaataat tttgtgttac tcatagcgcg
taatactGCTAGAgatCTGGCGAAAGGGGGATGl'GCTGCAAGGCGATTAAGTTGGGTAACGC CAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAATTGTAATACGACTCACTA TAGGGCGAATTGGGTACTGGCCAcagagcttggcccattgcatacgttgtatccatatcata atatgtacatttatattggctcatgtccaacattaccgccatgttgacattgattattgaet ag-ttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgt tacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgt caataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtg gagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgcc ccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgaccttat gggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcgg ttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctcca ccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtc gtaacaactocgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatata agcagagctcgtttagtgaaccgtcagatcgcctggagacgccatccacgctgttttgacct ccatagaagacaccgggaccgatccagcctgactctagCctAGCTCtgaagttggtggtgag gocctgggcaggttggtatcaaggttacaagacaggtttaaggagaccaatagaaactgggc atgtggagacagagaagactcttgggtttctgataggcactgactctctctgcctattggtc tattttcccacccttaggctgctggtctgagcctagGAGATCTCTCGAGGTCGAOGGTATcg atgcca CCATGGAGAA AATCGTCCTG TTGCTCGCTA TTGTGTCTCTAGTGAAGAGC GATCAAATTT GTATCGGCTA CCATGCCAAT AACTCAACAGAGCAGGTCGA TACTATCATG GAGAAAAACG TAACAGTTAC TCATGCCCAA GACATCTTGG AAAAGACCCA CAACGGCAAA CTTTGCGACC TGGATGGAGT GAAGCCCCTG ATCCTCCGGG ACTGTTCAGT CGCTGGTTGG CTGCTCGGGA ACCCTATGTG TGATGAGTTT ATCAACGTGC CTGAATGGTC TTACATTGTG GAGAAGGCTA ACCCTACCAA TGACCTCTGC TATCCTGGGT CATTTAACGA TTACGAGGAA CTGAAACACC TGTTGTCTAG AATTAACCAC TTTGAAAAGA TACAGATTAT ACCCAAGTCT AGTTGGAGTG ATCACGAAGC CTCCTCAGGC GTTAGCTCAG CGTGTCCCTA TCTGGGCTCT CCATCCTTCT TTAGAAATGT GGTCTGGTTA ATCAAAAAGA ACAGTACCTA CCCAACCATC AAAAAGTCTT ATAACAATAC CAATCAGGAG GACCTGCTCG TGTTGTGGGG TATCCATCAC CCGAACGACG CCGCTGAACA GACTAGGCTG TATCAGAACC CCACTACATA CATCAGTATT GGCACGAGTA CTCTGAACCA GCGATTAGTG CCAAAGATTG CAACACGGAG CAAAGTAAAT GGGCAATCTG GCAGGATGGA GTTTTTCTGG ACAATCTTAA AACCCAACGA TGCGATAAAT TTCGAGTCCA ATGGCAATTT CATCGCCCCT GAATACGCCT ATAAGATCGT GAAAAAGGGG GACTCTGCAA TTATGAAGTC CGAATTAGAG TATGGCAATT GCAACACGAA GTGCCAGACA CCAATGGGAG CCATTAATAG CTCAATGCCC TTCCATAATA TTCATCCATT GACCATTGGG GAGTGCCCAA AGTACGTGAA GTCCAACCGC CTGGTCCTCG CAACCGGTCT AAGAAATAGC CCGCAGAGAG AATCGCGGAG GAAGAAACGT GGCCTGTTTG GCGCGATTGC CGGATTCATC GAGGGAGGCT GGCAGGGTAT GGTCGATGGT TGGTACGGAT ACCACCATAG CAACGAACAG GGGTCCGGCT
ATGCAGCAGA TAAGGAGAGC ACTCAGAAAG CTATTGACGG AGTTACAAAC AAGGTTAATA GTATTATAGA TAAAATGAAC ACGCAATTCG AGGCCGTTGG GAGGGAGTTT AACAATCTGG AACGCCGGAT CGAAAATCTG AATAAGAAAA TGGAAGACGG CTTCCTTGAC GTGTGGACTT ATAATGCAGA GCTGCTTGTA CTCATGGAGA ACGAGAGGAC CCTGGATTTC CACGATAGCA ACGTGAAGAA 1401 CCTTTACGAC AAGGTGAGAC TTCAGCTCCG AGACAACGCC AAGGAGCTGGGGAATGGATG CTTCGAGTTT TACCACAAAT GTGACAATGA GTGCATGGAAAGTATACGCA ACGGGACCTA CAATTACCCT CAGTATAGCG AAGAGGCTCGGCTCAAACGC GAAGAGATAA GCGGGGTGAA ATTGGAATCA ATCGGAACATATCAAATCCT GTCCATCTAT TCCACCGTCG CCTCTTCGCT GGCCCTCGCT ATCATGATGG CTGGTCTGTC CCTATGGATG TGTTCCAATG GAAGCCTTCAGTGCCGTATT TGTATATGAg c
GGCCSCCCTATTCTATAGTGTCACCTAAATGCTAGaGerCGCTGATCAGCCTCGACTGTGCC
TT
CTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCC
ACTCCCAC
TGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTC
TGGGGGGT
GGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGC
GGTGGGCT CTATGGCTTCTGAGGCGGAAAGAACCAAAGCTtaacatcatc aataatatac cttattttgg attgaagcca atatgataat gagggggtgg agtttgtgac gtggcgcggg gcgtgggaac ggggcgggtg acgtagtagt gtggcggaag tgtgatgttg caagtgtggc ggaacacatg taagcgacgg atgtggcaaa agtgacgttt ttggtgtgcg ccggtgtaca caggaagtga caattttcgc gcggttttag gcggatgttg tagtaaattt gggcgtaacc gagtaagatt tggccatttt cgcgggaaaa ctgaataaga ggaagtgaaa tctgaataat tttgtgttac tcatagcgcg taatactgta atagtaatca attacggggt cattagttca tagcccatat atggagttcc gcgttacata acttacggta aatggcccgc ctggctgacc gcccaacgac ccccgcccat tgacgtcaat aatgacgtat gttcccatag taacgccaat agggactttc cattgacgtc aatgggtgga gtatttacgg taaactgccc acttggcagt acatcaagtg tatcatatgc caagtacgcc ccctattgac gtcaatgacg gtaaatggcc cgcctggcat tatgcccagt acatgacctt atgggacttt cctacttggc agtacatcta cgtattagtc atcgctatta ccatggtgat gcggttttgg cagtacatca atgggcgtgg atagcggttt gactcacggg gatttccaag tctccacccc attgacgtca atgggagttt gttttggcac caaaatcaac gggactttcc aaaatgtcgt aacaactccg ccccattgac gcaaatgggc ggtaggcgtg tacggtggga ggtctatata
agcagagctg gtttagtgaa ccgtcagatc cgctagAGArcroGgaaacgatatgggctgaatacggatccgtattcagcccatatcgtttc TCT AGA AAT AAA ΑΤΆ TCT TTA TTT TCA TTA CAT CTG TGT GTT GGT TTT TTG TGT GGC GG CCGCtcgagcct AAGCTTctag ataagatatc cgatccaccg gatctagata actgatcata atcagccata ccacatttgt agaggtttta cttgctttaa aaaacctccc acacctcccc ctgaacctga aacataaaat gaatgcaatt gttgttgtta acttgtttat tgcagcttat aatggttaca aataaagcaa tagcatcaca aatttcacaa ataaagcatt tttttcactg cattctagtt gtggtttgtc caaactcatc aatgtatctt aacgcggatc tgggcgtggt taagggtggg aaagaatata taaggtgggg gtcttatgta gttttgtatc tgttttgcag cagccgccgc cgccatgagc accaactcgt ttgatggaag cattgtg AGCTTgtcgactcg aagatctggg cgtggttaag ggtgggaaag aatatataag gtgggggtct tatgtagttt tgtatctgtt ttgcagcagc cgccgccgcc atgagcacca actcgtttga tggaagcatt gtgagctcat atttgacaac gcgcatgccc ccatgggccg gggtgcgtoa gaatgtgatg ggctccagca ttgatggtcg ccccgtcctg cccgcaaact ctactacctt gacctacgag accgtgtctg gaacgccgtt ggagactgca gcctccgccg ccgcttcagc cgctgcagcc accgcccgcg ggattgtgac tgactttgct ttcctgagcc cgcttgcaag cagtgcagct tcocgttcat ccgcccgcga tgacaagttg acggctcttt tggcacaatt ggattctttg acccgggaac ttaatgtcgt ttctcagcag ctgttggatc tgcgccagca ggtttctgcc ctgaaggctt cctcccctcc caatgcggtt taaaacataa ataaaaaacc agactctgtt tggatttgga tcaagcaagt gtcttgctgt ctttatttag gggttttgcg cgcgcggtag gcccgggacc agcggtctcg gtcgttgagg gtcctgtgta ttttttccag gacgtggtaa aggtgactct ggatgttcag atacatgggc ataagcccgt ctctggggtg gaggtagcao cactgcagag ottcatgctg cggggtggtg ttgtagatga tccagtcgta gcaggagcgc tgggcgtggt gcctaaaaat gtctttcagt agcaagctga ttgccagggg caggcccttg gtgtaagtgt ttacaaagcg gttaagctgg gatgggtgca tacgtgggga tatgagatgc atcttggact gtatttttag gttggctatg ttcccagcca tatccctccg gggattcatg ttgtgcagaa ccaccagcac agtgtatccg gtgcacttgg gaaatttgtc atgtagctta gaaggaaatg cgtggaagaa cttggagacg cccttgtgac ctccaagatt ttccatgcat tcgtccataa tgatggcaat gggcccacgg gcggcggcct gggcgaagat atttctggga tcactaacgt catagttgtg ttccaggatg agatcgtcat aggccatttt tacaaagcgc gggcggaggg tgccagactg cggtataatg gttccatccg gcccaggggc gtagttaccc tcacagattt gcatttccca cgctttgagt tcagatgggg ggatcatgtc tacctgcggg gcgatgaaga aaacggtttc cggggtaggg gagatcagct gggaagaaag caggttcctg agcagctgcg acttaccgca gccggtgggc ccgtaaatca cacctattac cgggtgcaac tggtagttaa gagagct g cagctgccgt catccctgag caggggggcc acttcgttaa gcatgtccct gactcgcatg ttttccctga ccaaatccgc cagaaggcgc tcgccgccca gcgatagcag ttcttgcaag gaagcaaagt ttttcaacgg tttgagaccg tccgccgtag gcatgctttt gagcgtttga ccaagcagtt ccaggcggtc ccacagctcg gtcacctgct ctacggcatc tcgatccagc atatctcctc gtttcgcggg ttggggcggo tttcgctgta cggcagtagt cggtgctcgt ccagacgggc cagggtcatg tctttccacg ggcgcagggt cctcgtcagc gtagtctggg tcacggtgaa ggggtgcgct ccgggctgcg cgctggccag ggtgcgcttg aggctggtcc tgctggtgct gaagcgctgc cggtcttcgc cctgcgogtc ggccaggtag catttgacca tggtgtcata gtccagcccc tccgcggcgt ggcccttggc gcgcagcttg cccttggagg aggcgccgca cgaggggcag tgcagacttt tgagggcgta gagcttgggc gcgagaaata ccgattccgg ggagtaggca tccgcgccgc aggccccgca gacggtctcg cattccacga gccaggtgag ctctggccgt tcggggtcaa aaaocaggtt tcccccatgc tttttgatgc gtttcttacc tctggtttcc atgagccggt gtccacgctc ggtgacgaaa aggctgtccg tgtccccgta tacagacttg agaggcctgt cctcgagcgg tgttccgcgg tcctcctcgt atagaaactc ggaccactct gagacaaagg ctcgcgtcca ggccagcaog aaggaggcta agtgggaggg gtagcggtcg ttgtccacta gggggtccac tcgctccagg gtgtgaagac acatgtcgcc ctcttcggca tcaaggaagg tgattggttt gtaggtgtag gccacgtgac cgggtgttcc tgaagggggg ctataaaagg gggtgggggc gcgttcgtcc tcactctctt ccgcatcgct gtctgcgagg gccagctgtt ggggtgagta ctccctctga aaagcgggca tgacttctgc gctaagattg tcagtttcca 6301 aaaacgagga ggatttgata ttcacctggc ccgcggtgat gcctttgagg gtggccgcat 6361 ccatctggtc agaaaagaca atctttttgt tgtcaagctt ggtggcaaac gacccgtaga 6421 gggcgttgga cagcaacttg gcgatggagc gcagggtttg gtttttgtcg cgatcggcgc 6481 gctccttggc cgcgatgttt agctgcacgt attcgcgcgc aacgcaccgc cattcgggaa 6541 agacggtggt gcgctcgtcg ggcaccaggt gcacgcgcca accgcggttg tgcagggtga 6601 caaggtcaac gctggtggct acctctccgc gtaggcgctc gttggtccag cagaggcggc 6661 cgcccttgcg cgagcagaat ggcggtaggg ggtctagctg cgtctcgtcc ggggggtctg 6721 cgtccacggt aaagaccccg ggcagcaggc gcgcgtcgaa gtagtctatc ttgcatcctt 6781 gcaagtctag cgcctgctgc catgcgcggg cggcaagcgc gcgctcgtat gggttgagtg 6841 ggggacccca tggcatgggg tgggtgagcg cggaggcgta catgccgcaa atgtcgtaaa 6901 cgtagagggg ctctctgagt attccaagat atgtagggta gcatcttcca ccgcggatgc 6961 tggcgcgcac gtaatcgtat agttcgtgcg agggagcgag gaggtcggga ccgaggttgc 7021 tacgggcggg ctgctctgct cggaagacta tctgcctgaa gatggcatgt gagttggatg 7081 atatggttgg acgctggaag acgttgaagc tggcgtctgt gagacctacc gcgtcacgca 7141 cgaaggaggc gtaggagtcg cgcagcttgt tgaccagctc ggcggtgacc tgcacgtcta 7201 gggcgcagta gtccagggtt tcct'tgatga tgtcatactt atcctgtccc ttttttttcc 7261 acagctcgcg gttgaggaca aactcttcgc ggtctttcca gtactc'ttgg atcggaaacc 7321 cgtcggcctc cgaacggtaa gagcctagca tgtagaactg gttgacggcc tggtaggcgc 7381 agcatccctt ttctacgggt agcgcgtatg cctgcgcggc cttccggagc gaggtgtggg 7441 tgagcgcaaa ggtgtccctg accatgactt tgaggtactg gtatttgaag tcagtgtcgt 7501 cgcatccgcc ctgctcccag agcaaaaagt ccgtgcgctt tttggaacgc ggatttggca 7561 gggcgaaggt gacatcgttg aagagtatct ttcccgcgcg aggcataaag ttgcgtgtga 7621 tgcggaaggg tcccggcacc tcggaacggt tgttaattac ctgggcggcg agcacgatct 7681 cgtcaaagcc gttgatgttg tggcccacaa tgtaaagttc caagaagcgc gggatgccct 7741 tgatggaagg caatttttta agttcctcgt aggtgagctc ttcaggggag ctgagcccgt 7801 gctctgaaag ggcccagtct gcaagatgag ggttggaagc gacgaatgag ctccacaggt 7861 cacgggccat tagcatttgc aggtggtcgc gaaaggtcct aaactggcga cctatggcca 7921 ttttttctgg ggtgatgcag tagaaggtaa gcgggtcttg ttcccagcgg tcccatccaa 7981 ggttcgcggc taggtctcgc gcggcagtca ctagaggctc atctccgccg aacttcatga 8041 ccagcatgaa gggcacgagc tgcttcccaa aggcccccat ccaagtatag gtctctacat 8101 cgtaggtgac aaagagacgc tcggtgcgag gatgcgagcc gatcgggaag aactggatct 8161 cccgccacca attggaggag tggctattga tgtggtgaaa gtagaagtcc ctgcgacggg 8221 ccgaacactc gtgctggctt. ttgtaaaaac gtgcgcagta ctggcagcgg tgcacgggct 8281 gtacatcctg cacgaggttg acctgacgac cgcgcacaag gaagcagagt gggaatttga 8341 gcccctcgcc tggcgggttt ggctggtggt cttctacttc ggctgcttgt ccttgaccgt 8401 ctggctgctc gaggggagtt acggtggatc ggaccaccac gccgcgcgag cccaaagtcc 8461 agatgtccgc gcgcggcggt cggagcttga tgacaacatc gcgcagatgg gagctgtcca 8521 tggtctggag ctcccgcggc gtcaggtcag gcgggagctc ctgcaggttt acctcgcata 8581 gacgggtoag ggcgcgggct agatccaggt gatacctaat ttccaggggc tggttggtgg 8641 cggcgtcgat ggcttgcaag aggccgcatc cccgcggcgc gactacggta ccgcgcggcg 8701 ggcggtgggc cgcgggggtg tccttggatg atgcatctaa aagcggtgac gcgggcgagc 8761 ccccggaggt agggggggct ccggacccgc cgggagaggg ggcaggggca cgtcggcgcc 8821 gcgcgcgggc aggagctggt gctgcgcgcg taggttgctg gcgaacgcga cgacgcggcg 8881 gttgatctcc tgaatctggc gcctctgcgt gaagacgacg ggcccggtga gcttgagcct 8941 gaaagagagt tcgacagaat caatttcggt gtcgttgacg gcggcctggc gcaaaatctc 9001 ctgcacgtct cctgagttgt cttgataggc gatctcggcc atgaactgct cgatctcttc 9061 ctcctggaga tctccgcgtc cggctcgctc cacggtggcg gcgaggtcgt tggaaatgcg 9121 ggccatgagc tgcgagaagg cgttgaggcc tccctcgttc cagacgcggc tgtagaccac 9181 gcccccttcg gcatcgcggg cgcgcatgac cacctgcgcg agattgagct ccacgtgccg 9241 ggcgaagacg gcgtagtttc gcaggcgctg aaagaggtag ttgagggtgg tggcggtgtg 9301 ttctgccacg aagaagtaca taacccagcg tcgcaacgtg gattcgttga tatcccccaa 9361 ggcctcaagg cgctccatgg cctcgtagaa gtccacggcg aagttgaaaa actgggagtt 9421 gcgcgccgac acggttaact cctcctccag aagacggatg agctcggcga cagtgtcgcg 9481 cacctcgcgc tcaaaggcta caggggcctc ttcttcttct tcaatctcct cttccataag 9541 ggcctcccct tcttcttctt ctggcggcgg tgggggaggg gggacacggc ggcgacgacg 9601 gcgcaccggg aggcggtcga caaagcgctc gatcatctcc ccgcggcgac ggcgcatggt 9661 ctcggtgacg gcgcggccgt tctcgcgggg gcgcagttgg aagacgccgc ccgtcatgtc 9721 ccggttatgg gttggcgggg ggctgccatg cggcagggat acggcgctaa cgatgcatct 9781 caacaattgt tgtgtaggta ctccgccgcc gagggacctg agcgagtccg catcgaccgg 9841 atcggaaaac ctctcgagaa aggcgtctaa ccagtcacag tcgcaaggta ggctgagcac 9901 cgtggcgggc ggcagcgggc ggcggtcggg gttgtttctg gcggaggtgc tgctgatgat 9961 gtaattaaag taggcggtct tgagacggcg gatggtcgac agaagcacca tgtccttggg 10021 tccggcctgc tgaatgcgca ggcggtcggc catgccccag gcttcgtttt gacatcggcg 10081 caggtctttg tagtagtctt gcatgagcct ttctaccggc acttcttctt ctccttcctc 10141 tt.gtcctgca tctcttgcat ctatcgctgc ggcggcggcg gagtttggcc gtaggtggcg 10201 ccctcttcct cccatgcgtg tgaccccgaa gcccctcatc ggctgaagca gggctaggtc 10261 ggcgacaacg cgctcggcta atatggcctg ctgcacctgc gtgagggtag actggaagtc 10321 atccatgtcc acaaagcggt ggtatgcgcc cgtgttgatg gtgtaagtgc agttggccat 10381 aacggaccag ttaacggtct ggtgacccgg ctgcgagagc tcggtgtacc tgagacgcga 10441 gtaagccctc gagtcaaata cgtagtcgtt gcaagtccgc accaggtact ggtatcccac 10501 caaaaagtgc ggcggcggct ggcggtagag gggccagcgt agggtggccg gggctccggg 10561 ggcgagatct tccaacataa ggcgatgata tccgtagatg tacctggaca tccaggtgat 10621 gccggcggcg gtggtggagg cgcgcggaaa gtcgcggacg cggttccaga tgttgcgcag 10681 cggcaaaaag tgctccatgg tcgggacgct ctggccggtc aggcgcgc:gc aatcgttgac 10741 gctctaccgt gcaaaaggag agcctgtaag cgggcactct tccgtggtct ggtggataaa 10801 ttcgcaaggg tatcatggcg gacgaccggg gttcgagccc cgtatccggc cgtccgccgt 10861 gatccatgcg gttaccgccc gcgtgtcgaa cccaggtgtg cgacgtcaga caacggggga 10921 gtgctccttt tggcttcctt ccaggcgcgg cggctgctgc gctagctttt ttggccactg 10981 gccgcgcgca gcgtaagcgg ttaggctgga aagcgaaagc attaagtggc tcgctccctg 11041 tagccggagg gttattttcc aagggttgag tcgcgggacc cccggttcga gtctcggacc 11101 ggccggactg cggcgaacgg gggtttgcct ccccgtcatg caagaccccg cttgcaaatt 11161 cctccggaaa cagggacgag cccctttttt gcttttccca gatgcatccg gtgctgcggc 11221 agatgcgccc ccctcctcag cagcggcaag agcaagagca gcggcagaca tgcagggcac 11281 cctcccctcc tcctaccgcg tcaggagggg cgacatccgc ggttgacgcg gcagcagatg 11341 gtgattacga acccccgcgg cgccgggccc ggcactacct ggacttggag gagggcgagg 11401 gcctggcgcg gctaggagcg ccctctcctg agcggtaccc aagggtgcag ctgaagcgtg 11461 atacgcgtga ggcgtacgtg ccgcggcaga acctgtttcg cgaccgcgag ggagaggagc 11521 ccgaggagat gcgggatcga aagttccacg cagggcgcga gctgcggcat ggcctgaatc 11581 gcgagcggtt gctgcgcgag gaggactttg agcccgacgc gcgaaccggg attagtcccg 11641 cgcgcgcaca cgtggcggcc gccgacctgg taaccgcata cgagcagacg gtgaaccagg 11701 agattaactt tcaaaaaagc tttaacaacc' acgtgcgtac gcttgtggcg cgcgaggagg 11761 tggctatagg actgatgcat ctgtgggact ttgtaagcgc gctggagcaa aacccaaata 11821 gcaagccgct catggcgcag ctgttcctta tagtgcagca cagcagggac aacgaggcat 11881 tcagggatgc gctgctaaac atagtagagc ccgagggccg ctggctgctc gatttgataa 11941 acatcctgca gagcatagtg gtgcaggagc gcagcttgag cctggctgac aaggtggccg 12001 ccatcaacta ttccatgctt agcctgggca agttttacgc ccgcaagata taccataccc 12061 cttacgttcc catagacaag gaggtaaaga tcgaggggtt ctacatgcgc atggcgctga 12121 aggtgcttac cttgagcgac gacctgggcg tttatcgcaa cgagcgcatc cacaaggccg 12181 tgagcgtgag ccggcggcgc gagctcagcg accgcgagct gatgcacagc ctgcaaaggg 12241 ccctggctgg cacgggcagc ggcgatagag aggccgagtc ctactttgac gcgggcgctg 12301 acctgcgctg ggccccaagc cgacgcgccc tggaggcagc tggggccgga cctgggctgg 12361 cggtggcacc cgcgcgcgct ggcaacgtcg gcggcgtgga ggaatatgac gaggacgatg 12421 agtacgagcc agaggacggc gagtactaag cggtgatgtt tctgatcaga tgatgcaaga 12481 cgcaacggac ccggcggtgc gggcggcgct gcagagccag ccgtccggcc ttaactccac 12541 ggacgactgg cgccaggtca tggaccgcat catgtcgctg actgcgcgca atcctgacgc 12601 gttccggcag cagccgcagg ccaaccggct ctccgcaatt ctggaagcgg tggtcccggc 12661 gcgcgcaaac cccacgcacg agaaggtgct ggcgatcgta aacgcgctgg ccgaaaacag 12721 ggccatccgg cccgacgagg ccggcctggt ctacgacgcg ctgcttcagc gcgtggctcg 12781 ttacaacagc ggcaacg.tgc agaccaacct ggaccggctg gtgggggatg tgcgcgaggc 12841 cgtggcgcag cgtgagcgcg cgcagcagca gggcaacctg ggctccatgg ttgcactaaa 12901 cgccttcctg agtacacagc ccgccaacgt gccgcgggga caggaggact acaccaactt 12961 tgtgagcgca ctgcggctaa tggtgactga gacaccgcaa agtgaggtgt accagtctgg 13021 gccagactat tttttccaga ccagtagaca aggcctgcag accgtaaacc tgagccaggc 13081 tttcaaaaac ttgcaggggc tgtggggggt gcgggctccc acaggcgacc gcgcgaccgt 13141 gtctagcttg ctgacgccca actcgcgcct gttgctgctg ctaatagcgc ccttcacgga 13201 cagtggcagc gtgtcccggg acacatacct aggtcacttg ctgacactgt accgcgaggc 13261 cataggtcag gcgcatgtgg acgagcatac tttccaggag attacaagtg tcagccgcgc 13321 gctggggcag gaggacacgg gcagcctgga ggcaacccta aactacctgc tgaccaaccg 13381 gcggcagaag atcccctcgt tgcacagttt aaacagcgag gaggagcgca ttttgcgcta 13441 cgtgcagcag agcgtgagcc ttaacctgat gcgcgacggg gtaacgccca gcgtggcgct 13501 ggacatgacc gcgcgcaaca tggaaccggg catgtatgcc tcaaaccggc cgtttatcaa 13561 ccgcctaatg gactacttgc atcgcgcggc cgccgtgaac cccgagtatt tcaccaatgc 13621 catcttgaac ccgcactggc taccgccccc tggtttctac accgggggat tcgaggtgcc 13681 cgagggtaac gatggattcc tctgggacga catagacgac agcgtgtttt ccccgcaacc 13741 gcagaccctg ctagagttgc aacagcgcga gcaggcagag gcggcgctgc gaaaggaaag 13801 cttccgcagg ccaagcagct tgtccgatct aggcgctgcg gccccgcggt cagatgctag 13861 tagcccattt ccaagcttga tagggtctct taccagcact cgcaccaccc gcccgcgcct 13921 gctgggcgag gaggagtacc taaacaactc gctgctgcag ccgcagcgcg aaaaaaacct 13981 gcctccggca tttcccaaca acgggataga gagcctagtg gacaagatga gtagatggaa 14041 gacgtacgcg caggagcaca gggacgtgcc aggcccgcgc ccgcccaccc gtcgtcaaag 14101 gcacgaccgt cagcggggtc tggtgtggga ggacgatgac tcggcagacg acagcagcgt 14161 cctggatttg ggagggagtg gcaacccgtt tgcgcacctt cgccccaggc tggggagaat 14221 gttttaaaaa aaaaaaagca tgatgcaaaa taaaaaactc accaaggcca tggcaccgag 14281 cgttggtttt cttgtattcc ccttagtatg cggcgcgcgg cgatgtatga ggaaggtcct 14341 cctccctcct acgagagtgt ggtgagcgcg gcgccagtgg cggcggcgct gggttctccc 14401 ttcgatgctc ccctggaccc gccgtttgtg cctccgcggt acctgcggcc taccgggggg 14461 agaaacagca tccgttactc tgagttggca cccctattcg acaccacccg tgtgtacctg 14521 gtggacaaca agtcaacgga tgtggcatcc ctgaactacc agaacgacca cagcaacttt 14581 otgaccacgg tcattcaaaa caatgactac agcccggggg aggcaagcac acagaccatc 14641 aatcttgacg accggtcgca ctggggcggc gacctgaaaa ccatcctgca taccaacatg 14701 ccaaatgtga acgagttcat gtttaccaat aagtttaagg cgcgggtgat ggtgtcgcgc 14761 ttgcctacta aggacaatca ggtggagctg aaatacgagt gggtggagtt cacgctgccc 14821 gagggcaact actccgagac catgaccata gaccttatga acaacgcgat cgtggagcac 14881 tacttgaaag tgggcagaca gaacggggtt ctggaaagcg acatcggggt aaagtttgac 14941 acccgcaact tcagactggg gtttgacccc gtcactggtc ttgtcatgcc tggggtatat 15001 acaaacgaag ccttccatcc agacatcatt ttgctgccag gatgcggggt ggacttcacc 15061 cacagccgcc tgagcaactt gttgggcatc cgcaagcggc aacccttcca ggagggcttt 15121 aggatcacct acgatgatct ggagggtggt aacattcccg cactgttgga tgtggacgcc 15181 taccaggcga gcttgaaaga tgacaccgaa cagggcgggg gtggcgcagg cggcagcaac 15241 agcagtggca gcggcgcgga agagaactcc aacgcggcag ccgcggcaat gcagccggtg 15301 gaggacatga acgatcatgc cattcgcggc gacacctttg ccacacgggc tgaggagaag 15361 cgcgctgagg ccgaagcagc ggccgaagct gccgcccccg ctgcgcaacc cgaggtcgag 15421 aagcctcaga agaaaccggt gatcaaaccc ctgacagagg acagcaagaa acgcagttac 15481 aacctaataa gcaatgacag caccttcacc cagtaccgca gctggtacct tgcatacaac 15541 tacggcgacc ctcagaccgg aatccgctca tggaccctgc tttgcactcc tgacgtaacc 15601 tgcggctcgg agcaggtcta ctggtcgttg ccagacatga tgcaagaccc cgtgaccttc 15661 cgctccacgc gccagatcag caactttccg gtggtgggcg ccgagctgtt gcccgtgcac 15721 tccaagagct tctacaacga ccaggccgtc tactcccaac tcatccgcca gtttacctct 15781 ctgacccacg tgttcaatcg ctttcccgag aaccagattt tggcgcgccc gccagccccc 15841 accatcacca ccgtcagtga aaacgttcct gctctcacag atcacgggac gctaccgctg 15901 cgcaacagca tcggaggagt ccagcgagtg accattactg acgccagacg ccgcacctgc 15961 ccctacgttt acaaggccct gggcatagtc tcgccgcgcg tcctatcgag ccgcactttt 16021 tgagcaagca tgtccåtcct tatatcgccc agcaataaca caggctgggg cctgcgcttc 16081 ccaagcaaga tgtttggcgg ggccaagaag cgctccgacc aacacccagt gcgcgtgcgc 16141 gggcactacc gcgcgccctg gggcgcgcac aaacgcggcc gcactgggcg caccaccgtc 16201 gatgacgcca tcgacgcggt ggtggaggag gcgcgcaact acacgcccac gccgccacca 16261 gtgtccacag tggacgcggc cattcagacc gtggtgcgcg gagcccggcg ctatgctaaa 16321 atgaagagac ggcggaggcg cgtagcacgt cgccaccgcc gccgacccgg cactgccgcc 16381 caacgcgcgg cggcggccct gcttaaccgc gcacgtcgca ccggccgacg ggcggccatg 16441 cgggccgctc gaaggctggc cgcgggtatt gtcactgtgc cccccaggtc caggcgacga 16501 gcggccgccg cagcagccgc ggccattagt gctatgactc agggtcgcag gggcaacgtg 16561 tattgggtgc gcgactcggt tagcggcctg·cgcgtgcccg tgcgcacccg ccccccgcgc 16621 aactagattg caagaaaaaa ctacttagac tcgtactgtt gtatgtatcc agcggcggcg 16681 gcgcgcaacg aagctatgtc caagcgcaaa atcaaagaag agatgctcca ggtcatcgog 16741 ccggagatct atggcccccc gaagaaggaa gagcaggatt acaagccccg aaagctaaag 16801 cgggtcaaaa agaaaaagaa agatgatgat gatgaacttg acgacgaggt ggaactgctg 16861 cacgctaccg cgcccaggcg acgggtacag tggaaaggtc gacgcgtaaa acgtgttttg 16921 cgacccggca ccaccgtagt ctttacgccc ggtgagcgct ccacccgcac ctacaagcgc 16981 gtgtatgatg aggtgtacgg cgacgaggac ctgcttgagc aggccaacga gcgcctcggg 17041 gagtttgcct acggaaagcg gcataaggac atgctggcgt tgccgctgga cgagggcaac 17101 ccaacaccta gcctaaagcc cgtaacactg cagcaggtgc tgcccgcgct tgcaccgtcc 17161 gaagaaaagc gcggcctaaa gcgcgagtct ggtgacttgg cacccaccgt gcagctgatg 17221 gtacccaagc gccagcgact ggaagatgtc ttggaaaaaa tgaccgtgga acctgggctg 17281 gagcccgagg tccgcgtgcg gccaatcaag caggtggcgc cgggactggg cgtgcagacc 17341 gtggacgttc agatacccac taccagtagc accagtattg ccaccgccac agagggcatg 17401 gagacacaaa cgtccccggt tgcctcagcg gtggcggatg ccgcggtgca ggcggtcgct 17461 gcggccgcgt ccaagacctc tacggaggtg caaacggacc cgtggatgtt tcgcgtttca 17521 gccccccggc gcccgcgcgg ttcgaggaag tacggcgccg ccagcgcgct actgcccgaa 17581 tatgccctac atccttccat tgcgcctacc cccggctatc gtggctacac ctaccgcccc 17641 agaagacgag caactacccg acgccgaacc accactggaa cccgccgccg ccgtcgccgt 17701 cgccagcccg tgctggcccc gatttccgtg cgcagggtgg ctcgcgaagg aggcaggacc 17761 ctggtgctgc caacagcgcg ctaccacccc agcatcgttt aaaagccggt ctttgtggtt 17821 cttgcagata tggccctcac ctgccgcctc cgtttcccgg tgccgggatt ccgaggaaga 17881 atgcaccgta ggaggggcat ggccggccac ggcctgacgg gcggcatgcg tcgtgcgcac 17941 caccggcggc ggcgcgcgtc gcaccgtcgc atgcgcggcg gtatcctgcc cctccttatt 18001 ccactgatcg ccgcggcgat tggcgccgtg cccggaattg catccgtggc cttgcaggcg 18061 cagagacact gattaaaaac aagttgcatg tggaaaaatc aaaataaaaa gtctggactc 18121 tcacgctcgc ttggtcctgt aactattttg tagaatggaa gacatcaact ttgcgtctct 18181 ggccccgcga cacggctcgc gcccgttcat gggaaactgg caagatatcg gcaccagcaa 18241 tatgagcggt ggcgccttca gctggggctc gctgtggagc ggcattaaaa atttcggttc 18301 caccgttaag aactatggca gcaaggcctg gaacagcagc acaggccaga tgctgaggga 18361 taagttgaaa gagcaaaatt tccaacaaaa ggtggtagat ggcctggcct ctggcattag 18421 cggggtggtg gacctggcca accaggcagt gcaaaataag attaacagta agcttgatcc 18481 ccgccctccc gtagaggagc ctccaccggc cgtggagaca gtgtctccag aggggcgtgg 18541 cgaaaagcgt ccgcgccccg acagggaaga aactctggtg acgcaaatag acgagcctcc 18601 ctcgtacgag gaggcactaa agcaaggcct gcccaccacc cgtcccatcg cgcccatggc 18661 taccggagtg ctgggccagc acacacccgt aacgctggac -ctgcctcccc ccgccgacac 18721 ccagcagaaa cctgtgctgc caggcccgac cgccgttgtt gtaacccgtc ctagccgcgc 18781 gtccctgcgc cgcgccgcca gcggtccgcg atcgttgcgg cccgtagcca gtggcaactg 18841 gcaaagcaca ctgaacagca tcgtgggtct gggggtgcaa tccctgaagc gccgacgatg 18901 cttctgaata gctaacgtgt cgtatgtgtg tcatgtatgc . gtccatgtcg ccgccagagg 18961 agctgctgag ccgccgcgcg cccgctttcc aagatggcta ccccttcgat gatgccgcag '19021 tggtcttaca tgcacatctc gggccaggac gcctcggagt acctgagccc cgggctggtg 19081 cagtttgccc gcgocaccga gacgtacttc agcctgaata acaagtttag aaaccccacg 19141 gtggcgccta cgcacgacgt gaccacagac cggtcccagc gtttgacgct gcggttcatc 19201 cctgtggacc gtgaggatac tgcgtactcg tacaaggcgc ggttcaccct agctgtgggt 19261 gataaccgtg tgctggacat ggcttccacg tactttgaca tccgcggcgt gctggacagg 19321 ggccctactt ttaagcccta ctctggcact gcctacaacg ccctggctcc caagggtgcc 19381 ccaaatcctt gcgaatggga tgaagctgct actgctcttg aaataaacct agaagaagag 19441 gacgatgaca acgaagacga agtagacgag caagctgagc agcaaaaaac tcacgtattt 19501 gggcaggcgc cttattctgg tataaatatt acaaaggagg gtattcaaat aggtgtcgaa 19561 ggtcaaacac ctaaatatgc cgataaaaca tttcaacctg aacctcaaat aggagaatct Ί9621 cagtggtacg aaactgaaat taatcatgca gctgggagag tccttaaaaa gactacccca 19681 atgaaaccat gttacggttc atatgcaaaa cccacaaatg aaaatggagg gcaaggcatt 19741 cttgtaaagc aacaaaatgg aaagctagaa agtcaagtgg aaatgcaatt tttctcaact 19801 actgaggcga ccgcaggcaa tggtgataac ttgactccta aagtggtatt gtacagtgaa 19861 gatgtagata tagaaacccc agacactcat atttcttaca tgcccactat taaggaaggt 19921 aactcacgag aactaatggg ccaacaatct atgcccaaca ggcctaatta cattgctttt 19981 agggacaatt ttattggtct aatgtattac aacagcacgg gtaatatggg tgttctggcg 20041 ggccaagcat cgcagttgaa tgctgttgta gatttgcaag acagaaacac agagctttca 20101 taccagcttt tgcttgattc cattggtgat agaaccaggt acttttctat gtggaatcag 20161 gctgttgaca gctatgatcc agatgttaga attattgaaa atcatggaac tgaagatgaa 20221 cttccaaatt actgctttcc actgggaggt gtgattaata cagagactct taccaaggta 20281 aaacctaaaa caggtcagga aaatggatgg gaaaaagatg ctacagaatt ttcagataaa 20341 aatgaaataa gagttggaaa taattttgcc atggaaatca atctaaatgc caacctgtgg 20401 agaaatttcc tgtactccaa catagcgctg tatttgcccg acaagctaaa gtacagtcct 20461 tccaacgtaa aaatttctga taacccaaac acctacgact acatgaacaa gcgagtggtg 20521 gctcccgggt tagtggactg ctacattaac cttggagcac gctggtccct tgactatatg 20581 gacaacgtca acccatttaa ccaccaccgc aatgctggcc tgcgctaccg ctcaatgttg 20641 ctgggcaatg gtcgctatgt gcccttccac atccaggtgc ctcagaagtt ctttgccatt 20701 aaaaacctcc ttctcctgcc gggctcatac acctacgagt ggaacttcag gaaggatgtt. 20761 aacatggttc tgcagagctc cctaggaaat gacctaaggg ttgacggagc cagcattaag 20821 tttgatagca tttgccttta cgccaccttc ttccccatgg cccacaacac cgcctccacg 20881 cttgaggcca tgcttagaaa cgacaccaac gaccagtcct ttaacgacta tctctccgcc 20941 gccaacatgc tctaccctat acccgccaac gctaccaacg tgcccatatc catcccctcc 21001 cgcaactggg cggctttccg cggctgggcc ttcacgcgcc ttaagactaa ggaaacccca 21061 tcactgggct cgggctacga cccttattac acctactctg gctctatacc ctacctagat 21121 ggaacctttt acctcaacca cacctttaag aaggtggcca ttacctttga ctcttctgtc 21181 agctggcctg gcaatgaccg cctgcttacc cccaacgagt ttgaaattaa gcgctcagtt 21241 gacggggagg gttacaacgt tgcccagtgt aacatgacca aagactggtt cctggtacaa 21301 atgctagcta actacaacat tggctaccag ggcttctata tcccagagag ctacaaggac 21361 cgcatgtact ccttctttag aaacttccag cccatgagcc gtcaggtggt ggatgatact 21421 aaatacaagg actaccaaca ggtgggcatc ctacaccaac acaacaactc tggatttgtt 21481 ggctaccttg cccccaccat gcgcgaagga caggcctacc ctgctaactt cccctatccg 21541 cttataggca agaccgcagt tgacagcatt acccagaaaa agtttctttg cgatcgcacc 21601 ctttggcgca tcccattctc cagtaacttt atgtccatgg gcgcactcac agacctgggc 21661 caaaaccttc tctacgccaa ctccgcccac gcgctagaca tgacttttga ggtggatccc 21721 atggacgagc ccacccttct ttatgttttg tttgaagtct ttgacgtggt ccgtgtgcac 21781 cggccgcacc gcggcgtcat cgaaaccgtg tacctgcgca cgcccttctc ggccggcaac 21841 gccacaacat aaagaagcaa gcaacatcaa caacagctgc cgccatgggc tccagtgagc 21901 aggaactgaa agccattgtc aaagatcttg gttgtgggcc atattttttg ggcacctatg 21961 acaagcgctt tccaggcttt gtttctccac acaagctcgc ctgcgccata gtcaatacgg 22021 ccggtcgcga gactgggggc gtacactgga tggcctttgc ctggaacccg cactcaaaaa 22081 catgctacct ctttgagccc tttggctttt ctgaccagcg actcaagcag gtttaccagt 22141 ttgagtacga gtcactcctg cgccgtagcg ccattgcttc ttcccccgac cgctgtataa 22201 cgctggaaaa gtccacccaa agcgtacagg ggcccaactc ggccgcctgt ggactattct 22261 gctgcatgtt tctccacgcc tttgccaact ggccccaaac tcccatggat cacaacccca 22321 ccatgaacct tattaccggg gtacccaact ccatgctcaa cagtccccag gtacagccca 22381 ccctgcgtcg caaccaggaa cagctctaca gcttcctgga gcgccactcg ccctacttcc 22441 gcagccacag tgcgcagatt aggagcgcca cttctttttg tcacttgaaa aacatgtaaa 22501 aataatgtac tagagacact ttcaataaag gcaaatgctt ttatttgtac actctcgggt 22561 gattatttac ccccaccctt gccgtctgcg ccgtttaaaa atcaaagggg ttctgccgcg 22621 catcgctatg cgccactggc agggacacgt tgcgatactg gtgtttagtg ctccacttaa 22681 actoaggcac aaccatccgc ggcagctcgg tgaagttttc actccacagg ctgcgcacca 22741 tcaccaacgc gtttagcagg tcgggcgccg atatcttgaa gtcgcagttg gggcctccgc 22801 cctgcgcgcg cgagttgcga tacacagggt tgcagcactg gaacactatc agcgccgggt 22861 ggtgcacgct ggccagcacg ctcttgtcgg agatcagatc cgcgtccagg tcctccgcgt 22921 tgctcagggc gaacggagtc aactttggta gctgccttcc caaaaagggc gcgtgcccag 22981 gctttgagtt gcactcgcac cgtagtggca tcaaaaggtg accgtgcccg gtctgggcgt 23041 taggatacag cgcctgcata aaagccttga tctgcttaaa agccacctga gcctttgcgc 23101 cttcagagaa gaacatgccg caagacttgc cggaaaactg attggccgga caggccgcgt 23161 cgtgcacgca gcaccttgcg tcggtgttgg agatctgcac cacatttcgg ccccaccggt 23221 tcttcacgat cttggccttg ctagactgct ccttcagcgc gcgctgcccg ttttcgctcg 23281 tcacatccat ttcaatcacg tgctccttat ttatcataat gcttccgtgt agacacttaa 23341 gctcgccttc gatctcagcg cagcggtgca gccacaacgc gcagcccgtg ggctcgtgat 23401 gcttgtaggt cacctctgca aacgactgca ggtacgcctg caggaatcgc cccatcatcg 23461 tcacaaaggt cttgttgctg gtgaaggtca gctgcaaccc gcggtgctcc tcgttcagcc 23521 aggtcttgca tacggccgcc agagcttcca cttggtoagg cagtagtttg aagttcgcct 23581 ttagatogtt atccacgtgg tacttgtcca tcagcgcgcg cgcagcctcc atgcccttct 23641 cccacgcaga cacgatcggc acactcagcg ggttcatcac cgtaatttca ctttccgctt 23701 cgctgggctc ttcctcttcc tcttgcgtcc gcataccacg cgccactggg tcgtcttcat 23761 tcagccgccg cactgtgcgc ttacctcctt tgccatgctt gattagcacc ggtgggttgc 23821 tgaaacccac catttgtagc gccacatctt ctctttcttc ctcgctgtcc acgattacot 23881 ctggtgatgg cgggcgctcg ggcttgggag aagggcgctt ctttttcttc ttgggcgcaa 23941 tggccaaatc cgccgccgag gtcgatggcc gcgggctggg tgtgcgcggc accagcgcgt 24001 cttgtgatga gtcttcctcg tcctcggact cgatacgccg cctcatccgc ttttttgggg 24061 gcgcccgggg aggcggcggc gacggggacg gggacgacac gtcctccatg gttgggggac 24121 gtcgcgccgc accgcgtccg cgctcggggg tggtttcgcg ctgctcctct tcccgactgg 24181 ccatttcctt ctcctatagg cagaaaaaga tcatggagtc agtcgagaag aaggacagcc 24241 taaccgcccc ctctgagttc gccaccaccg cctccaccga tgccgccaac gcgcctacca 24301 ccttccccgt cgaggcaccc ccgcttgagg aggaggaagt gattatcgag caggacccag 24361 gttttgtaag cgaagacgac gaggaccgct cagtaccaac agaggataaa aagcaagacc 24421 aggacaacgc agaggcaaac gaggaacaag tcgggcgggg ggacgaaagg catggcgact 24481 acctagatgt gggagacgac gtgctgttga agcatctgca gcgccagtgc gccattatct 24541 gcgacgcgtt gcaagagcgc agcgatgtgc ccctcgccat agcggatgtc agccttgcct 24601 acgaacgcca cctattctca ccgcgcgtac cccccaaacg ccaagaaaac ggcacatgcg 24661 agcccaaccc gcgcctcaac ttctaccccg tatttgccgt gccagaggtg cttgccacct 24721 atcacatctt tttccaaaac tgcaagatac ccctatcctg ccgtgccaac cgcagccgag 24781 cggacaagca gctggccttg cggcagggcg ctgtcatacc tgatatcgcc tcgctcaacg 24841 aagtgccaaa aatctttgag ggtcttggac gcgacgagaa gcgcgcggca aacgctctgc 24901 aacaggaaaa cagcgaaaat gaaagtcact ctggagtgtt ggtggaactc gagggtgaca 24961 acgcgcgcct agccgtacta aaacgcagca tcgaggtcac ccactttgcc tacccggcac 25021 ttaacctacc ccccaaggtc atgagcacag tcatgagtga gctgatcgtg cgccgtgcgc 25081 agcccctgga gagggatgca aatttgcaag aacaaacaga ggagggccta cccgcagttg 25141 gcgacgagca gctagcgcgc tggcttcaaa cgcgcgagcc tgccgacttg gaggagcgac 25201 gcaaactaat gatggccgca gtgctcgtta ccgtggagct tgagtgcatg cagcggttct 25261 ttgctgaccc ggagatgcag cgcaagctag aggaaacatt gcactacacc tttcgacagg 25321 gctacgtacg ccaggcctgc aagatctcca acgtggagct ctgcaacctg gtctcctacc 25381 ttggaatttt gcacgaaaac cgccttgggc aaaacgtgct tcattccacg ctcaagggcg 25441 aggcgcgccg cgactacgtc cgcgactgcg tttacttatt tctatgctac acctggcaga 25501 cggccatggg cgtttggcag cagtgcttgg aggagtgcaa cctcaaggag ctgcagaaac 25561 tgctaaagca aaacttgaag gacctatgga cggccttcaa cgagcgctcc gtggccgcgc 25621 acctggcgga catcattttc cccgaacgcc tgcttaaaac cctgcaacag ggtctgccag 25681 acttcaccag tcaaagcatg ttgcagaact ttaggaactt tatcctagag cgctcaggaa 25741 tcttgcccgc cacctgctgt gcacttccta gcgactttgt gcccattaag taccgcgaat 25801 gccctccgcc gctttggggc cactgctacc ttctgcagct agccaactac cttgcctacc 25861 actctgacat aatggaagac gtgagcggtg acggtctact ggagtgtcac tgtcgctgca 25921 acctatgcac cccgcaccgc tccctggttt gcaattcgca gctgcttaac gaaagtcaaa 25981 ttatcggtac ctttgagctg cagggtccct cgcctgacga aaagtccgcg gctccggggt 26041 tgaaactcac tccggggctg tggacgtcgg cttaccttcg caaatttgta cctgaggact 26101 accacgccca cgagattagg ttctacgaag accaatcccg cccgccaaat gcggagctta 26161 ccgcctgcgt cattacccag ggccacattc ttggccaatt gcaagccatc aacaaagccc 26221 gccaagagtt tctgctacga aagggacggg gggtttactt ggacccccag tccggcgagg 26281 agctcaaccc aatccccccg ccgccgcagc cctatcagca gcagccgcgg gcccttgctt 26341 cccaggatgg cacccaaaaa gaagctgcag ctgccgccgc cacccacgga cgaggaggaa 26401 tactgggaca gtcaggoaga ggaggttttg gacgaggagg aggaggacat gatggaagac 26461 tgggagagcc tagacgagga agcttccgag gtcgaagagg tgtcagacga aacaccgtca 26521 ccctcggtcg cattcccctc gccggcgccc cagaaatcgg caaccggttc cagcatggct 26581 acaacctccg ctcctcaggc gccgccggca ctgcccgttc gccgacccaa ccgtagatgg 26641 gacaccactg gaaccagggc cggtaagtcc aagcagccgc cgccgttagc'ccaagagcaa 26701 caacagcgcc aaggctaccg ctcatggcgc gggcacaaga acgccatagt tgcttgcttg 26761 caagactgtg ggggcaacat ctccttcgcc cgccgctttc ttctctacca tcacggcgtg 26821 gccttccccc gtaacatcct gcattactac cgtcatctct acagcccata ctgcaccggc 26881 ggcagcggca gcggcagcaa cagcagcggc cacacagaag caaaggcgac cggatagcaa 26941 gactctgaca aagcccaaga aatccacagc ggcggcagca gcaggaggag gagcgctgcg 27001 tctggcgccc aacgaacccg tatcgacccg cgagcttaga aacaggattt ttcccactct 27061 gtatgctata tttcaacaga gcaggggcca agaacaagag ctgaaaataa aaaacaggtc 27121 tctgcgatcc ctcacccgca gctgcctgta tcacaaaagc gaagatcagc ttcggcgcac 27181 gctggaagac gcggaggctc tcttcagtaa atactgcgcg ctgactctta aggactagtt 27241 tcgcgccctt tctcaaattt aagcgcgaaa actacgtcat ctccagcggc cacacccggc 27301 gccagcacct gtcgtcagcg ccattatgag caaggaaatt cccacgccct acatgtggag 27361 ttaccagcca caaatgggac ttgcggctgg agctgcccaa gactactcaa cccgaataaa 27421 ctacatgagc gcgggacccc acatgatatc ccgggtcaac ggaatccgcg cccaccgaaa 27481 ccgaattctc ttggaacagg cggctattac caccacacct cgtaataacc ttaatccccg 27541 tagttggccc gctgccctgg tgtaccagga aagtcccgct cccaccactg tggtacttcc 27601 cagagacgcc caggccgaag ttcagatgac taactcaggg gcgcagcttg cgggcggctt 27661 tcgtcacagg gtgcggtcgc ccgggcaggg tataactcac ctgacaatca gagggcgagg 27721 tattcagctc aacgacgagt cggtgagctc ctcgcttggt ctccgtccgg acgggacatt 27781 tcagatcggc ggcgccggcc gtccttcatt cacgcctcgt caggcaatcc taactctgca 27841 gacctcgtcc tctgagccgc gctctggagg cattggaact ctgcaattta ttgaggagtt 27901 tgtgccatcg gtctacttta accccttctc gggacctccc ggccactatc cggatcaatt 27961 tattcctaac tttgacgcgg taaaggactc ggcggacggc tacgactgaa tgttaagtgg 28021 agaggcagag caactgcgcc tgaaacacct ggtccactgt cgccgccaca agtgctttgc 28081 ccgcgactcc ggtgagtttt gctactttga attgcccgag gatcatatcg agggcccggc 28141 gcacggcgtc cggcttaccg cccagggaga gcttgcccgt agcctgattc gggagtttac 28201 ccagcgcccc ctgctagttg agcgggacag gggaccctgt gttctcactg tgatttgcaa 28261 ctgtcctaac cttggattac atcaagatcc tctagttata actagagtac ccggggatct 28321 tattcccttt aactaataaa aaaaaataat aaagcatcac ttacttaaaa tcagttagca 28381 aatttctgtc cagtttattc agcagcacct ccttgccctc ctcccagctc tggtattgca 28441 gcttcctcct ggctgcaaac tttctccaca atctaaatgg aatgtcagtt tcctcctgtt 28501 cctgtccatc cgcacccact atcttcatgt tgttgcagat gaagcgcgca agaccgtctg 28561 aagatacctt caaccccgtg tatccatatg acacggaaac cggtcctcca actgtgcctt 28621 ttcttactcc tccctttgta tcccccaatg ggtttcaaga gagtccccct ggggtactct 28681 ctttgcgcct atccgaacct ctagttacct ccaatggcat gcttgcgctc aaaatgggca 28741 acggcctctc tctggacgag gccggcaacc ttacctccca aaatgtaacc actgtgagcc 28801 cacctctcaa aaaaaccaag tcaaacataa acctggaaat atctgcaccc ctcacagtta 28861 cctcagaagc cctaactgtg gctgccgccg cacctctaat ggtcgcgggc aacacactca 28921 ccatgcaatc acaggccccg ctaaccgtgc acgactccaa acttagcatt gccacccaag 28981 gacccctcac agtgtcagaa ggaaagctag ccctgcaaac atcaggcccc ctcaccacca 29041 ccgatagcag tacccttact atcactgcct caccccctct aactactgcc actggtagct 29101 tgggcattga cttgaaagag cccatttata cacaaaatgg aaaactagga ctaaagtacg 29161 gggctccttt gcatgtaaca gacgacctaa acactttgac cgtagcaact ggtccaggtg 29221 tgactattaa taatacttcc ttgcaaacta aagttactgg agccttgggt tttgattcac 29281 aaggcaatat gcaacttaat gtagcaggag gactaaggat tgattctcaa aacagacgcc 29341 ttatacttga tgttagttat ccgtttgatg ctcaaaacca actaaatcta agactaggac 29401 agggccctct ttttataaac tcagcccaca acttggatat taactacaac aaaggccttt 29461 acttgtttac agcttcaaac aattccaaaa agcttgaggt taacctaagc actgccaagg 29521 ggttgatgtt tgacgctaca gccatagcca ttaatgcagg agatgggctt gaatttggtt 29581 cacctaatgc accaaacaca aatcccctca aaacaaaaat tggccatggc ctagaatttg 29641 attcaaacaa ggctatggtt cctaaactag gaactggcct tagttttgac agcacaggtg 29701 ccattacagt aggaaacaaa aataatgata agctaacttt gtggaccaca ccagctccat 29761 ctcctaactg tagactaaat gcagagaaag atgctaaact cactttggtc ttaacaaaat 29821 gtggcagtca aatacttgct acagtttcag ttttggctgt taaaggcagt ttggctccaa 29881 tatctggaac agttcaaagt gctcatctta ttataagatt tgacgaaaat ggagtgctac 29941 taaacaattc c-ttcctggac ccagaatatt ggaactttag aaatggagat cttactgaag 30001 gcacagccta tacaaacgct gttggattta tgcctaacct atcagcttat ccaaaatctc 30061 acggtaaaac tgccaaaagt aacattgtca gtcaagttta cttaaacgga gacaaaacta 30121 aacctgtaac actaaccatt acactaaacg gtacacagga aacaggagac acaactccaa 30181 gtgcatactc tatgtcattt tcatgggact ggtctggcca caactacatt aatgaaatat 30241 ttgccacatc ctcttacact ttttcataca ttgcccaaga ataaagaatc gtttgtgtta 30301 tgtttcaacg tgtttatttt tcaattgcag aaaatttcaa gtcatttttc attcagtagt 30361 atagccccac caccacatag cttatacaga tcaccgtacc ttaatcaaac tcacagaacc 30421 ctagtattca acctgccacc tccctcccaa cacacagagt acacagtcct ttctccccgg 30481 ctggccttaa aaagcatcat atcatgggta acagacatat tcttaggtgt tatattccac 30541 acggtttcct gtcgagccaa acgctcatca gtgatattaa taaactcccc gggcagctca 30601 cttaagttca tgtcgctgtc cagctgctga gccacaggct gctgtccaac ttgcggttgc 30661 ttaacgggcg gcgaaggaga agtccacgcc tacatggggg tagagtcata atcgtgcatc 30721 aggatagggc ggtggtgctg cagcagcgcg cgaataaact gctgccgccg ccgctccgtc 30781 ctgcaggaat acaacatggc agtggtctcc tcagcgatga ttcgcaccgc ccgcagcata 30841 aggcgccttg tcctccgggc acagcagcgc accctgatct cacttaaatc agcacagtaa 30901 ctgcagcaca gcaccacaat attgttcaaa atcccacagt gcaaggcgct gtatccaaag 30961 ctcatggcgg ggaccacaga acccacgtgg ccatcatacc acaagcgcag gtagattaag 31021 tggcgacccc tcataaacac gctggacata aacattacct cttttggcat gttgtaattc 31081 accacctccc ggtaccatat aaacctctga ttaaacatgg cgccatccac caccatccta 31141 aaccagctgg ccaaaacctg cccgccggct atacactgca gggaaccggg actggaacaa 31201 tgacagtgga gagcccagga ctcgtaacca tggatcatca tgctcgtcat gatatcaatg 31261 ttggcacaac acaggcacac gtgcatacac ttcctcagga ttacaagctc ctcccgcgtt 31321 agaaccatat cccagggaac aacccattcc tgaatcagcg taaatcccac actgcaggga 31381 agacctcgca cgtaactoac gttgtgcatt gtcaaagtgt tacattcggg cagcagcgga 31441 tgatcctcca gtatggtagc gcgggtttct gtctcaaaag gaggtagacg atccctactg 31501 tacggagtgc gccgagacaa ccgagatcgt gttggtcgta gtgtcatgcc aaatggaacg 31561 ccggacgtag tcatatttcc tgaagcaaaa ccaggtgcgg gcgtgacaaa cagatctgcg 3Ί621 tctccggtct cgccgcttag atcgctctgt gtagtagttg tagtatatcc actctctcaa 31681 agcatccagg cgccccctgg cttcgggttc tatgtaaact ccttcatgcg ccgctgccct 31741 gataacatcc accaccgcag aataagccac acccagccaa cctacacatt cgttctgcga 31801 gtcacacacg. ggaggagcgg gaagagctgg aagaaccatg tttttttttt tattccaaaa 31861 gattatccaa aacctcaaaa tgaagatcta ttaagtgaac gcgctcccct ccggtggcgt 31921 ggtcaaactc tacagccaaa gaacagataa tggcatttgt aagatgttgc acaatggctt 31981 ccaaaaggca aacggccctc acgtccaagt ggacgtaaag gctaaaccct tcagggtgaa 32041 tctcctctat aaacattcca gcaccttcaa ccatgcccaa ataattctca tctcgccacc 32101 ttctcaatat atctctaagc aaatcccgaa tattaagtcc ggccattgta aaaatctgct 32161 ccagagcgcc ctccaccttc agcctcaagc agcgaatcat gattgcaaaa attcaggttc 32221 ctcacagacc tgtataagat tcaaaagcgg aacattaaca aaaataccgc gatcccgtag 32281 gtcccttcgc agggccagct gaacataatc gtgcaggtct gcacggacca gcgcggccac 32341 ttccccgcca ggaaccttga caaaagaacc cacactgatt atgacacgca tactcggagc 32401 tatgctaacc agcgtagccc cgatgtaagc tttgttgcat gggcggcgat ataaaatgca 32461 aggtgctgct caaaaaatca ggcaaagcct cgcgcaaaaa agaaagcaca tcgtagtcat 32521 gctcatgcag ataaaggcag gtaagctccg gaaccaccac agaaaaagac accatttttc 32581 tctcaaacat gtctgcgggt ttctgcataa acacaaaata aaataacaaa aaaacattta . 32641 aacattagaa gcctgtctta caacaggaaa aacaaccctt ataagcataa gacggactac 32701 ggccatgccg gcgtgaccgt aaaaaaactg gtcaccgtga ttaaaaagca ccaccgacag. 32761 ctcctcggtc atgtccggag tcataatgta agactcggta aacacatcag gttgattcat 32821 cggtcagtgc taaaaagcga ccgaaatagc ccgggggaat acatacccgc aggcgtagag 32881 acaacattac agcccccata ggaggtataa caaaattaat aggagagaaa aacacataaa 32941 cacctgaaaa accctcctgc ctaggcaaaa tagcaccctc ccgctccaga acaacataca 33001 gcgcttcaca gcggcagcct aacagtcagc cttaccagta aaaaagaaaa cctattaaaa 33061 aaacaccact cgacacggca ccagctcaat cagtcacagt gtaaaaaagg gccaagtgca 33121 gagcgagtat atataggact aaaaaatgac gtaacggtta aagtccacaa aaaacaccca 33181 gaaaaccgca cgcgaaccta cgcccagaaa cgaaagccaa aaaacccaca acttcctcaa 33241 atcgtcactt ccgttttccc acgttacgta acttcccatt ttaagaaaac tacaattccc 33301 aacacataca agttactccg ccctaaaacc tacgtcaccc gccccgttcc cacgccccgc 33361 gccacgtcac aaactccacc ccctcattat catattggct tcaatccaaa ataaggtata 33421 ttattgatga tnnnnnttaa t SEQ ID NO:17 (ND1.1 214) 1 taaggatccn nncctgtcct cgaccgatgc ccttgagagc cttcaaccca gtcagctcct 61 tccggtgggc gcggggcatg actatcgtcg ccgcacttat gactgtcttc tttatcatgc 121 aactcgtagg acaggtgccg gcagcgctct gggtcatttt cggcgaggac cgctttcgct 181 ggagcgcgac gatgatcggc ctgtcgcttg cggtattcgg aatcttgcac gccctcgctc 241 aagccttcgt cactggtccc gccaccaaac gtttcggcga gaagcaggcc attatcgccg 301 gcatggcggc cgacgcgctg ggctacgtct tgctggcgtt cgcgacgcga ggctggatgg 361 ccttccccat tatgattctt ctcgcttccg gcggcatcgg gatgcccgcg ttgcaggcca 421 tgctgtccag gcaggtagat gacgaccatc agggacagct tcaaggatcg ctcgcggctc 481 ttaccagcct aacttcgatc actggaccgc tgatcgtcac ggcgatttat gccgcctcgg 541 cgagcacatg gaacgggttg gcatggattg taggcgccgc cctatacctt gtctgcctcc 601 ccgcgttgcg tcgcggtgca tggagccggg ccacctcgac ctgaatggaa gccggcggca 661 cctcgctaac ggattcacca ctccaagaat tggagccaat caattcttgc ggagaactgt 721 gaatgcgcaa accaaccctt ggcagaacat atccatcgcg tccgccatct ccagcagccg 781 cacgcggcgc atctcgggca gcgttgggtc ctggccacgg gtgcgcatga tcgtgctcct 841 gtcgttgagg acccggctag gctggcgggg ttgccttact ggttagcaga atgaatcacc 901 gatacgcgag cgaacgtgaa gcgactgctg ctgcaaaacg tctgcgacct gagcaacaac 961 atgaatggtc ttcggtttcc gtgtttcgta aagtctggaa acgcggaagt cagcgccctg 1021 caccattatg ttccggatct gcatcgcagg atgctgctgg ctaccctgtg gaacacctac 1081 atctgtatta acgaagcgct ggcattgacc ctgagtgatt tttctctggt cccgccgcat 1141 ccataccgcc agttgtttac cctcacaacg ttccagtaac cgggcatgtt catcatcagt 1201 aacccgtatc gtgagcatcc tctctcgttt catcggtatc attaccccca tgaacagaaa 1261 ttccccctta cacggaggca tcaagtgacc aaacaggaaa aaaccgccct taacatggcc 1321 cgctttatca gaagccagac attaacgctt ctggagaaac tcaacgagct ggacgcggat 1381 gaacaggcag acatctgtga atcgcttcac gaccacgctg atgagcttta ccgcagctgc 1441 ctcgcgcgtt tcggtgatga cggtgaaaac ctctgacaca tgcagctccc ggagacggtc 1501 acagcttgtc tgtaagcgga tgccgggagc agacaagccc gtcagggcgc gtcagcgggt. 1561 gttggcgggt gtcggggcgc agccatgacc cagtcacgta gcgatagcgg agtgtatact 1621 ggcttaacta tgcggcatca gagcagattg tactgagagt gcaccatatg cggtgtgaaa 1681 taccgcacag atgcgtaagg agaaaatacc gcatcaggcg ctcttccgct tcctcgctca 1741 ctgactcgct gcgctcggtc gttcggctgc ggcgagcggt atcagctcac tcaaaggcgg 1801 taatacggtt atccacagaa tcaggggata acgcaggaaa gaacatgtga gcaaaaggcc 1861 agcaaaaggc caggaaccgt. aaaaaggccg cgttgctggc gtttttccat aggctccgcc 1921 cccctgacga gcatcacaaa aatcgacgct caagtcagag gtggcgaaac ccgacaggac 1981 tataaagata ccaggcgttt ccccctggaa gctccctcgt gcgctctcct gttccgaccc 2041 tgccgcttac cggatacctg tccgcctttc tcccttcggg aagcgtggcg ctttctcaat 2101 gctcacgctg taggtatctc agttcggtgt aggtcgttcg ctccaagctg ggctgtgtgc 2161 acgaaccccc cgttcagccc gaccgctgcg ccttatccgg taactatcgt cttgagtcca 2221 acccggtaag acacgactta tcgccactgg cagcagccac tggtaacagg attagcagag 2281 cgaggtatgt aggcggtgct acagagttct tgaagtggtg gcctaactac ggctacacta 2341 gaaggacagt atttggtatc tgcgctctgc tgaagccagt taccttcgga aaaagagttg 2401 gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tggttttttt gtttgcaagc 2461 agcagattac gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt tctacggggt 2521 ctgacgctca gtggaacgaa aactcacgtt aagggatttt ggtcatgaga ttatcaaaaa 2581 ggatcttcac ctagatcctt ttaaattaaa aatgaagttt taaatcaatc taaagtatat 2641 atgagtaaac ttggtctgac agttaccaat gcttaatcag tgaggcacct atctcagcga 2701 tctgtctatt tcgttcatcc atagttgcct gactccccgt cgtgtagata actacgatac 2761 gggagggctt accatctggc cccagtgctg caatgatacc gcgagaccca cgctcaccgg 2821 ctccagattt atcagcaata aaccagccag ccggaagggc cgagcgcaga agtggtcctg 2881 caactttatc cgcctccatc cagtctatta attgttgccg ggaagctaga gtaagtagtt 2941 cgccagttaa tagtttgcgc aacgttgttg ccattgctgc agccatga gattatcaaa aaggatcttc acctagatcc ttttcacgta gaaagccagt ccgcagaaac ggtgctgacc ccggatgaat gtcagctact gggctatctg gacaagggaa aacgcaagcg caaagagaaa gcaggtagct tgcagtgggc ttacatggcg atagctagac tgggcggttt tatggacagc aagcgaaccg gaattgccag ctggggcgcc ctctggtaag gttgggaagc cctgcaaagt aaactggatg gctttctcgc cgccaaggat ctgatggcgc aggggatcaa gctctgatca agagacagga tgaggatcgt ttcgcatgat tgaacaagat ggattgcacg caggttctcc ggccgcttgg gtggagaggc tattcggcta tgactgggca caacagacaa tcggctgctc tgatgccgcc gtgttccggc tgtcagcgca ggggcgcccg gttctttttg tcaagaccga cctgtccggt gccctgaatg aactgcaaga cgaggcagcg cggctatcgt ggctggccac gacgggcgtt ccttgcgcag ctgtgctcga cgttgtcact gaagcgggaa gggactggct gctattgggc gaagtgccgg ggcaggatct cctgtcatct caccttgctc ctgccgagaa agtatccatc atggctgatg caatgcggcg gctgcatacg cttgatccgg ctacctgccc attcgaccac caagcgaaac atcgcatcga gcgagcacgt actcggatgg aagccggtct tgtcgatcag gatgatctgg acgaagagca tcaggggctc gcgccagccg aactgttcgc caggctcaag gcgagcatgc ccgacggcga ggatctcgtc gtgacccatg gcgatgcctg cttgccgaat atcatggtgg aaaatggccg cttttctgga ttcatcgact gtggccggct gggtgtggcg gaccgctatc aggacatagc gttggctacc cgtgatattg ctgaagagct tggcggcgaa tgggctgacc gcttcctcgt gctttacggt atcgccgctc ccgatitcgca gcgcatcgcc ttctatcgcc ttcttgacga gttcttctga attttgttaa aatttttgtt aaatcagctc attttttaac caataggccg aaatcggcaa catcccttat aaatcaaaag aatagaccgc gatagggttg agtgttgttc cagtttggaa caagagtcca ctattaaaga acgtggactc caacgtcaaa gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg aaccatcacc caaatcaagt tttttgcggt cgaggtgccg taaagctcta aatcggaacc ctaaagggag cccccgattt agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg aagggaagaa agcgaaagga gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc gcgtaaccac cacacccgcg cgcttaatgc gccgctacag ggcgcgtcca ttcgccattc aggatcgaat taattcttaa ttaacatcatc aataatatac cttattttgg attgaagcca atatgataat gagggggtgg agtttgtgac gtggcgcggg gcgtgggaac ggggcgggtg acgtagtagt gtggcggaag tgtgatgttg caagtgtggc ggaacacatg taagcgacgg atgtggcaaa agtgacgttt ttggtgtgcg ccggtgtaca caggaagtga caattttcgc gcggttttag gcggatgttg tagtaaattt gggcgtaacc gagtaagatt tggccatttt cgcgggaaaa ctgaataaga ggaagtgaaa tctgaataat tttgtgttac tcatagcgcg
taatactGCTAGAgatCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGC CAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAATTGTAATACGACTCACTA TAGGGCGAATTGGGTACTGGCCAcagagcttggcccattgcatacgttgtatccatatcata atatgtacatttatattggctcatgtccaacattaccgccatgttgacattgattattgact agttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgt tacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgt caataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtg gagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgcc ccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgaccttat gggacttteetacttggcagtacatctacgtattagtcategetattaccatggtgatgcgg ttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctcca ccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtc gtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatata agcagagctcgtttagtgaaccgtcagatcgcctggagacgccatccacgctgttttgacct ccatagaagacaccgggaccgatccagcctgåetctagCctAGCTCtgaagttggtggtgag gccctgggcaggttggtatcaaggttacaagacaggtttaaggagaccaatagaaactgggc atgtggagacagagaagactcttgggtttetgataggcactgactctctctgcctattggtc tattttcccacccttaggctgctggtctgagcctagGAGATCTCTCGAGGTCGACGGTATcg atgcca ccATGGAGAA AATCGTCCTG TTGCTCGCTA TTGTGTCTCTAGTGAAGAGC GATCAAATTT GTATCGGCTA CCATGCCAAT AACTCAACAGAGCAGGTCGA TACTATCATG GAGAAAAACG TAACAGTTAC TCATGCCCAA GACATCTTGG AAAAGAC C C A CAACGGCAAA CTTTGCGACC TGGATGGAGT GAA6CCCCTG ATCCTCCGGG ACTGTTCAGT CGCTGGTTGG CTGCTCGGGA ACCCTATGTG TGATGAGTTT ATCAACGTGC CTGAATGGTC TTACATTGTG GAGAAGGCTA ACCCTACCAA TGACCTCTGC TATCCTGGGT CATTTAACGA TTACGAGGAA CTGAAACACC TGTTGTCTAG AATTAACCAC TTTGAAAAGA TACAGATTAT ACCCAAGTCT AGTTGGAGTG ATCACGAAGC CTCCTCAGGC GTTAGCTCAG CGTGTCCCTA TCTGGGCTCT CCATCGTTCT TTAGAAATGT GGTCTGGTTA ATCAAAAAGA ACAGTACCTA CCCAAGCATC AAAAAGTCTT ATAACAATAC CAATCAGGAG GACCTGCTCG TGTTGTGGGG TATCCATCAC CCGAACGACG CCGCTGAACA GACTAGGCTG TATCAGAACC CCACTACATA CATCAGTATT GGCACGAGTA CTCTGAACCA GCGATTAGTG CCAAAGATTG CAACACGGAG CAAAGTAAAT GGGCAATCTG GCAGGATGGA GTTTTTCTGG ACAATCTTAA AACCCAACGA TGCGATAAAT TTCGAGTCCA ATGGCAATTT CATCGCCCCT GAATACGCCT ATAAGATCGT GAAAAAGGGG GACTCTGCAA TTATGAAGTC CGAATTAGAG TATGGCAATT GCAACACGAA GTGCCAGACA CCAATGGGAG CCATTAATAG CTCAATGCCC TTCCATAATA TTCATCCATT GACCATTGGG GAGTGCCCAA AGTACGTGAA GTCCAACCGC CTGGTCCTCG CAACCGGTCT AAGAAATAGC CCGCAGAGAG AATCGCGGAG GAAGAAACGT GGCCTGTTTG GCGCGATTGC CGGATTCATC GAGGGAGGCT GGCAGGGTAT GGTCGATGGT TGGTACGGAT ACCACCATAG CAACGAACAG GGGTCCGGCT ATGCAGCAGA TAAGGAGAGC ACTCAGAAAG CTATTGACGG AGTTACAAAC AAGGTTAATA GTATTATAGA TAAAATGAAC ACGCAATTCG AGGCCGTTGG GAGGGAGTTT AACAATCTGG AACGCCGGAT CGAAAATCTG AATAAGAAAA TGGAAGACGG CTTCCTTGAC GTGTGGACTT ATAATGCAGA GCTGCTTGTA CTCATGGAGA ACGAGAGGAC CCTGGATTTC CACGATAGCA ACGTGAAGAA CCTTTACGAC AAGGTGAGAC TTCAGCTCCG AGACAACGCC AAGGAGCTGGGGAATGGATG CTTCGAGTTT TACCACAAAT GTGACAAT GA GTGCATGGAAAGTATACGCA ACGGGACCTA CAATTACCCT CAGTATAGCG AAGAGGCTCGGCTCAAACGC GAAGAGATAA GCGGGGTGAA ATTGGAATCA ATCGGAACATATCAAATCCT GTCCATCTAT TCCACCGTCG CCTCTTCGCT GGCCCTCGCT ATCATGATGG CTGGTCTGTC CCTATGGATG TGTTCCAATG GAAGCCTTCAGTGCCGTATT TGTATATGAg c
GGCCGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTGTGCC
TT
CTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCC
ACTCCCAC
TGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTC
TGGGGGGT
GGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGC
GGTGGGCT CTATGGCTTCTGAGGCGGAAAGAACCAAAGCTtaacatcatc aataatatac cttattttgg attgaagcca atatgataat gagggggtgg. agtttgtgac gtggcgcggg gcgtgggaac ggggcgggtg acgtagtagt gtggcggaag tgtgatgttg caagtgtggc ggaacacatg taagcgacgg atgtggcaaa agtgacgttt ttggtgtgcg ccggtgtaca caggaagtga caattttcgc gcggttttag gcggatgttg tagtaaattt gggcgtaacc gagtaagatt tggccatttt cgcgggaaaa ctgaataaga ggaagtgaaa tctgaataat tttgtgttac tcatagcgcg taatactgta atagtaatca attacggggt cattagttca tagcccatat atggagttcc gcgttacata acttacggta aatggcccgc ctggctgacc gcccaacgac ccccgcccat tgacgtcaat aatgacgtat gttcccatag taacgccaat agggactttc cattgacgfcc aatgggtgga gtatttacgg taaactgccc acttggcagt acatcaagtg tatcatatgc caagtacgcc ccctattgac gtcaatgacg gtaaatggcc cgcctggcat tatgcccagt acatgacctt atgggacttt cctacttggc agtacatcta cgtattagtc atcgctatta ccatggtgat gcggttttgg cagtacatca atgggcgtgg atagcggttt gactcacggg gatttccaag tctccacccc attgacgtca atgggagttt gttttggcac caaaatcaac gggactttcc aaaatgtcgt aacaactccg ccccattgac gcaaatgggc ggtaggcgtg tacggtggga ggtctatata
agcagagctg gtttagtgaa ccgtcagatc cqctaqAGATCTGGgaaacgatatgggctgaatacggatoagta ttcagcccata tcgtttc TCT AGA AAT AAA ATA TCT TTA TTT TCA TTA CAT CTG TGT GTT GGT TTT TTG TGT GGC GG CCGCtcgagcct AAGCTTctag ataagatatc cgatccaccg gatctagata actgatcata atcagccata ccacatttgt agaggtttta cttgctttaa aaaacctccc acacctcccc ctgaacctga aacataaaat gaatgcaatt gttgttgtta acttgtttat tgcagcttat aatggttaca aataaagcaa tagcatcaca aatttcacaa ataaagcatt tttttcactg cattctagtt gtggtttgtc caaactcatc aatgtatctt aacgcggatc tgggcgtggt taagggtggg aaagaatata taaggtgggg gtcttatgta gttttgtatc tgttttgcag cagccgccgc cgccatgagc accaactcgt ttgatggaag cattgtg AGCTTgtcgactcg aagatctggg cgtggttaag ggtgggaaag aatatataag gtgggggtct tatgtagttt tgtatctgtt ttgcagcagc cgccgccgcc atgagcacca actcgtttga tggaagcatt gtgagctcat atttgacaac gcgcatgccc ccatgggccg gggtgcgtca gaatgtgatg ggctccagca ttgatggtcg ccccgtcctg cccgcaaact otactacctt gacctacgag accgtgtctg gaacgccgtt ggagactgca gcctccgccg ccgcttcagc cgctgcagcc accgcccgcg ggattgtgac tgactttgct ttcctgagcc cgcttgcaag cagtgcagct tcccgttcat ccgcccgcga tgacaagttg acggctcttt tggcacaatt ggattctttg acccgggaac ttaatgtcgt ttctcagcag ctgttggatc tgcgccagca ggtttctgcc ctgaaggctt cctcccctcc caatgcggtt taaaacataa ataaaaaacc agactctgtt tggatttgga tcaagcaagt gtcttgctgt ctttatttag gggttttgcg cgcgcggtag gcccgggacc agcggtctcg gtcgttgagg gtcctgtgta ttttttccag gacgtggtaa aggtgactct ggatgttcag atacatgggc ataagcccgt ctctggggtg gaggtagcac cactgcagag cttcatgctg cggggtggtg ttgtagatga tccagtcgta gcaggagcgc tgggcgtggt gcctaaaaat gtctttcagt agcaagctga ttgccagggg caggcccttg gtgtaagtgt ttacaaagcg gttaagctgg gatgggtgca tacgtgggga tatgagatgc atcttggact gtatttttag gttggctatg ttcccagcca tatccctccg gggattcatg ttgtgcagaa ccaccagcac agtgtatccg gtgcacttgg gaaatttgtc atgtagctta gaaggaaatg cgtggaagaa cttggagacg cccttgtgac ctccaagatt ttccatgcat tcgtccataa tgatggcaat gggcccacgg gcggcggcct gggcgaagat atttctggga tcactaacgt catagttgtg ttccaggatg agatcgtcat aggccatttt tacaaagcgc gggcggaggg tgccagactg cggtataatg gttccatccg gcccaggggc gtagttaccc tcacagattt gcatttccca cgctttgagt tcagatgggg ggatcatgtc tacctgcggg gcgatgaaga aaacggtttc cggggtaggg gagatcagct gggaagaaag caggttcctg agcagctgcg acttaccgca gccggtgggc ccgtaaatca cacctattac cgggtgcaac tggtagttaa gagagct g cagctgccgt catccctgag caggggggcc acttcgttaa gcatgtccct gactcgcatg ttttccctga ccaaatccgc cagaaggcgc tcgccgccca gcgatagcag· ttcttgcaag gaagcaaagt ttttcaacgg tttgagaccg tccgccgtag gcatgctttt gagcgtttga ccaagcagtt ccaggcggtc ccacagctcg gtcacctgct ctacggcatc tcgatccagc atatctcctc gtttcgcggg ttggggcggc tttcgctgta cggcagtagt cggtgctcgt ccagacgggc cagggtcatg tctttccacg ggcgcagggt cctcgtcagc gtagtctggg tcacggtgaa ggggtgcgct ccgggctgcg cgctggccag ggtgcgcttg aggctggtcc tgctggtgct gaagcgctgc cggtcttcgc cctgcgcgtc ggccaggtag catttgacca tggtgtcata gtccagcccc tccgcggcgt ggcccttggc gcgcagcttg cccttggagg aggcgccgca cgaggggcag tgcagacttt tgagggcgta gagcttgggc gcgagaaata ccgattccgg ggagtaggca tccgcgccgc aggccccgca gacggtctcg cattccacga gccaggtgag ctctggccgt tcggggtcaa aaaccaggtt tcccccatgc tttttgatgc gtttcttacc tctggtttcc atgagccggt gtccacgctc ggtgacgaaa aggctgtccg tgtccccgta tacagacttg agaggcctgt cctcgagcgg tgttccgcgg tcctcctcgt atagaaactc ggaccactct gagacaaagg ctcgcgtcca ggccagcacg aaggaggcta agtgggaggg gtagcggtcg ttgtccacta gggggtccac tcgctccagg gtgtgaagac acatgtcgcc ctcttcggca tcaaggaagg tgattggttt gtaggtgtag gccacgtgac cgggtgttcc tgaagggggg ctataaaagg gggtgggggc gcgttcgtcc tcactctctt ccgcatcgct gtctgcgagg gccagctgtt ggggtgagta ctccctctga aaagcgggca tgacttctgc gctaagattg tcagtttcca 6301 aaaacgagga ggatttgata ttcacctggc ccgcggtgat gcctttgagg gtggccgcat 6361 ccatctggtc agaaaagaca atctttttgt tgtcaagctt ggtggcaaac gacccgtaga 6421 gggcgttgga cagcaacttg gcgatggagc gcagggtttg gtttttgtcg cgatcggcgc 6481 gctccttggc cgcgatgttt agctgcacgt attcgcgcgc aacgcaccgc cattcgggaa 6541 agacggtggt gcgctcgtcg ggcaccaggt gcacgcgcca accgcggttg tgcagggtga 6601 caaggtcaac gctggtggct acctctccgc gtaggcgctc gttggtccag cagaggcggc 6661 cgcccttgcg cgagcagaat ggcggtaggg ggtctagctg cgtctcgtcc ggggggtctg 6721 cgtccacggt aaagaccccg ggcagcaggc gcgcgtcgaa gtagtetatc ttgcatcctt 6781 geaagtetag cgcctgctgc catgcgcggg cggcaagcgc gegetegtat gggttgagtg 6841 ggggacccca tggcatgggg tgggtgagcg eggaggegta catgccgcaa atgtcgtaaa 6901 cgtagagggg etetetgagt attecaagat atgtagggta gcat'cttcca ccgcggatgc 6961 tggcgcgcac gtaatcgtat agttegtgeg agggagegag gaggtcggga ccgaggttgc 7021 tacgggcggg ctgctctgct cggaagacta tetgeetgaa gatggcatgt gagttggatg 7081 atatggttgg acgctggaag aegttgaage tggcgtctgt gagacctacc gcgtcacgca 7141 egaaggagge gtaggagteg cgcagcttgt tgaccagctc ggcggtgacc tgeaegteta 7201 gggcgcagta gtccagggtt tccttgatga tgtcatactt atcctgtccc ttttttttcc 7261 acagctcgcg gttgaggaca aactcttcgc ggtctttcca gtactcttgg atcggaaacc 7321 cgtcggcctc cgaacggtaa gagcctagca tgtagaactg gttgacggcc tggtaggcgc 7381 agcatccctt ttctacgggt agcgcgtatg cctgcgcggc cttccggagc gaggtgtggg 7441 tgagcgoaaa ggtgtccctg accatgactt tgaggtactg gtatttgaag tcagtgtcgt 7501 cgcatccgcc ctgctcccag agcaaaaagt ccgtgcgctt tttggaacgc ggatttggca 7561 gggcgaaggt gacatcgttg aagagtatct ttcccgcgcg aggcataaag ttgcgtgtga 7621 tgcggaaggg tcccggcacc tcggaacggt tgttaattac ctgggcggcg agcacgatct 7681 cgtcaaagcc gttgatgttg tggcccacaa tgtaaagttc caagaagcgc gggatgccct 7741 tgatggaagg caatttttta agttcctcgt aggtgagctc ttcaggggag ctgagcccgt 7801 gctctgaaag ggcccagtct gcaagatgag ggttggaagc gacgaatgag ctccacaggt 7861 cacgggccat tagcatttgc aggtggtcgc gaaaggtcct aaactggcga cctatggcca 7921 ttttttctgg ggtgatgcag tagaaggtaa gcgggtcttg ttcccagcgg tcccatccaa 7981 ggttcgcggc taggtctcgc gcggcagtca ctagaggctc atctccgccg aacttcatga 8041 ccagcatgaa gggcacgagc tgcttcccaa aggcccccat ccaagtatag gtctctacat 8101 cgtaggtgac aaagagacgc tcggtgcgag gatgcgagcc gatcgggaag aactggatct 8161 cccgccacca attggaggag tggctattga tgtggtgaaa gtagaagtcc ctgcgacggg 8221 ccgaacactc gtgctggctt ttgtaaaaac gtgcgcagta ctggcagcgg tgcacgggct 8281 gtacatcctg cacgaggttg acctgacgac cgcgcacaag gaagcagagt gggaatttga 8341 gcccctcgcc tggcgggttt ggctggtggt cttctacttc ggctgcttgt ccttgaccgt 8401 ctggctgctc gaggggagtt acggtggatc ggaccaccac gccgcgcgag cccaaagtcc 8461 agatgtccgc gcgcggcggt cggagcttga tgacaacatc gcgcagatgg gagctgtcca 8521 tggtctggag ctcccgcggc gtcaggtcag gcgggagctc ctgcaggttt acctcgcata 8581 gacgggtcag ggcgcgggct agatccaggt gatacctaat ttccaggggc tggttggtgg 8641 cggcgtcgat ggcttgcaag aggccgcatc cccgcggcgc gactacggta ccgcgcggcg 8701 ggcggtgggc cgcgggggtg tccttggatg atgcatctaa aagcggtgac gcgggcgagc 8761 ccccggaggt agggggggct ccggacccgc cgggagaggg ggcaggggca cgtcggcgcc 8821 gcgcgcgggc aggagctggt gctgcgcgcg taggttgctg gcgaacgcga cgacgcggcg 8881 gttgatctcc tgaatctggc gcctctgcgt gaagacgacg ggcccggtga gcttgagcct 8941 gaaagagagt tcgacagaat caatttcggt gtcgttgacg gcggcctggc gcaaaatctc 9001 ctgcacgtct cctgagttgt cttgataggc gatctcggcc atgaactgct cgatctcttc 9061 ctcctggaga tctccgcgtc cggctcgctc cacggtggcg gcgaggtcgt tggaaatgcg 9121 ggccatgagc tgcgagaagg cgttgaggcc tccctcgttc cagacgcggc tgtagaccac 9181 gcccccttcg gcatcgcggg cgcgcatgac cacctgcgcg agattgagct ccacgtgccg 9241 ggcgaagacg gcgtagtttc gcaggcgctg aaagaggtag ttgagggtgg tggcggtgtg 9301 ttctgccacg aagaagtaca taacccagcg tcgcaacgtg gattcgttga tatcccccaa 9361 ggcctcaagg cgctccatgg cctcgtagaa gtccacggcg aagttgaaaa actgggagtt 9421 gcgcgccgac acggttaact cctcctccag aagacggatg agctcggcga cagtgtcgcg 9481 cacctcgcgc tcaaaggcta caggggcctc ttcttcttct tcaatctcct cttccataag 9541 ggcctcccct tcttcttctt ctggcggcgg tgggggaggg gggacacggc ggcgacgacg 9601 gcgcaccggg aggcggtcga caaagcgctc gatcatctcc ccgcggcgac ggcgcatggt 9661 ctcggtgacg gcgcggccgt tctcgcgggg gcgcagttgg aagacgccgc ccgtcatgtc 9721 ccggttatgg gttggcgggg ggctgccatg cggcagggat acggcgctaa cgatgcatct 9781 caacaattgt tgtgtaggta ctccgccgcc gagggacctg agcgagtccg catcgaccgg 9841 atcggaaaac ctctcgagaa aggcgtctaa ccagtcacag tcgcaaggta ggctgagcac 9901 cgtggcgggc ggcagcgggc ggcggtcggg gttgtttctg gcggaggtgc tgctgatgat 9961 gtaattaaag taggcggtct tgagacggcg gatggtcgac agaagcacca tgtccttggg 10021 tccggcctgc tgaatgcgca ggcggtcggc catgccccag gcttcgtttt gacatcggcg 10081 caggtctttg tagtagtctt gcatgagcct ttctaccggc acttcttctt ctccttcctc 10141 ttgtcctgca tctcttgcat ctatcgctgc ggcggcggcg gagtttggcc gtaggtggcg 10201 ccctcttcct cccatgcgtg tgaccccgaa gcccctcatc ggctgaagca gggctaggtc 10261 ggcgacaacg cgcfccggcta atatggcctg ctgcacctgc gtgagggtag actggaagtc 10321 atccatgtcc acaaagcggt ggtatgcgcc cgtgttgatg gtgtaagtgc agttggccat 10381 aacggaccag ttaacggtct ggtgacccgg ctgcgagagc tcggtgtacc tgagacgcga 10441 gtaagccctc gagtcaaata cgtagtcgtt gcaagtccgc accaggtact ggtatcccac 10501 caaaaagtgc ggcggcggct ggcggtagag gggccagcgt agggtggccg gggctccggg 10561 ggcgagatct tccaacataa ggcgatgata tccgtagatg tacctggaca tccaggtgat 10621 gccggcggcg gtggtggagg cgcgcggaaa gtcgcggacg cggttccaga tgttgcgcag 10681 cggcaaaaag tgctccatgg tcgggacgct ctggccggtc aggcgcgcgc aatcgttgac 10741 gctctaccgt gcaaaaggag agcctgtaag cgggcactct tccgtggtct ggtggataaa 10801 ttcgcaaggg tatcatggcg gacgaccggg gttcgagccc cgtatccggc cgtccgccgt 10861 gatccatgcg gttaccgccc gcgtgtcgaa cccaggtgtg cgacgtcaga caacggggga 10921 gtgctccttt tggcttcctt ccaggcgcgg cggctgctgc gctagctttt ttggccactg 10981 gccgcgcgca gcgtaagcgg ttaggctgga aagcgaaagc attaagtggc tcgctccctg 11041 tagccggagg gttattttcc aagggttgag tcgcgggacc cccggttcga gtctcggacc 11101 ggccggactg cggcgaacgg gggtttgcct ccccgtcatg caagaccccg cttgcaaatt 11161 cctccggaaa cagggacgag cccctttttt gcttttccca gatgcatccg gtgctgcggc 11221 agatgcgocc ccctcctcag cagcggcaag agcaagagca gcggcagaca tgoagggcac 11281 cctcccctcc tcctaccgcg tcaggagggg cgacatccgc ggttgacgcg gcagcagatg 11341 gtgattacga acccccgcgg cgccgggccc ggcactacct ggacttggag gagggcgagg 11401 gcctggcgcg gctaggagcg ccctctcctg agcggtaccc aagggtgcag ctgaagcgtg 11461 atacgcgtga ggcgtacgtg ccgcggcaga acctgtttcg cgaccgcgag ggagaggagc 11521 ccgaggagat gcgggatcga aagttccacg cagggcgcga gctgcggcat ggcctgaatc 11581 gcgagcggtt gctgcgcgag gaggactttg agcccgacgc gcgaaccggg attagtcccg 11641 cgcgcgcaca cgtggcggcc gccgacctgg taaccgcata cgagcagacg gtgaaccagg 11701 agattaactt tcaaaaaagc tttaacaacc acgtgcgtac gcttgtggcg cgcgaggagg 11761 tggctatagg actgatgcat ctgtgggact ttgtaagcgc gctggagcaa aacccaaata 11821 gcaagccgct catggcgcag ctgttcctta tagtgcagca cagcagggac aacgaggcat 11881 tcagggatgc gctgctaaac atagtagagc ccgagggccg ctggctgctc gatttgataa 11941 acatcctgca gagcatagtg gtgcaggagc gcagcttgag cctggctgac aaggtggccg 12001 ccatcaacta ttccatgctt agcctgggca agttttacgc ccgcaagata taccataccc 12061 cttacgttcc catagacaag gaggtaaaga tcgaggggtt ctacatgcgc atggcgctga 12121 aggtgcttac cttgagcgac gacctgggcg tttatcgcaa cgagcgcatc cacaaggccg 12181 tgagcgtgag ccggcggcgc gagctcagcg accgcgagct gatgcacagc ctgcaaaggg 12241 ccctggctgg cacgggcagc ggcgatagag aggccgagtc ctactttgac gcgggcgctg 12301 acctgcgctg ggccccaagc cgacgcgccc tggaggcagc tggggccgga cctgggctgg 12361 cggtggcacc cgcgcgcgct ggcaacgtcg gcggcgtgga ggaatatgac gaggacgatg 12421 agtacgagcc agaggacggc gagtactaag cggtgatgtt tctgatcaga tgatgcaaga 12481 cgcaacggac ccggcggtgc gggcggcgct gcagagccag ccgtccggcc ttaactccac 12541 ggacgactgg cgccaggtca tggaccgcat catgtcgctg actgcgcgca atcctgacgc 12601 gttccggcag cagccgcagg ccaaccggct ctccgcaatt ctggaagcgg tggtcccggc 12661 gcgcgcaaac cccacgcacg agaaggtgct ggcgatcgta aacgcgctgg ccgaaaacag 12721 ggccatccgg cccgacgagg ccggcctggt ctacgacgcg ctgcttcagc gcgtggctcg 12781 ttacaacagc ggcaacgtgc agaccaacct ggaccggctg gtgggggatg tgcgcgaggc 12841 cgtggcgcag cgtgagcgcg cgcagcagca gggcaacctg ggctccatgg ttgcactaaa 12901 cgccttcctg agtacacagc ccgccaacgt gccgcgggga caggaggact acaccaactt 12961 tgtgagcgca ctgcggctaa tggtgactga gacaccgcaa agtgaggtgt accagtctgg 13021 gccagactat tttttccaga ccagtagaca aggcctgcag accgtaaacc tgagccaggc 13081 tttcaaaaac ttgcaggggc tgtggggggt gcgggctccc acaggcgacc gcgcgaccgt 13141 gtctagcttg ctgacgccca actcgcgcct gttgctgctg ctaatagcgc ccttcacgga 13201 cagtggcagc gtgtcccggg acacatacct aggtcacttg ctgacactgt accgcgaggc 13261 cataggtcag gcgcatgtgg acgagcatac tttccaggag attacaagtg tcagccgcgc 13321 gctggggcag gaggacacgg gcagcctgga ggcaacccta aactacctgc tgaccaaccg 13381 gcggcagaag atcccctcgt tgcacagttt aaacagcgag gaggagcgca ttttgcgcta 13441 cgtgcagcag agcgtgagcc ttaacctgat gcgcgacggg gtaacgccca gcgtggcgct 13501 ggacatgacc gcgcgcaaca tggaaccggg catgtatgcc tcaaaccggc cgtttatcaa 13561 ccgcctaatg gactacttgc atcgcgcggc cgccgtgaac cccgagtatt tcaccaatgc 13621 catcttgaac ccgcactggc taccgccccc tggtttctac accgggggat tcgaggtgcc 13681 cgagggtaac gatggattcc tctgggacga catagacgac agcgtgtttt ccccgcaacc 13741 gcagaccctg ctagagttgc aacagcgcga gcaggcagag gcggcgctgc gaaaggaaag 13801 cttccgcagg ccaagcagct tgtccgatct aggcgctgcg gccccgcggt cagatgctag 13861 tagcccattt ccaagcttga tagggtctct taccagcact cgcaccaccc gcccgcgcct 13921 gctgggcgag gaggagtacc taaacaactc gctgctgcag ccgcagcgcg aaaaaaacct 13981 gcctccggca tttcccaaca acgggataga gagcctagtg gacaagatga gtagatggaa 14041 gacgtacgcg caggagcaca gggacgtgcc aggcccgcgc ccgcccaccc gtcgtcaaag 14101 gcacgaccgt cagcggggtc tggtgtggga ggacgatgac tcggcagacg acagcagcgt 14161 cctggatttg ggagggagtg gcaacccgtt tgcgcacctt cgccccaggc tggggagaat 14221 gttttaaaaa aaaaaaagca tgatgcaaaa taaaaaactc accaaggcca tggcaccgag 14281 cgttggtttt cttgtattcc ccttagtatg cggcgcgcgg cgatgtatga ggaaggtcct 14341 cctccctcct acgagagtgt ggtgagcgcg gcgccagtgg cggcggcgct gggttctccc 14401 ttcgatgctc ccctggaccc gccgtttgtg cctccgcggt acctgcggcc taccgggggg 14461 agaaacagca tccgttactc tgagttggca cccctattcg acaccacccg tgtgtacctg .14521 gtggacaaca agtcaacgga tgtggcatcc ctgaactacc agaacgacca cagcaacttt 14581 ctgaccacgg tcattcaaaa caatgactac agcccggggg aggcaagcac acagaccatc 14641 aatcttgacg accggtcgca ctggggcggc gacctgaaaa ccatcctgca taccaacatg 14701 ccaaatgtga acgagttcat gtttaccaat aagtttaagg cgcgggtgat ggtgtcgcgc 14761 ttgcctacta aggacaatca ggtggagctg aaatacgagt gggtggagtt cacgctgccc 14821 gagggcaact actccgagac catgaccata gaccttatga acaacgcgat cgtggagcac 14881 tacttgaaag tgggcagaca gaacggggtt ctggaaagcg acatcggggt aaagtttgac 14941 acccgcaact tcagactggg gtttgacccc gtcactggtc ttgtcatgcc tggggtatat 15001 acaaacgaag ccttccatcc agacatcatt ttgctgccag gatgcggggt ggacttcacc 15061 cacagccgcc tgagcaactt gttgggcatc cgcaagcggc aacccttcca ggagggcttt 15121 aggatcacct acgatgatct ggagggtggt aacattcccg cactgttgga tgtggacgcc 15181 taccaggcga gcttgaaaga tgacaccgaa cagggcgggg gtggcgcagg cggcagcaac 15241 agcagtggca gcggcgcgga agagaactcc aacgcggcag ccgcggcaat gcagccggtg 15301 gaggacatga acgatcatgc cattcgcggc gacacctttg ccacacgggc tgaggagaag 153 61 cgcgctgagg ccgaagcagc ggccgaagct gc.cgcccccg ctgcgcaacc cgaggtcgag 15421 aagcctcaga agaaaccggt gatcaaaccc ctgacagagg acagcaagaa acgcagttac 15481 aacctaataa gcaatgacag caccttcacc cagtaccgca gctggtacct tgcatacaac 15541 tacggcgacc ctcagaccgg aatccgctca tggaccctgc tttgcactcc tgacgtaacc 15601 tgcggctcgg agcaggtcta ctggtcgttg ccagacatga tgcaagaccc cgtgaccttc 15661 cgctccacgc gccagatcag caactttccg gtggtgggcg ccgagctgtt gcccgtgcac 15721 tccaagagct tctacaacga ccaggccgtc tactcccaac tcatccgcca gtttacctct 15781 ctgacccacg tgttcaatcg ctttcccgag aaccagattt tggcgcgccc gccagccccc 15841 accatcacca ccgtcagtga aaacgttcct gctctcacag atcacgggac gctaccgctg 15901 cgcaacagca tcggaggagt ccagcgagtg accattactg acgccagacg ccgcacctgc 15961 ccctacgttt acaaggccct gggcatagtc tcgccgcgcg tcctatcgag ccgcactttt 16021 tgagcaagca tgtccatcct tatatcgccc agcaataaca caggctgggg cctgcgcttc 16081 ccaagcaaga tgtttggcgg ggccaagaag cgctccgacc aacacccagt gcgcgtgcgc 16141 gggcactacc gcgcgccctg gggcgcgcac aaacgcggcc gcactgggcg caccaccgtc 16201 gatgacgcca tcgacgcggt ggtggaggag gcgcgcaact acacgcccac gccgccacca 16261 gtgtccacag tggacgcggc cattcagacc gtggtgcgcg gagcccggcg ctatgctaaa 16321 atgaagagac ggcggaggcg cgtagcacgt cgccaccgcc gccgacccgg cactgccgcc 16381 caacgcgcgg cggcggccct gcttaaccgc gcacgtcgca ccggccgacg ggcggccatg 16441 cgggccgctc gaaggctggc cgcgggtatt gtcactgtgc cccccaggtc caggcgacga 16501 gcggccgccg cagcagccgc ggccattagt gctatgactc agggtcgcag gggcaacgtg 16561 tattgggtgc gcgactcggt tagcggcctg cgcgtgcccg tgcgcacccg ccccccgcgc 16621 aactagattg caagaaaaaa ctacttagac tcgtactgtt gtatgtatcc agcggcggcg 16681 gcgcgcaacg aagctatgtc caagcgcaaa atcaaagaag agatgctcca ggtcatcgcg 16741 ccggagatct atggcccccc gaagaaggaa gagcaggatt acaagccccg aaagctaaag 16801 cgggtcaaaa agaaaaagaa agatgatgat gatgaacttg acgacgaggt ggaactgctg 16861 cacgctaccg cgcccaggcg acgggtacag tggaaaggtc gacgcgtaaa acgtgttttg 16921 cgacccggca ccaccgtagt ctttacgccc ggtgagcgct ccacccgcac ctacaagcgc 16981 gtgtatgatg aggtgtacgg cgacgaggac ctgcttgagc aggccaacga gcgcctcggg 17041 gagtttgcct acggaaagcg gcataaggac atgctggcgt tgccgctgga cgagggcaac 17101 ccaacaccta gcctaaagcc cgtaacactg cagcaggtgc tgcccgcgct tgcaccgtcc 17161 gaagaaaagc gcggcctaaa gcgcgagtct ggtgacttgg cacccaccgt gcagctgatg 17221 gtacccaagc gccagcgact ggaagatgtc ttggaaaaaa tgaccgtgga acctgggctg 17281 gagcccgagg tccgcgtgcg gccaatcaag caggtggcgc cgggactggg cgtgcagacc 17341 gtggacgttc agatacccac taccagtagc accagtattg ccaccgccac agagggcatg 17401 gagacacaaa cgtccccggt tgcctcagcg gtggcggatg ccgcggtgca ggcggtcgct 17461 gcggccgcgt ccaagacctc tacggaggtg caaacggacc cgtggatgtt tcgcgtttca 17521 gccccccggc gcccgcgcgg ttcgaggaag tacggcgccg ccagcgcgct actgcccgaa 17581 tatgccctac atccttccat tgcgcctacc cccggctatc gtggctacac ctaccgcccc 17641 agaagacgag caactacccg acgccgaacc accactggaa cccgccgccg ccgtcgccgt 17701 cgccagcccg tgctggcccc gatttccgtg cgcagggtgg ctcgcgaagg aggcaggacc 17761 ctggtgctgc caacagcgcg ctaccacccc agcatcgttt aaaagccggt ctttgtggtt 17821 cttgcagata tggccctcac ctgccgcctc cgtttcccgg tgccgggatt ccgaggaaga 17881 atgcaccgta ggaggggcat ggccggccac ggcctgacgg gcggcatgcg tcgtgcgcac 17941 caccggcggc ggcgcgcgtc gcaccgtcgc atgcgcggcg gtatcctgcc cctccttatt 18001 ccactgatcg ccgcggcgat tggcgccgtg cccggaattg catccgtggc cttgcaggcg 18061 cagagacact gattaaaaac aagttgcatg tggaaaaatc aaaataaaaa gtctggactc 18121 tcacgctcgc ttggtcctgt aactattttg tagaatggaa gacatcaact ttgcgtctct 18181 ggccccgcga cacggctcgc gcccgttcat gggaaactgg caagatatcg gcaccagcaa 18241 tatgagcggt ggcgccttca gctggggctc gctgtggagc ggcattaaaa atttcggttc 18301 caccgttaag aactatggca gcaaggcctg gaacagcagc acaggccaga tgctgaggga 18361 taagttgaaa gagcaaaatt tccaacaaaa ggtggtagat ggcctggcct ctggcattag 18421 cggggtggtg gacctggcca accaggcagt gcaaaataag attaacagta agcttgatcc 18481 ccgccctccc gtagaggagc ctccaccggc cgtggagaca gtgtctccag aggggcgtgg 18541 cgaaaagcgt ccgcgccccg acagggaaga aactctggtg acgcaaatag’acgagcctcc 18601 ctcgtacgag gaggcactaa agcaaggcct gcccaccacc cgtcccatcg cgcccatggc 18661 taccggagtg ctgggccagc acacacccgt aacgctggac ctgcctcccc ccgccgacac 18721 ccagcagaaa cctgtgctgc caggcccgac cgccgttgtt gtaacccgtc ctagccgcgc 18781 gtccctgcgc cgcgccgcca gcggtccgcg atcgttgcgg cccgtagcca gtggcaactg 18841 gcaaagcaca ctgaacagca tcgtgggtct gggggtgcaa tccctgaagc gccgacgatg 18901 cttctgaata gctaacgtgt cgtatgtgtg tcatgtatgc gtccatgtcg ccgccagagg 18961 agctgctgag ccgccgcgcg cccgctttcc aagatggcta ccccttcgat gatgccgcag 19021 tggtcttaca tgcacatctc gggccaggac gcctcggagt acctgagccc cgggctggtg 19081 cagtttgccc gcgccaccga gacgtacttc agcctgaata acaagtttag aaaccccacg 19141 gtggcgccta cgcacgacgt gaccacagac cggtcccagc gtttgacgct gcggttcatc 19201 cctgtggacc gtgaggatac tgcgtactcg tacaaggcgc ggttcaccct agctgtgggt 19261 gataaccgtg tgctggacat ggcttccacg tactttgaca tccgcggcgt gctggacagg 19321 ggccctactt ttaagcccta ctctggcact gcctacaacg ccctggctcc caagggtgcc 19381 ccaaatcctt gcgaatggga tgaagctgct actgctcttg aaataaacct agaagaagag 19441 gacgatgaca acgaagacga agtagacgag caagctgagc agcaaaaaac tcacgtattt . 19501 gggcaggcgc cttattctgg tataaatatt acaaaggagg gtattcaaat aggtgtcgaa 19561 ggtcaaacac ctaaatatgc cgataaaaca tttcaacctg aacctcaaat aggagaatct 19621 cagtggtacg aaactgaaat taatcatgca gctgggagag tccttaaaaa gactacccca 19681 atgaaaccat gttacggttc atatgcaaaa cccacaaatg aaaatggagg gcaaggcatt 19741 cttgtaaagc aacaaaatgg aaagctagaa agtcaagtgg aaatgcaatt tttctcaact 19801 actgaggcga ccgcaggcaa tggtgataac ttgactccta aagtggtatt gtacagtgaa 19861 gatgtagata tagaaacccc aga'cactcat atttcttaca tgcccactat taaggaaggt 19921 aactcacgag aactaatggg ccaacaatct atgcccaaca ggcctaatta cattgctttt 19981 agggacaatt ttattggtct aatgtattac aacagcacgg gtaatatggg tgttctggcg 20041 ggccaagcat cgcagttgaa tgctgttgta gatttgcaag acagaaacac agagctttca 20101 taccagcttt tgcttgattc cattggtgat agaaccaggt acttttctat gtggaatcag 20161 gctgttgaca gctatgatcc agatgttaga attattgaaa atcatggaac tgaagatgaa 20221 cttccaaatt actgctttcc actgggaggt gtgattaata cagagactct taccaaggta 20281 aaacctaaaa caggtcagga aaatggatgg gaaaaagatg ctacagaatt ttcagataaa 20341 aatgaaataa gagttggaaa taattttgcc atggaaatca atctaaatgc caacctgtgg 20401 agaaatttcc tgtactccaa catagcgctg tatttgcccg acaagctaaa gtacagtcct 20461 tccaacgtaa aaatttctga taacccaaac acctacgact acatgaacaa gcgagtggtg 20521 gctcccgggt tagtggactg ctacattaac cttggagcac gctggtccct tgactatatg 20581 gacaacgtca acccatttaa ccaccaccgc aatgctggcc tgcgctaccg ctcaatgttg 20641 ctgggcaatg gtcgctatgt gcccttccac atccaggtgc ctcagaagtt ctttgccatt 20701 aaaaacctcc ttctcctgcc gggctcatac acctacgagt ggaacttcag gaaggatgtt 20761 aacatggttc tgcagagctc cctaggaaat gacctaaggg ttgacggagc cagcattaag 20821 tttgatagca tttgccttta cgccaccttc ttccccatgg cccacaacac cgcctccacg 20881 cttgaggcca tgcttagaaa cgacaccaac gaccagtcct ttaacgacta tctctccgcc 20941 gccaacatgc tctaccctat acccgccaac gctaccaacg tgcccatatc catcccctcc 21001 cgcaactggg cggctttccg cggctgggcc ttcacgcgcc ttaagactaa ggaaacccca 21061 tcactgggct cgggctacga cccttattac acctactctg gctctatacc ctacctagat 21121 ggaacctttt acctcaacca cacctttaag aaggtggcca ttacctttga ctcttctgtc 21181 agctggcctg gcaatgaccg cctgcttacc cccaacgagt ttgaaattaa gcgctcagtt 21241 gacggggagg gttacaacgt tgcccagtgt aacatgacca aagactggtt cctggtacaa 21301 atgctagcta actacaacat tggctaccag ggcttctata tcccagagag ctacaaggac 21361 cgcatgtact ccttctttag aaacttccag cccatgagcc gtcaggtggt ggatgatact 21421 aaatacaagg actaccaaca ggtgggcatc ctacaccaac acaacaactc tggatttgtt 21481 ggctaccttg cccccaccat gcgcgaagga caggcctacc ctgctaactt cccctatccg 21541 cttataggca agaccgcagt tgacagcatt acccagaaaa agtttctttg cgatcgcacc 21601 ctttggcgca tcccattctc cagtaacttt atgtccatgg gcgcactcac agacctgggc 21661 caaaaccttc tctacgccaa ctccgcccac gcgctagaca tgacttttga ggtggatccc 21721 atggacgagc ccacccttct ttatgttttg tttgaagtct ttgacgtggt ccgtgtgcac 21781 cggccgcacc gcggcgtcat cgaaaccgtg tacctgcgca cgcccttctc ggccggcaac 21841 gccacaacat aaagaagcaa gcaacatcaa caacagctgc cgccatgggc tccagtgagc 21901 aggaactgaa agccattgtc aaagatcttg gttgtgggcc atattttttg ggcacctatg 21961 acaagcgctt tccaggcttt gtttctccac acaagctcgc ctgcgccata gtcaatacgg 22021 ccggtcgcga gactgggggc gtacactgga tggcctttgc ctggaacccg cactcaaaaa 22081 catgctacct ctttgagccc tttggctttt ctgaccagcg actcaagcag gtttaccagt 22141 ttgagtacga gtcactcctg cgccgtagcg ccattgcttc ttcccccgac cgctgtataa 22201 cgctggaaaa gtccacccaa agcgtacagg ggcccaactc ggccgcctgt ggactattct. 22261 gctgcatgtt tctccacgcc tttgccaact ggccccaaac tcccatggat cacaacccca 22321 ccatgaacct tattaccggg gtacccaact ccatgctcaa cagtccccag gtacagccca 22381 ccctgcgtcg caaccaggaa cagctctaca gcttcctgga gcgccactcg ccctacttcc 22441 gcagccacag tgcgcagatt aggagcgcca cttctttttg tcacttgaaa aacatgtaaa 22501 aataatgtac tagagacact ttcaataaag gcaaatgctt ttatttgtac actctcgggt 22561 gattatttac ccccaccctt gccgtctgcg ccgtttaaaa atcaaagggg ttctgccgcg · 22621 catcgctatg cgccactggc agggacacgt tgcgatactg gtgtttagtg ctccacttaa 22681 actcaggcac aaccatccgc ggcagctcgg tgaagttttc actccacagg ctgcgcacca 22741 tcaccaacgc gtttagcagg tcgggcgccg atatcttgaa gtcgcagttg gggcctccgc 22801 cctgcgcgcg cgagttgcga tacacagggt tgcagcactg gaacactatc agcgccgggt 22861 ggtgcacgct ggccagcacg ctcttgtcgg agatcagatc cgcgtccagg tcctccgcgt 22921 tgctcagggc gaacggagtc aactttggta gctgccttcc caaaaagggc gcgtgcccag 22981 gctttgagtt .gcactcgcac cgtagtggca tcaaaaggtg accgtgcccg gtctgggcgt 23041 taggatacag cgcctgcata aaagccttga tctgcttaaa agccacctga gcctttgcgc 23101 cttcagagaa gaacatgccg caagacttgc cggaaaactg attggccgga caggccgcgt 23161 cgtgcacgca gcaccttgcg tcggtgttgg agatctgcac cacatttcgg ccccaccggt 23221 tcttcacgat cttggccttg ctagactgct ccttcagcgc gcgctgcccg ttttcgctcg 23281 tcacatccat ttcaatcacg tgctccttat ttatcataat gcttccgtgt agacacttaa 23341 gctcgccttc gatctcagcg cagcggtgca gccacaacgc gcagcccgtg ggctcgtgat 23401 gcttgtaggt cacctctgca aacgactgca ggtacgcctg caggaatcgc cccatcatcg 23461 tcacaaaggt cttgttgctg gtgaaggtca gctgcaaccc gcggtgctcc tcgttcagcc 23521 aggtcttgca tacggccgcc agagcttcca cttggtcagg cagtagtttg aagttcgcct 23581 ttagatcgtt atccacgtgg tacttgtcca tcagcgcgcg cgcagcctcc atgcccttct 23641 cccacgcaga cacgatcggc acactcagcg ggttcatcac cgtaatttca ctttccgctt 23701 cgctgggctc ttcctcttcc tcttgcgtcc gcataccacg cgccactggg tcgtcttcat 23761 tcagccgccg cactgtgcgc ttacctcctt tgccatgctt gattagcacc ggtgggttgc 23821 tgaaacccac catttgtagc gccacatctt ctctttcttc ctcgctgtcc acgattacct 23881 ctggtgatgg cgggcgctcg ggcttgggag aagggcgctt ctttttcttc ttgggcgcaa 23941 tggccaaatc cgccgccgag gtcgatggcc gcgggctggg tgtgcgcggc accagcgcgt 24001 ottgtgatga gtcttcctcg tcctcggact cgatacgccg cctcatccgc ttttttgggg 24061 gcgcccgggg aggcggcggc gacggggacg gggacgacac gtcctccatg gttgggggac 24121 gtcgcgccgc accgcgtccg cgctcggggg tggtttcgcg ctgctcctct tcccgactgg 24181 ccatttcctt ctoctatagg cagaaaaaga tcatggagtc agtcgagaag aaggacagcc 24241 taaccgcccc ctctgagttc gccaccaccg cctccaccga tgccgccaac gcgcctacca 24301 ccttccccgt cgaggcaccc ccgcttgagg aggaggaagt gattatcgag caggacccag 24361 gttttgtaag cgaagacgac gaggaccgct cagtaccaac agaggataaa aagcaagacc 24421 aggacaacgc agaggcaaac gaggaacaag tcgggcgggg ggacgaaagg catggcgact 24481 acctagatgt gggagacgac gtgctgttga agcatctgca gcgccagtgc gccattatct 24541 gcgacgcgtt gcaagagcgc agcgatgtgc ccctcgccat agcggatgtc agccttgcct 24601 acgaacgcca cctattctca ccgcgcgtac cccccaaacg ccaagaaaac ggcacatgcg 24661 agcccaaccc gcgcctcaac ttctaccccg tatttgccgt gccagaggtg cttgccacct 24721 atcacatctt tttccaaaac tgcaagatac ccctatcctg ccgtgccaac cgcagccgag 24781 cggacaagca gctggccttg cggcagggcg ctgtcatacc tgatatcgcc tcgctcaacg 24841 aagtgccaaa aatctttgag ggtcttggac gcgacgagaa gcgcgcggca aacgctctgc 24901 aacaggaaaa cagcgaaaat gaaagtcact ctggagtgtt ggtggaactc gagggtgaca 24961 acgcgcgcct agccgtacta aaacgcagca tcgaggtcac ccactttgcc tacccggcac 25021 ttaacctacc ccccaaggtc atgagcacag tcatgagtga gctgatcgtg cgccgtgcgc 25081 agcccctgga gagggatgca aatttgcaag aacaaacaga ggagggccta cccgcagttg 25141 gcgacgagca gctagcgcgc tggcttcaaa cgcgcgagcc tgccgacttg gaggagcgac 25201 gcaaactaat gatggccgca gtgctcgtta ccgtggagct tgagtgcatg cagcggttct 25261 ttgctgaccc ggagatgcag' cgcaagctag aggaaacatt gcactacacc tttcgacagg 25321 gctacgtacg ccaggcctgc aagatctcca acgtggagct ctgcaacctg gtctcctacc 25381 ttggaatttt gcacgaaaac cgccttgggc aaaacgtgct tcattccacg ctcaagggcg 25441 aggcgcgccg cgactacgtc cgcgactgcg tttacttatt tctatgctac acctggcaga 25501 cggccatggg cgtttggcag cagtgcttgg aggagtgcaa cctcaaggag ctgcagaaac 25561 tgctaaagca aaacttgaag gacctatgga cggccttcaa cgagcgctcc gtggccgcgc 25621 acctggcgga catcattttc cccgaacgcc tgcttaaaac cctgcaacag ggtctgccag 25681 acttcaccag tcaaagcatg ttgcagaact ttaggaactt tatcctagag cgctcaggaa 25741 tcttgcccgc cacctgctgt gcacttccta gcgactttgt gcccattaag taccgcgaat 25801 gccctccgcc gctttggggc cactgctacc ttctgcagct agccaactac cttgcctacc 25861 actctgacat aatggaagac gtgagcggtg acggtctact ggagtgtcac tgtcgctgca 25921 acctatgcac cccgcaccgc tccctggttt gcaattcgca gctgcttaac gaaagtcaaa 25981 ttatcggtac ctttgagctg cagggtccct cgcctgacga aaagtccgcg gctccggggt 26041 tgaaactcac tccggggctg tggacgtcgg cttaccttcg caaatttgta cctgaggact 26101 accacgccca cgagattagg ttctacgaag accaatcccg cccgccaaat gcggagctta 26161 ccgcctgcgt cattacccag ggccacattc ttggccaatt gcaagccatc aacaaagccc 26221 gccaagagtt tctgctacga aagggacggg gggtttactt ggacccccag tccggcgagg 26281 agctcaaccc aatccccccg ccgccgcagc cctatcagca gcagccgcgg gcccttgctt 26341 cccaggatgg cacccaaaaa gaagctgcag ctgccgccgc cacccacgga cgaggaggaa 26401 tactgggaca gtcaggcaga ggaggttttg gacgaggagg aggaggacat gatggaagac 26461 tgggagagcc tagacgagga agcttccgag gtcgaagagg tgtcagacga aacaccgtca 26521 ccctcggtcg cattcccctc gccggogccc cagaaatcgg caaccggttc cagcatggct 26581 acaacctccg ctcctcaggc gccgccggca ctgcccgttc gccgacccaa ccgtagatgg 26641 gacaccactg gaaccagggc cggtaagtcc aagcagccgc cgccgttagc ccaagagcaa 26701 caacagcgcc aaggctaccg ctcatggcgc gggcacaaga acgccatagt tgcttgcttg 26761 caagactgtg ggggcaacat ctccttcgcc cgccgctttc ttctctacca tcacggcgtg 26821 gccttccccc gtaacatcct gcattactac cgtcatctct acagcccata ctgcaccggc 26881 ggcagcggca gcggcagcaa cagcagcggc cacacagaag caaaggcgac cggatagcaa 26941 gactctgaca aagcccaaga aatccacagc ggcggcagca gcaggaggag gagcgctgcg 27001 tctggcgccc aacgaacccg tatcgacccg cgagcttaga aacaggattt ttcccactct 27061 gtatgctata tttcaacaga gcaggggcca agaacaagag ctgaaaataa aaaacaggtc 27121 tctgcgatcc ctcacccgca gctgcctgta tcacaaaagc gaagatcagc ttcggcgcac 27181 gctggaagac gcggaggctc tcttcagtaa atactgcgcg ctgactctta aggactagtt 27241 tcgcgccctt tctcaaattt aagcgcgaaa actacgtcat ctccagcggc cacacccggc 27301 gccagcacct gtcgtcagcg ccattatgag caaggaaatt cccacgccct acatgtggag 27361 ttaccagcca caaatgggac ttgcggctgg agctgcccaa gactactcaa cccgaataaa 27421 ctacatgagc gcgggacccc acatgatatc ccgggtcaac ggaatccgcg cccaccgaaa 27481 ccgaattctc ttggaacagg cggctattac caccacacct cgtaataacc ttaatccccg 27541 tagttggccc gctgccctgg tgtaccagga aagtcccgct cccaccactg tggtacttcc 27601 cagagacgcc caggccgaag ttcagatgac taactcaggg gcgcagcttg cgggcggctt 27661 tcgtcacagg gtgcggtcgc ccgggcaggg tataactcac ctgacaatca gagggcgagg 27721 tattcagctc aacgacgagt cggtgagctc ctcgcttggt ctccgtccgg acgggacatt 27781 tcagatcggc ggcgccggcc gtccttcatt cacgcctcgt caggcaatcc taactctgca 27841 gacctcgtcc tctgagccgc gctctggagg cattggaact ctgcaattta ttgaggagtt 27901 tgtgccat:cg gtctacttta accccttctc gggacctccc ggccactatc cggatcaatt 27961 tattcctaac tttgacgcgg taaaggactc ggcggacggc tacgactgaa tgttaagtgg 28021 agaggcagag caactgcgcc tgaaacacct ggtccactgt cgccgccaca agtgctttgc 28081 ccgcgactcc ggtgagtttt gctactttga attgcccgag gatcatatcg agggcccggc 28141 gcacggcgtc cggcttaccg cccagggaga gcttgcccgt agcctgattc gggagtttac 28201 ccagcgcccc ctgctagttg agcgggacag gggaccctgt gttctcactg tgatttgcaa 28261 ctgtcctaac cttggattac atcaagatcc tctagttata actagagtac ccggggatct 28321 tattcccttt aactaataaa aaaaaataat aaagcatcac ttacttaaaa tcagttagca 28381 aatttctgtc cagtttattc agcagcacct ccttgccctc ctcccagctc tggtattgca 28441 gcttcctcct ggctgcaaac tttctccaca atctaaatgg aatgtcagtt tcctcctgtt 28501 cctgtccatc cgcacccact atcttcatgt tgttgcagat gaagcgcgca agaccgtctg 28561 aagatacctt caaccccgtg tatccatatg acacggaaac cggtcctcca actgtgcctt 28621 ttcttactcc tccctttgta tcccccaatg ggtttcaaga gagtccccct ggggtactct 28681 ctttgcgcct atccgaacct ctagttacct ccaatggcat gcttgcgctc aaaatgggca 28741 acggcctctc tctggacgag gccggcaacc ttacctccca aaatgtaacc actgtgagcc 28801 cacctctcaa aaaaaccaag tcaaacataa acctggaaat atctgcaccc ctcacagtta 28861 cctcagaagc cctaactgtg gctgccgccg cacctctaat ggtcgcgggc aacacactca 28921 ccatgcaatc acaggccccg ctaaccgtgc acgactccaa acttagcatt gccacccaag 28981 gacccctcac agtgtcagaa ggaaagctag ccctgcaaac atcaggcccc ctcaccacca 29041 ccgatagcag tacccttact atcactgcct caccccctct aactactgcc actggtagct 29101 tgggcattga cttgaaagag cccatttata cacaaaatgg aaaactagga ctaaagtacg 29161 gggctccttt gcatgtaaca gacgacctaa acactttgac cgtagcaact ggtccaggtg 29221 tgactattaa taatacttcc ttgcaaacta aagttactgg agccttgggt tttgattcac 29281 aaggcaatat gcaacttaat gtagcaggag gactaaggat tgattctcaa aacagacgcc 29341 ttatacttga tgttagttat ccgtttgatg ctcaaaacca actaaatcta agactaggac 29401 agggccctct ttttataaac tcagcccaca acttggatat taactacaac aaaggccttt 29461 acttgtttac agcttcaaac aattccaaaa agcttgaggt taacctaagc actgccaagg 29521 ggttgatgtt tgacgctaca gccatagcca ttaatgcagg agatgggctt gaatttggtt 29581 cacctaatgc accaaacaca aatcccctca aaacaaaaat tggccatggc ctagaatttg 29641 attcaaacaa ggctatggtt cctaaactag gaactggcct tagttttgac agcacaggtg 29701 ccattacagt aggaaacaaa aataatgata agctaacttt gtggaccaca ccagctccat 29761 ctcctaactg tagactaaat gcagagaaag atgctaaact cactttggtc ttaacaaaat 29821 gtggcagtca aatacttgct acagtttcag ttttggctgt taaaggcagt ttggctccaa 29881 tatctggaac agttcaaagt gctcatctta ttataagatt tgacgaaaat ggagtgctac 29941 taaacaattc cttcctggac ccagaatatt ggaactttag aaatggagat cttactgaag 30001 gcacagccta tacaaacgct gttggattta tgcctaacct atcagcttat ccaaaatctc 30061 acggtaaaac.tgccaaaagt aacattgtca gtcaagttta cttaaacgga gacaaaacta 30121 aacctgtaac actaaccatt acactaaacg gtacacagga aacaggagac acaactccaa 30181 gtgcatactc tatgtcattt tcatgggact ggtctggcca caactacatt aatgaaatat 30241 ttgccacatc ctcttacact ttttcataca ttgcccaaga ataaagaatc gtttgtgtta 30301 tgtttcaacg tgtttatttt tcaattgcag aaaatttcaa gtcatttttc attcagtagt 30361 atagccccac caccacatag cttatacaga tcaccgtacc ttaatcaaac tcacagaacc 30421 ctagtattca acctgccacc tccctcccaa cacacagagt acacagtcct ttctccccgg 30481 ctggccttaa aaagcatcat atcatgggta acagacatat tcttaggtgt tatattccac 30541 acggtttcct gtcgagccaa acgctcatca gtgatattaa taaactcccc gggcagctca 30601 cttaagttca tgtcgctgtc cagctgctga gccacaggct gctgtccaac ttgcggttgc 30661 ttaacgggcg gcgaaggaga agtccacgcc tacatggggg tagagtcata atcgtgcatc 30721 aggatagggc ggtggtgctg cagcagcgcg cgaataaact gctgccgccg ccgctccgtc 30781 ctgcaggaat acaacatggc agtggtctcc tcagcgatga ttcgcaccgc ccgcagcata 30841 aggcgccttg tcctccgggc acagcagcgc accctgatct cacttaaatc agcacagtaa 30901 ctgcagcaca gcaccacaat attgttcaaa atcccacagt gcaaggcgct gtatccaaag 30961 ctcatggcgg ggaccacaga acccacgtgg ccatcatacc acaagcgcag gtagattaag 31021 tggcgacccc tcataaacac gctggacata aacattacct cttttggcat gttgtaattc 31081 accacctccc ggtaccatat aaacctctga ttaaacatgg cgccatccac caccatccta 31141 aaccagctgg ccaaaacctg cccgccggct atacactgca gggaaccggg actggaacaa 31201 tgacagtgga gagcccagga ctcgtaacca tggatcatca tgctcgtcat gatatcaatg 31261 ttggcacaac acaggcacac gtgcatacac ttcctcagga ttacaagctc ctcccgcgtt 31321 agaaccatat cccagggaac aacccattcc tgaatcagcg taaatcccac actgcaggga 31381 agacctcgca cgtaactcac gttgtgcatt gtcaaagtgt tacattcggg cagcagcgga 31441 tgatcctcca gtatggtagc gcgggtttct gtctcaaaag gaggtagacg atccctactg '31501 tacggagtgc gccgagacaa ccgagatcgt gttggtcgta gtgtcatgcc aaatggaacg 31561 ccggacgtag tcatatttcc tgaagcaaaa ccaggtgcgg gcgtgacaaa cagatctgcg 31621 tctccggtct cgccgcttag atcgctctgt gtagtagttg tagtatatcc actctctcaa 31681 agcatccagg cgccccctgg cttcgggttc tatgtaaact ccttcatgcg ccgctgccct 31741 gataacatcc accaccgcag aataagccac acccagccaa cctacacatt cgttctgcga 31801 gtcacacacg ggaggagcgg gaagagctgg aagaaccatg tttttttttt tattccaaaa 31861 gattatccaa aacctcaaaa tgaagatcta ttaagtgaac gcgctcccct ccggtggcgt 31921 ggtcaaactc tacagccaaa gaacagataa tggcatttgt aagatgttgc acaatggctt 31981 ccaaaaggca aacggccctc acgtccaagt ggacgtaaag gctaaaccct tcagggtgaa 32041 tctcctctat aaacattcca gcaccttcaa ccatgcccaa ataattctca tctcgccacc 32101 ttctcaatat atctctaagc aaatcccgaa tattaagtcc ggccattgta aaaatctgct 32161 ccagagcgcc ctccaccttc agcctcaagc agcgaatcat gattgcaaaa attcaggttc 32221 ctcacagacc tgtataagat tcaaaagcgg aacattaaca aaaataccgc gatcccgtag 32281 gtcccttcgc agggccagct gaacataatc gtgcaggtct gcacggacca gcgcggccac 32341 ttccccgcca ggaaccttga caaaagaacc cacactgatt atgacacgca tactcggagc 32401 tatgctaacc agcgtagccc cgatgtaagc tttgttgcat gggcggcgat ataaaatgca 32461 aggtgctgct caaaaaatca ggcaaagcct cgcgcaaaaa agaaagcaca tcgtagtcat 32521 gctcatgcag ataaaggcag gtaagctccg gaaccaccac agaaaaagac accatttttc 32581 tctcaaacat gtctgcgggt ttctgcataa acacaaaata aaataacaaa aaaacattta 32641 aacattagaa gcctgtctta caacaggaaa aacaaccctt ataagcataa gacggactac 32701 ggccatgccg gcgtgaccgt aaaaaaactg gtcaccgtga ttaaaaagca ccaccgacag 32761 ctcctcggtc atgtccggag tcataatgta agactcggta aacacatcag gttgattcat 32821 cggtcagtgc taaaaagcga ccgaaatagc ccgggggaat acatacccgc aggcgtagag 32881 acaacattac agcccccata ggaggtataa caaaattaat aggagagaaa aacacataaa 32941 cacctgaaaa accctcctgc ctaggcaaaa tagcaccctc ccgctccaga acaacataca 33001 gcgcttcaca gcggdagcct aacagtcagc cttaccagta aaaaagaaaa cctattaaaa 33061 aaacaccact cgacacggca ccagctcaat cagtcacagt gtaaaaaagg gccaagtgca 33121 gagcgagtat atataggact aaaaaatgac gtaacggtta aagtccacaa aaaacaccca 33181 gaaaaccgca cgcgaaccta cgcccagaaa cgaaagccaa aaaacccaca acttcctcaa 33241 atcgtcactt ccgttttccc acgttacgta acttcccatt ttaagaaaac tacaattccc 33301 aacacataca agttactccg ccctaaaacc tacgtcaCcc gccccgttcc cacgccccgc 33361 gccacgtcac aaactccacc ccctcattat catattggct tcaatccaaa ataaggtata 33421 ttattgatga tnnnnnttaa t
REFERENCES CITED IN THE DESCRIPTION
This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.
Patent documents cited in the description • US65J.1845B [0001] • W02005014038A [00011 • .US5185440A [0056] • US5739026A røSSSl • US65660933 [00561 • US5814482A [0056] • US4474757A [0066] • US20Q4043952A f00661 • US50.75j.09A ; 00 631 • USS928647A :00091 • US581 f 128A [0009] • US5820883A f00691 • W004020592A [00711 • US4579945A [0073] • US443538-3A [00731 • US45Q5899A [0073] • US4436727A [0073] • US4436728A [0073] • US4505900A TO0731 • US5057540A [0073] • EP0362279A [00731 • WQ9633739A [0073] • VV09611711A f00731 • WQ942Q07BA [00771 • WQ94237Q1A [0077] • US4376110A [0088] • US4452901A FOOSSl • US3817827A [00881 • US3850752A [0088] • U33901654A [00881 • US3935074A [0088] • US3984533A Γ00881 • US3996345A [00881 . US4098876A :00881
Non-patent literature cited in the description . POLO, J. M.DUBENSKY, T. W„ JR.Drug Discov Today, 2002, vol. 7, 13719-727 [0001] • NEMES etal.ProcSoc Exp Biol Med., 1969, vol. 132. 776- [00111 • SCHAFER et al.Nature, 1970, vol. 226, 449- [00111
• FENJE et al.Nature, 1970, vol. 226,171- TOPHI • MACKICHANIAVI Report., 2005, vol. 9, 1-5 [0015) • ABREU et al.J Immunol, 2005, vol. 174, 84453-4460 [00151 [60301 • MATSUMOTO, M et al.24Biochem Biophys Res Commun, 2002, 1364- {0016] • BOUTEILLER et al.J Biol Chem, 2005, vol. 18, 38133-45 {0016] • BATZER et al.Nucleic Acid Res., 1991, vol. 19. 5081- [00201 • OHTSUKAet al.J. Biol. Chem., 1985, vol. 260, 2605-2608{0020] • ROSSOLINI et al.Mol. Cell. Probes, 1994, vol. 8, 91-98 100201 • CREIGHTONProteins, 1984, [0036] • TIJSSENOverview of principles of hybridization and the strategy of nucleic acid assaysTechniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Probes, 1993, [60381 • HARLOWLANEAntibodies, A Laboratory Manual, 1988, {0042] . SMITHWATERMANAdv. Appl. Math., 1981, vol. 2, 482- [00461 • NEED LEM ANWUNSCHJ. Mol. Biol., 1970, vol. 48, 443- [0646] . PEARSON LI PM AN Proc. Nat'l. Acad. Sci. USA, 1988, vol. 85, 2444-{0046] • Current Protocols in Molecular Biologyl 9950000 [06461 • FENGDOOLITTLEJ. Mol. Evol., 1987, vol. 35, 351-360 [0047] . HIGGINSSHARPCABIOS, 1989, vol. 5, 151-153 [06471 • DEVEREAUXet al.Nuc. Acids Res., 1984, vol. 12, 387-395 [06471 . ALTSCHUL et al.Nuc. Acids Res., 1977, vol. 25, 3389-3402 [0048] . ALTSCHUL et al.J. Mol. Biol., 1990. vol. 215. 403-410 [00481 . HENIKOFFHENIKOFFProc. Natl. Acad. Sci. USA, 1989, vol. 89, 10915- [6048] . KARLINALTSCHULProc. Nat'l. Acad. Sci. USA, 1993, vol. 90, 5873-5787 [004S1 • LUBECK et al.Proc Natl Acad Sci USA, 1989, vol. 86, 176763-6767 [06521 [00661 . SHEN et al.J Virol, 2001, vol. 75, 94297-4307 [0052] • BAILEY et al.Virology, 1994, vol. 202. 2695-706 [00521 . SHIVER et al.Nature, 2002, vol. 415, 6869331- [6055] . DONNELLY et al.J Infect Dis., 1996, vol. 173. 314- [60551 • LUBECK et al.PNAS, 1989, vol. 86, 6763- [60551 . DONNELLY et al.Vaccine, 1997, vol. 15, 865- [0055] • DUBENSKY et al.J Virol, 1996, vol. 70, 1508-519 [06561 • PETRAKOVA et al.J Virol, 2005, vol. 79, 127597-608 [0056] • WU et al.lnfection and Immunity, 2001, vol. 69, 127695- [00571 • Current Protocols in Molecular Biology20010000 [60611 • ALEXOPOULOU et al.Nature, 2001, vol. 413, 732-8 [0063] • MATSUMOTO et al.Biochem. Biophys. Res. Common., 2002, vol. 24,1364- [00851 • BOUTEILLER et al.J Biol. Chem., 2005, vol. 18, 38133-45 [0065] • CHOURASIAJAINJ Pharm Pharm Sci, 2003, vol. 6, 133-66 [00061 • ROLLANDCrit Rev. Therap. Drug Carrier Systems, 1998, vol. 15, 143-198 [60671 • ANDERSONCROWLEInfect. Immun., 1981, vol. 31, 1413-418 [0071] • ROTERMAN et al.J. Physiol. Pharmacol, 1993, vol. 44, 3213-32 [0071] . ARORACROWLEJ. Reticuloendothel., 1978, vol. 24, 3271-86 [0071] • CROWLEMAYInfect. Immun., 1982, vol. 38, 3932-7 160711 • HENGGE et al.Lancet Infect. Dis., 2001, vol. 1.3189-98 rø072f . COOMBESet al.Vaccine, 1996, vol. 14, 1429-1438 f007Sl • BROSSARTBEVANBlood, 1997, vol. 90, 41594-1599 [00861 . LENZ et al.J. Exp. Med., 2000, vol. 192, 81135-1142 fOOSSl • TUCKER et al.Mol Therapy, 2003, vol. 8, 392-399 [06881 . TUCKER et al.Vaccine, 2004, vol. 22, 2500-2504 [06881 • WIDE et al.Radioimmunoassay Methodsl 9700000 [0088] • BROWN et al.J. Biol. Chem., 1980, vol. 255, 4980-4983 [06881 • RAINES et al.J. Biol. Chem., 1982, vol. 257, 5154-5160 [0088] • BROOKS et al.Clin Exp. Immunol., 1980. vol. 39. 477- [0088] • BOWEN-POPE et al.Proc. Natl. Acad. Sci. USA, 1984, vol. 81,2396-2400 [00881 • TUCKER et al.Mol Therapy, 2004, vol. 8, 392- [01031
Claims (12)
1
1. Kimærisk adenoviral ekspressionsvektor, hvilken vektor omfatter en ekspressionskassette, der omfatter følgende elementer: 5 (a) en første promoter, der er operativt bundet til en nukleinsyre, der koder for en Toll-lignende receptor-3- (TLR-3) agonist, hvor TLR-3-agonisten er heterologt dsRNA, og hvor nukleinsyren, der koder for TLR-3-agonisten, omfatter en sekvens, der er udvalgt fra gruppen bestående af: SEQ ID NO: 3, 4, 5, 8, 9, 10, 11 og 12; og 10 (b) en anden promoter, der er operativt bundet til en nukleinsyre, der koder for et immunogent heterologt polypeptid.
2. Kimærisk adenoviral ekspressionsvektor ifølge krav 1, hvor den første promoter og den anden promoter er de samme, eventuelt hvor den første promoter 15 og den anden promoter hver er en CMV-promoter.
3. Immunogen sammensætning, der omfatter ekspressionsvektoren ifølge et hvilket som helst af de foregående krav og en farmaceutisk acceptabel bærer.
4. Kimærisk adenoviral ekspressionsvektor, hvilken vektor omfatter en eks pressionskassette, der omfatter følgende elementer: (a) en første promoter, der er operativt bundet til en nukleinsyre, der koder for en Toll-lignende receptor-3- (TLR-3) agonist, hvor TLR-3-agonisten er heterologt dsRNA; og 25 (b) en anden promoter, der er operativt bundet til en nukleinsyre, der koder for et immunogent heterologt polypeptid, til anvendelse i en fremgangsmåde til behandling, der frembringer et immunrespons, hvilken fremgangsmåde omfatter administration af en immunogeneffektiv mængde af vektoren til et pattedyrsindivid, såsom et menneske, hvor immun responset er rettet mod det heterologe po-30 lypeptid, og hvor administrationsvejen er udvalgt fra gruppen bestående af oral, intranasal og mukosal, såsom vaginal. 2
5. Vektor til anvendelse ifølge krav 4, hvor det heterologe polypeptid er udtrykt i en celle, der er udvalgt fra gruppen bestående af en dendritisk celle, en M-celle og en intestinal epithelcelle.
6. Vektor ifølge krav 1, hvor det heterologe dsRNA er kort hårnåls-RNA (shRNA).
7. Immunogen sammensætning, hvilken sammensætning omfatter: (a) en kimærisk adenoviral ekspressionsvektor, der omfatter en promoter, 10 der er operativt bundet til en nukleinsyre, der koder for et immunogent heterologt polypeptid; (b) en TLR-3-agonist, hvor TLR-3-agonisten er heterologt dsRNA; og (c) en farmaceutisk acceptabel bærer; til anvendelse i en fremgangsmåde, der frembringer et immunrespons, hvil-15 ken fremgangsmåde omfatter administration af en immunogen effektiv mængde af sammensætningen til et pattedyrsindivid, såsom et menneske, hvor immunresponset er rettet mod det heterologe polypeptid, og hvor administrationsvejen er udvalgt fra gruppen bestående af oral, intranasal og mukosal, såsom vaginal.
8. Sammensætning til anvendelse ifølge krav 7, hvor promoteren er en CMV- promoter.
9. Sammensætning til anvendelse ifølge krav 7, hvor TLR-3-agonisten er en nukleinsyre, der omfatter en sekvens, der er udvalgt fra gruppen bestående af 25 SEQ ID NO: 3, 4, 5, 8, 9, 10, 11 og 12.
10. Sammensætning til anvendelse ifølge krav 7, hvor det heterologe polypeptid er udtrykt i en celle, der er udvalgt fra gruppen bestående af en dendritisk celle, en M-celle og en intestinal epithelcelle. 30
11. Sammensætning til anvendelse ifølge krav 7, hvor det heterologe dsRNA er kort hårnåls-RNA (shRNA). 3
12. Vektor ifølge krav 1, vektor til anvendelse ifølge krav 4 eller sammensætning til anvendelse ifølge krav 7, hvor det heterologe polypeptid er: (a) et HIV env-polypeptid, såsom et polypeptid udvalgt fra gruppen bestående af gp41, gp120 og gp160; 5 (b) et influenza HA-polypeptid; (c) et antigen fra herpes simplex virus (HSV) eller (d) et antigen fra humant papillomavirus (HPV).
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77802606P | 2006-02-28 | 2006-02-28 | |
| US80164506P | 2006-05-19 | 2006-05-19 | |
| US80299206P | 2006-05-22 | 2006-05-22 | |
| US82149206P | 2006-08-04 | 2006-08-04 | |
| US84665806P | 2006-09-22 | 2006-09-22 | |
| US84819506P | 2006-09-28 | 2006-09-28 | |
| PCT/US2007/005386 WO2007100908A2 (en) | 2006-02-28 | 2007-02-28 | Chimeric adenoviral vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1996238T3 true DK1996238T3 (da) | 2016-08-01 |
Family
ID=38459683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07752109.4T DK1996238T3 (da) | 2006-02-28 | 2007-02-28 | Kimæriske adenovirale vektorer og DsRNA som TLR3-agonist |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US7879602B2 (da) |
| EP (1) | EP1996238B1 (da) |
| JP (1) | JP5016614B2 (da) |
| KR (2) | KR101273836B1 (da) |
| CN (2) | CN103122360A (da) |
| AP (1) | AP2844A (da) |
| AU (1) | AU2007220988B2 (da) |
| BR (1) | BRPI0708344B8 (da) |
| CA (1) | CA2638757C (da) |
| DK (1) | DK1996238T3 (da) |
| EA (1) | EA014757B1 (da) |
| ES (1) | ES2573456T3 (da) |
| HR (1) | HRP20160795T1 (da) |
| HU (1) | HUE030281T2 (da) |
| IL (2) | IL193684A (da) |
| LT (1) | LT1996238T (da) |
| MY (1) | MY154956A (da) |
| NZ (1) | NZ571010A (da) |
| PL (1) | PL1996238T3 (da) |
| PT (1) | PT1996238T (da) |
| RS (1) | RS54843B1 (da) |
| SI (1) | SI1996238T1 (da) |
| WO (1) | WO2007100908A2 (da) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7879602B2 (en) * | 2006-02-28 | 2011-02-01 | Vaxart, Inc. | Chimeric adenoviral vectors |
| WO2009073133A1 (en) * | 2007-11-29 | 2009-06-11 | Vaxinnate Corporation | Compositions of toll-like receptor agonists and papillomavirus antigens and uses thereof |
| EP2331119A4 (en) * | 2008-09-24 | 2012-05-30 | Univ Johns Hopkins | MALARIA VACCINE |
| BR112012008060A2 (pt) * | 2009-07-31 | 2016-11-22 | Paxvax Inc | vetores baseados em adenovírus |
| WO2011034950A1 (en) * | 2009-09-16 | 2011-03-24 | Vaxart, Inc. | Immunization strategy to prevent h1n1 infection |
| US9198959B2 (en) * | 2011-02-22 | 2015-12-01 | Regents Of The University Of Minnesota | Adenovirus vaccine vector and methods of use |
| US10183069B2 (en) | 2011-03-21 | 2019-01-22 | Altimmune Inc. | Rapid and prolonged immunologic-therapeutic |
| AU2013357367B2 (en) | 2012-12-11 | 2019-10-24 | Osivax Sas | Modified coiled coil type proteins having improved properties |
| CA2923406A1 (en) * | 2013-09-06 | 2015-03-12 | Altimmune Inc. | Methods and compositions for viral vectored vaccines |
| EA033248B1 (ru) | 2014-02-20 | 2019-09-30 | Вэксарт, Инк. | Композиция и способ индукции иммунного ответа |
| EP3421046A1 (en) | 2014-11-04 | 2019-01-02 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv16 vaccines |
| US10570417B2 (en) | 2015-04-14 | 2020-02-25 | Janssen Vaccines & Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
| JP6912394B2 (ja) | 2015-06-12 | 2021-08-04 | バクサート インコーポレイテッド | Rsvおよびノロウイルス抗原の小腸送達のための製剤 |
| EA037295B1 (ru) | 2015-08-20 | 2021-03-05 | Янссен Вэксинс Энд Превеншн Б.В. | Терапевтические вакцины против hpv18 |
| GB201603577D0 (en) | 2016-03-01 | 2016-04-13 | Oxford Genetics Ltd | Promoter |
| BR112018072372A2 (pt) | 2016-05-02 | 2019-02-19 | Janssen Vaccines & Prevention B.V. | combinações de vacina terapêutica contra o hpv |
| KR102573534B1 (ko) | 2016-05-12 | 2023-08-31 | 얀센 백신스 앤드 프리벤션 비.브이. | 강력하고 균형 잡힌 양방향성 프로모터 |
| WO2017220499A1 (en) | 2016-06-20 | 2017-12-28 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
| CA3046489A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| US11205103B2 (en) | 2016-12-09 | 2021-12-21 | The Research Foundation for the State University | Semisupervised autoencoder for sentiment analysis |
| EP3554344A1 (en) | 2016-12-14 | 2019-10-23 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tlr modulator |
| MX2019008105A (es) * | 2017-01-06 | 2020-07-22 | Stabilitech Biopharma Ltd | Virus. |
| CA3053212C (en) | 2017-02-09 | 2021-04-13 | Janssen Vaccines & Prevention B.V. | Potent and short promoter for expression of heterologous genes |
| US20250242012A1 (en) * | 2020-02-25 | 2025-07-31 | Symvivo Corporation | Gene delivery system |
| WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| EP4161571A4 (en) * | 2020-06-05 | 2024-08-21 | Vaxart, Inc. | CHIMERIC ADENOVIRAL VECTORS |
| WO2022165360A2 (en) * | 2021-02-01 | 2022-08-04 | Vaxart, Inc. | Chimeric adenoviral vectors |
| US20230226050A1 (en) | 2020-07-02 | 2023-07-20 | Viiv Healthcare Company | Method of achieving hiv viral remission using long-acting antiretroviral agents |
| AU2024333337A1 (en) | 2023-08-25 | 2026-03-12 | Assaad A. Eid | Remote-controlled alteration/induction of cellular apoptosis and methods of use |
| CN119925586A (zh) * | 2025-01-24 | 2025-05-06 | 中国疾病预防控制中心病毒病预防控制所 | 一种内置核酸佐剂的新冠病毒b.1.1.529变异株口服疫苗及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6511845B1 (en) * | 1992-08-07 | 2003-01-28 | Alan R. Davis | Methods for producing an immune response against HIV-1 |
| US5676950A (en) * | 1994-10-28 | 1997-10-14 | University Of Florida | Enterically administered recombinant poxvirus vaccines |
| US20020182223A1 (en) | 2000-06-02 | 2002-12-05 | Lacount Douglas J. | Method of rapidly generating double-stranded RNA and methods of use thereof |
| US20020155127A1 (en) * | 2000-06-02 | 2002-10-24 | Danher Wang | Genetic vaccine against human immunodeficiency virus |
| EP1327688A1 (en) * | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviruses with enhanced lytic potency |
| EP1540004A4 (en) * | 2002-07-31 | 2007-10-03 | Nucleonics Inc | DOUBLE-STRING RNA STRUCTURES AND CONSTRUCTS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| US20070219149A1 (en) | 2003-08-11 | 2007-09-20 | The Research Foundation For Microbial Diseases Of Osaka University | Novel Vaccine Containing Adjuvant Capable Of Inducing Mucosal Immunity |
| GB0321615D0 (en) * | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| EP1586654A1 (en) * | 2004-04-15 | 2005-10-19 | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg | Replication competent viruses capable of silencing virus inhibitory factor expression |
| WO2007026190A2 (en) * | 2004-07-18 | 2007-03-08 | Csl Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
| US7879602B2 (en) * | 2006-02-28 | 2011-02-01 | Vaxart, Inc. | Chimeric adenoviral vectors |
-
2007
- 2007-02-28 US US11/712,794 patent/US7879602B2/en active Active
- 2007-02-28 PL PL07752109.4T patent/PL1996238T3/pl unknown
- 2007-02-28 JP JP2008557403A patent/JP5016614B2/ja active Active
- 2007-02-28 AP AP2008004612A patent/AP2844A/xx active
- 2007-02-28 CN CN2013100288300A patent/CN103122360A/zh active Pending
- 2007-02-28 WO PCT/US2007/005386 patent/WO2007100908A2/en not_active Ceased
- 2007-02-28 AU AU2007220988A patent/AU2007220988B2/en active Active
- 2007-02-28 RS RS20160431A patent/RS54843B1/sr unknown
- 2007-02-28 MY MYPI20083328A patent/MY154956A/en unknown
- 2007-02-28 ES ES07752109.4T patent/ES2573456T3/es active Active
- 2007-02-28 SI SI200731784A patent/SI1996238T1/sl unknown
- 2007-02-28 BR BRPI0708344A patent/BRPI0708344B8/pt active Search and Examination
- 2007-02-28 EA EA200801907A patent/EA014757B1/ru not_active IP Right Cessation
- 2007-02-28 KR KR1020117027773A patent/KR101273836B1/ko active Active
- 2007-02-28 CA CA2638757A patent/CA2638757C/en active Active
- 2007-02-28 HU HUE07752109A patent/HUE030281T2/en unknown
- 2007-02-28 NZ NZ571010A patent/NZ571010A/xx unknown
- 2007-02-28 HR HRP20160795TT patent/HRP20160795T1/hr unknown
- 2007-02-28 EP EP07752109.4A patent/EP1996238B1/en active Active
- 2007-02-28 KR KR1020087023613A patent/KR101105511B1/ko active Active
- 2007-02-28 PT PT77521094T patent/PT1996238T/pt unknown
- 2007-02-28 CN CN2007800153452A patent/CN101432291B/zh active Active
- 2007-02-28 LT LTEP07752109.4T patent/LT1996238T/lt unknown
- 2007-02-28 DK DK07752109.4T patent/DK1996238T3/da active
-
2008
- 2008-08-25 IL IL193684A patent/IL193684A/en active IP Right Grant
-
2010
- 2010-11-12 US US12/945,358 patent/US8222224B2/en active Active
-
2012
- 2012-06-25 US US13/532,701 patent/US8999946B2/en active Active
-
2013
- 2013-11-20 IL IL229523A patent/IL229523A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1996238T3 (da) | Kimæriske adenovirale vektorer og DsRNA som TLR3-agonist | |
| EP3385387B1 (en) | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof | |
| US12305173B2 (en) | Immunostimulatory compositions | |
| CA3045976A1 (en) | Chimpanzee adenovirus constructs with lyssavirus antigens | |
| AU2024205755A1 (en) | Treatment of covid-19 and methods therefor | |
| KR101153845B1 (ko) | Kras G12V RNA를 특이적으로 인지할 수 있는 트랜스-스플라이싱 그룹 I 리보자임 | |
| RU2799523C1 (ru) | Иммуностимулирующие композиции | |
| CN115698306A (zh) | 复制缺陷型禽腺病毒载体、其设计和用途 | |
| KR20120064656A (ko) | Kras G12V RNA를 특이적으로 인지할 수 있는 트랜스-스플라이싱 그룹 I 리보자임 |